In vitro and in VIVO recording of cell based dynamics using intracelluar protein tapes
CytoTape addresses the limitations of existing technologies by enabling weeks-long, multiplexed recording of cellular activities, facilitating the analysis of complex gene regulatory networks through a self-assembling protein assembly system, suitable for brain-wide single-cell recording and gene regulation dynamics.
Patent Information
- Application Number
- PCT/US2026/027126
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-28
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies are inadequate for multiplexed, long-term, single-cell recording of transcriptional activities in live cells, as they require continuous microscopy and cannot capture complex temporal dynamics of gene regulatory networks due to limitations in spatial and temporal scales, and often destroy the spatial and molecular information of intact cells and tissues.
The development of CytoTape, a genetically encoded, self-assembling protein assembly system, allows for weeks-long, multiplexed recording of cellular activities using distinct molecular tags, enabling simultaneous spatiotemporally resolved recording of transcription factor activities and immediate early gene expression, with flexible and thin protein assemblies stabilized by increased electrostatic interactions.
CytoTape enables weeks-long, multiplexed recording of cellular activities, providing a powerful platform for dissecting complex cellular dynamics and revealing spatial heterogeneity, with applications in brain-wide single-cell recording and analysis of gene regulation dynamics.
Smart Images

Figure US2026027126_12112026_PF_FP_ABST
Abstract
Description
IN VITRO AND IN VIVO RECORDING OF CELL BASED DYNAMICS USING INTRACELLUAR PROTEIN TAPESCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 801,605, filed May 7, 2025, and U.S. Provisional Application No. 63 / 852,288, filed July 28, 2025, and U.S. Provisional Application No. 63 / 852,319, filed July 28, 2025, the content of each of which are herein incorporated by reference in their entirety.STATEMENT REGARDING FEDERAL FUNDING
[0002] This invention was made with government support under MH140133 awarded by the National Institutes of Health. The government has certain rights in the invention.SEQUENCE LISTING STATEMENT
[0003] The contents of the electronic sequence listing titled “UM_45281_601_SequenceListing.xml” (Size: 68,425 bytes; and Date of Creation: May 7, 2026) is herein incorporated by reference in its entirety.FIELD
[0004] The present disclosure relates to compositions, systems, and methods for single-cell, spatiotemporally resolved, multiplexed recording of cellular activity in mammalian cells, including in living mammalian brain tissue, using genetically encoded self-assembling protein recorders. The disclosure further relates to brain-wide single-cell recording in non-human mammalian subjects, including the recording of immediate-early-gene transcriptional activity at single-cell resolution across multiple anatomically distinct brain regions over multi-day recording windows.BACKGROUND
[0005] Gene regulatory networks orchestrate intricate biological processes within cells, determining cellular fates, coordinating environmental responses, and, when disrupted, contributing to disease states. These networks involve a collection of dynamic components (e.g., transcription factors) that interact with each other to achieve network dynamics that ultimatelydrive complex cellular computations and outcomes. However, such dynamic interactions can barely be adequately captured via static snapshots or time-resolved measurement of the activity of a single network component. Even if one could perform time-resolved measurement of each component separately in distinct cell populations, critical relationships among the components within single cells would be lost. For example, even a straightforward inverse relationship — A is high when B is low, and vice versa — cannot be established when A and B are measured in two separate cell populations. Recent studies suggest gene regulatory networks exhibit far more complex dynamical rules of action, including intricate activation-inhibition patterns and temporal sequences. Dissecting the fundamental principles of gene regulatory networks in action would greatly benefit from a technology that provides simultaneous, time-resolved recording of the temporal dynamics of multiple interacting network components within the same cell, capturing both their activation and inhibition patterns over time.
[0006] Despite growing interest in decoding the dynamics of gene regulatory networks, existing technologies fall short of meeting the combined demands of days- to weeks-long, single-cell multiplexed, and scalable recording of transcriptional activities in live cells. Genetically encoded fluorescent reporters allow real-time imaging of cellular activities in live cells (10, 11, 12) and can be multiplexed via spectral multiplexing (Y. Zhao, el al., Science, 2011, PMC3560286), spatial multiplexing (C. Linghu et al., Cell, 2020, PMC7771521), and temporal multiplexing (Y. Qian et al., Cell, 2023, PMC 10843875). However, long-term live imaging of these reporters typically requires continuous microscopy access, precise environmental control for long-term imaging, and repeated manual interventions, with restricted spatial and temporal scales due to limited field of view sizes of imaging systems and photobleaching effects of fluorescent probes over days and weeks. Nucleic acid-based molecular recorders have expanded the ability to capture and reconstruct intracellular events across large cell populations by encoding molecular information stably in nucleic acid sequences for downstream high-throughput sequencing readout. Nevertheless, these methods do not yet support multiplexed recording of the complex temporal waveforms of cellular signals within single mammalian cells (13, 14, 15, 16) and typically require cell lysis and / or tissue dissociation that does not preserve the spatial and molecular information of intact cells and tissues that one often wants to examine in situ. Postfixation readout methods support multiplexed spatial analysis of intact cells and tissues, but are generally limited to one or two time points (17, 18). To study cellular processes beyond a fewhours, such as gene regulation dynamics that often span over many days and weeks, there is an urgent need for a technology that provides long-term, multiplexed measurements of cellular activities.SUMMARY
[0007] Molecular recorder concept via intracellular linear protein assemblies allows cellular measurements over days across large cell populations, because cellular activity is stored in situ for post-fixation scalable readout (by encoding temporal signals along the spatial dimension; analogous to how tree rings encode physiological histories of a growing tree), thus eliminating the need for live-cell imaging. However, current protein-based “ticker tape” recorders do not support simultaneous recording of multiple cellular signals, nor do they allow weeks-long recording due to the rigid structure of the protein assembly being restricted by the size of a cell.
[0008] The present technology addresses this enduring technological gap through artificial intelligence (AI) guided protein engineering and generation of a new protein assembly, herein referred to as “CytoTape” — a temporally precise and flexible protein assembly / tape system that achieves single-cell multiplexed, weeks-long recording in live cells in a highly modular manner (Fig. 1a; the protein design of the CytoTape monomer is shown in Fig. 1b. Multiplexed recording can now be achieved on the same protein assembly by using distinct molecular tags where the distinct tags encode one kind of cellular signal. By stabilizing the molecular dynamics of monomers of the assembly and increasing the electrostatic interaction level of the lateral binding surfaces of the monomer can now encourage the assembly to be thin and flexible, allowing recording over weeks. Using CytoTape, simultaneous, spatiotemporally scalable recording of five cell plasticity-associated transcription factor activities and immediate early gene (IEG) transcriptional activities, namely cAMP response element-binding protein (CREB), c-fos, Arc, Egrl, and Npas4 activities, and additional activities including, without limitation, HSPA1 A heatshock activity, Fos-family activity (e.g., via an F-RAM promoter), CREB activity (e.g., via a 6xCRE-CMVMin promoter), and Arc I Npas4 activity (e.g., via SARE-ArcMin orN-RAM promoters), was achieved within the same protein assemblies in individual live cells (transcription factor activities measured using transcription factor-responsive promoters are written in non-italic font, whereas gene transcriptional activities measured via their respective gene promoters are italicized to distinguish between the two). The disclosure also provides a newprotein assembly, herein referred to as “CytoTape-vivo” or “BrainTape” See, e.g., FIG. 41 — a temporally precise and flexible protein assembly / tape system that achieves single-cell multiplexed, weeks-long recording in live cells in vivo in a highly modular manner. As disclosed herein, CytoTape-vivo was discovered to be useful for spatiotemporally resolved and scalable single-cell recording in the living brain, and for recording immediate early gene (IEG) expression capable of revealing spatial heterogeneity in the hippocampus. In some aspects, CytoTape-vivo integrates doxycycline-inducible timestamps to enable time interpolation without invasive dye injections. In other aspects, Cyto-Tape-vivo can be used to record IEG expression in the brain (e.g., hippocampus) before, during, and after stimulation (e.g., with kainic acid) in order to monitor cellular activity (e.g., in vivo gene expression) over long periods of time (e.g., hours, days, weeks, or longer). These capabilities surpass existing state-of-the-art methodologies in both temporal and multiplexed scalability, offering a powerful new platform for dissecting complex cellular dynamics.
[0009] The utility of CytoTape and Cyto-Tape-vivo is demonstrated herein as it was employed to analyze the long-term temporal coupling between CREB activity and downstream IEG expression at single-cell resolution — an experiment otherwise infeasible with existing tools. Recent studies suggest that dynamic transcriptional signatures play important roles in regulating CREB-Fos regulation, but the underlying temporal logic remains unclear. Using CytoTape, CREB activation and Fos expression was observed to become decoupled in cells exhibiting active Fos transcriptional activity prior to stimulation, suggesting a potential role for transcriptional history in shaping downstream responses. In primary cultured neurons, it was also observed that Arc- and Egrl -promoter-driven gene expression display complex, multi -peak activation dynamics following a single upstream stimulation, revealing distinct temporal couplings that depend on the type of stimulus. Together, these results highlight how temporal features of gene activity and signaling history contribute to transcriptional outcomes, offering a framework to dissect gene regulation dynamics in diverse cellular contexts.
[0010] The disclosure further provides a system and methods for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject in vivo, referred to herein as a " GLOBE recording system" and the corresponding methods as " GLOBE recording" (sinGle-cell spatiotemporaL recording Brain-widE). In some embodiments, the GLOBE recording system comprises three modular, genetically encoded protein componentsdelivered to single cells through brain-wide gene transduction: a structural monomer expressed under a constitutive regulatory element and configured to self-assemble into an intracellular protein filament that elongates over time; a signal monomer expressed under an activitydependent regulatory element and incorporated along the elongating filament such that activitydependent expression is recorded as a corresponding spatial pattern of signal-monomer incorporation; and a timestamp monomer expressed under a small-molecule-inducible regulatory element and incorporated along the elongating filament such that one or more user-defined induction events are recorded as one or more spatially detectable timestamps. Each monomer is fused to a distinct epitope tag, enabling reconstruction of their relative spatial location along the filament by post-fixation immunofluorescence and providing a time-resolved readout of cellular activity within individual cells. In some aspects, the GLOBE recording system is modular with respect to the choice of recording substrate, and may be implemented using XRI, CytoTape, CytoTape-vivo, or any further self-assembling protein monomer satisfying defined functional criteria as a recording substrate.
[0011] In some aspects, GLOBE recording provides simultaneous single-cell recording of cellular activity from at least approximately 1,000; at least approximately 10,000; at least approximately 100,000; at least approximately 200,000; or more cells per subject. In one nonlimiting embodiment, GLOBE recording is achieved at a local recording density of from approximately 50% to approximately 95%, or from approximately 69% to approximately 90%, of Nissl-positive neurons within a recorded brain region. In further embodiments, GLOBE recording is performed across at least two, at least three, at least five, at least ten, or at least twenty distinct anatomically defined brain regions in the same subject, including, without limitation, isocortex, olfactory areas, cortical subplate, hippocampal formation, pallidum, striatum, thalamus, hypothalamus, and midbrain. In some embodiments, the recording window during which GLOBE recording is performed is from approximately 1 day to approximately 30 days, from approximately 3 days to approximately 14 days, or approximately 5.5 days, and may be extended to from approximately 1 week to approximately 20 weeks in further embodiments employing extended-duration recording substrates including, without limitation, CytoTape or CytoTape-vivo. In further aspects, GLOBE recording supports non -invasive, reversible, multievent timestamping by oral administration of a tetracycline-class antibiotic such as doxycyclinein drinking water, providing reversible in vivo temporal references along the recorded filament with sub-day-scale timestamp accuracy after global temporal alignment.
[0012] In further aspects, the disclosure provides an artificial-intelligence-powered, parallelcomputing-accelerated, high-throughput computational pipeline for brain-wide automated segmentation, skeletonization, signal extraction, and readout of intracellular protein filaments and cell morphology from multi-channel volumetric microscopy images of mammalian brain tissue, referred to herein as a " GLOBE Tape Reader" pipeline. The pipeline accepts as input multi-channel volumetric image data comprising structural-monomer, signal-monomer, timestamp-monomer, and cytosol-selective stain channels, and produces per-fiber intensity profiles, per-cell time-resolved cellular activity histories, and quality metrics. In some aspects, the disclosure further provides methods for generating a brain-wide spatiotemporal functional atlas of cellular activity in a non-human mammalian subject by performing GLOBE recording, extracting per-cell signal traces aligned to an absolute time axis, summarizing each per-cell signal trace as a time-binned activity vector, applying dimensionality reduction (for example, by Uniform Manifold Approximation and Projection (UMAP), t-distributed Stochastic Neighbor Embedding (t-SNE), Principal Component Analysis (PCA), or Diffusion Maps) to generate a low-dimensional activity manifold (referred to as a "memory manifold" when the manipulation comprises a learning-and-recall paradigm), assigning each cell a temporal -mode classification, and registering spatial coordinates to a common anatomical coordinate framework. The brainwide spatiotemporal functional atlas enables identification of brain region-dependent spatial distributions of temporal modes, comparison of atlases between conditions or genetic backgrounds, and detection of cells exhibiting mildly suppressed activity that may be difficult to detect by snapshot-based labeling methods.
[0013] In further aspects, the disclosure provides compositions, including, without limitation, recombinant viral vector compositions formulated for multi-site, multi-depth intracranial administration or intravenous administration, kits comprising one or more nucleic acids or recombinant viral vectors encoding the structural, signal, and timestamp monomers, and corresponding reagents (including, without limitation, antibodies against the detectable tags, fluorescent secondary antibodies, cytosol-selective stains, expansion microscopy reagents, and RNA fluorescence in situ hybridization reagents). In further aspects, GLOBE-recorded samples are compatible with downstream cell-type and molecular readouts in the same recorded tissue,including conventional immunohistochemistry, multi-round rolling-circle-amplification-based RNA fluorescence in situ hybridization, and expansion microscopy, performed separately, sequentially, or in combination, enabling correlation of GLOBE-recorded cellular activity histories with cell-type identity, RNA transcript levels, and end-point cellular state features in the same cells. In further aspects, the disclosure provides methods of using GLOBE recording to identify an effect of a candidate agent or candidate manipulation on brain-wide cellular activity, by comparing brain-wide spatiotemporal functional atlases between subjects receiving and not receiving the candidate agent or candidate manipulation, supporting drug discovery, target validation, and mechanism-of-action studies in research contexts.DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1 depicts the design of CytoTape. (a) Schematic of a CytoTape system for longterm, multiplexed recording of cellular physiological histories via elongating protein selfassembly. CytoTape is formed by structural monomers that create the intracellular protein assembly. Timestamp monomers, which encode temporal information, are sparsely incorporated along this assembly to embed the time axis along the spatial dimension. Signal monomers encode cellular physiological activities and are also incorporated along the same assembly to achieve recording, (b) Top row, AlphaFold3-predicted structure of the CytoTape monomer. Bottom row, design strategy of CytoTape using XRI as a template. Al-assisted protein design (A family designs; CPDiffusion and ProtSSN are used for sequence generation and site mutation, respectively, using 1POK(E239Y) as the template) and rational design (B and C family designs; 1POK(E239Y) was replaced with other assembly proteins, and the linker and MBP were optimized by tuning their sequence lengths, adjusting the number of their tandem repeats, and replacing them with homologous sequences) were combined to develop the CytoTape monomer. After in silico design, design candidates were screened in cultured neurons. The UbC promoter was used to drive the steady expression of candidate protein monomers, (c) Statistical analysis of protein assembly width for different protein designs that showed fiber-like structures in cultured neurons at 7 days, 14 days, and 18 days after transfection. The sample size (n) is listed below as (X, Y, Z), which denotes n = X protein assemblies from Y neurons from Z cultures. XRI: 7d (31, 25, 5), 14d (26, 20, 5), 18d (32, 30, 5). A1-1: 7d (10, 5, 1). A1-2: 7d (10, 6, 1). A1-3: 7d (10, 7, 1). A1-4: 7d (10, 6, 1). A1-5: 7d (10, 7, 1). A2-1: 7d (15, 10, 2), 14d (15, 15, 2), 18d (15, 12,3). A2-2: 7d (17, 10, 2), 14d (10, 10, 2), 18d (15, 15, 2). B-1: 7d (31, 28, 4), 14d (25, 20, 6), 18d (25, 25, 3). C-l: 7d (15, 12, 3). C-4: 7d (28, 20, 3), 14d (30, 30, 4), 18d (10, 10, 2). C-5: 7d (31, 30, 2), 14d (24, 20, 2), 18d (18, 15, 3). CytoTape: 7d (16, 16, 3), 14d (28, 20, 5), 18d (25, 20, 5). The plasmid constructs of all protein assembly designs are listed in FIG. 18. The details of protein assembly width quantification are shown in FIG. 27 and described in the Experimental section, herein. For each design group (7, 14, and 18 days), Kruskal-Wallis analysis of variance followed by Dunn’s post hoc tests was used; *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant. To compare the width of XRI and CytoTape, Mann-Whitney U test was used; ***, P < 0.001. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points, (d) Schematic constructs of XRI (top row) and CytoTape (bottom row). AA, amino acid, (e) AlphaFold3-predicted structure of the CytoTape monomer with an epitope tag fused at the C-terminus (left panel) and the superposition of XRI monomer structure (red) and CytoTape monomer structure (right panel). The alignment on Cais conducted by the PyMOL software, (f) Position of the L349K mutation (highlighted; also indicated by arrows) in the octamer structure (obtained from Protein Data Bank, ID: 1POK) of the original E. coli ladA protein. Each shaded domain in the octamer structure represents an individual, identical monomer. The E239Y mutation enables the octamers to further selfassemble longitudinally into a fiber, (g) Free energy landscape of a single XRI or CytoTape protein monomer calculated from MD simulations. The radius of gyration (7?g) is the root mean square distance of the monomer from the center of mass of the structure. RMSD is the root mean squared deviation of the structure in the first MD snapshot after equilibration, (h) Distance between the centroid of the scaffold (1POK(E239Y) for XRI, 1POK(E239Y, L349K) for CytoTape) and the insulator (MBP for XRI, dMBP for CytoTape) obtained from MD simulations. The details of MD simulation are described in Methods. ***, P < 0.001; Mann-Whitney U test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points. See FIG. 38 for details of statistical analysis. The detailed confidence analysis of CytoTape and XRI monomer predicted by AlphaFold3 (b, e, and h) is presented in FIG. 28 in the Supplementary Information.
[0015] FIG. 2 shows that CytoTape forms thin and flexible fibers in live mammalian cells for weeks-long molecular recording, (a) Confocal images of cultured primary mouse hippocampal neurons expressing XRI (top row) and CytoTape (bottom row) fused to the HA tag, taken afterfixation at different time points (7, 14, and 18 days after calcium phosphate transfection) and then Nissl staining and immunostaining against the HA tag. Scale bars, 10 pm. (b) Kinetics of protein assembly width (left panel) and length (right panel) for XRI and CytoTape in cultured neurons over 18 days. The dashed lines indicate the slope of fiber width after reaching the plateau (left panel) and the slope of fiber length (right panel) between XRI and CytoTape. *, P < 0.05; Mann-Whitney U test, (c) Maximum curvature along each XRI or CytoTape assembly in cultured neurons on day 18. ***, P < 0.001; Mann-Whitney U test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; dots, individual data points, (d) Left panel, first row, schematic of the constructs transfected into cultured neurons and the experimental timeline. XRI-V5 or CytoTape-V5 refers to XRI or CytoTape fused to the V5 tag as the signal monomer, which is driven by the Egrl (also known as zif / 268) promoter. Confocal images of cultured mouse hippocampal neurons expressing XRI (middle row) and CytoTape (bottom row) fused to the HA tag and the V5 tag, taken after fixation on day 15, followed by Nissl staining and immunostaining against the HA and V5 tags. Neurons were stimulated with 55 mM KC1 for 1 h. Right panel, V5 signal relative to baseline (calculated as the ratio of V5 signal to the baseline V5 signal at the center of the protein assembly) plotted as a function of the fraction of the HA intensity line integral. ***, P < 0.001; Mann-Whitney U test for the peak amplitude of the V5 signal between XRI and CytoTape. Scale bars, 10 pm. (e) Left panel, schematic of the constructs transfected into neuron cultures and the experimental timeline. Middle panel, confocal images of cultured mouse hippocampal neurons expressing CytoTape with the HA and V5 tags, taken after fixation on day 7, followed by Nissl staining and immunostaining against the HA and V5 tags. Neurons were stimulated twice with 55 mM KC1 for 0.5 h. The two stimulations are 12 h apart. Right panel, V5 signal relative to baseline plotted as a function of the fraction of the HA intensity line integral. *, P < 0.05; **, P < 0.01; Mann-Whitney U test between the amplitude of each of the two sequential peaks and the baseline of the V5 signal. Scale bars, 10 pm. (f) Confocal images of XRI and CytoTape in HEK and HeLa cells. The constructs transfected into cells are shown at the left row. Confocal images were taken after fixation, Nissl staining, and immunostaining against the HA tag. Scale bars, 10 pm. See FIG. 38 for details of statistical analysis.
[0016] FIG. 3 shows CytoTape resolves and encodes timestamps with minutes-to-days intervals in single cells, (a) Schematic of the constructs transfected into HEK cells. CytoTape-HaloTagincorporates JF dyes, permitting labeling of the protein assembly with fiducial timestamps, (b) Time points of JF585and JF635addition (left panel) and expected dye distribution along the protein fiber (right panel), (c) Low-magnification images of CytoTape labeled with JF585and JF635in HEK cells, which is taken after fixation on day 3, and Nissl staining and immunostaining against the HA tag. Scale bar, 100 pm. Some fibers do not display clear timestamp transitions in this low magnification image, because the optimal image contrasts for each color channel to display the timestamp transitions are different across individual cells. See (d) for the images of individual cells with the optimal image contrast to display the timestamp transitions. The success rate of CytoTape showing clear timestamps is shown in FIG. lOi. (d) Enlarged confocal images of HEK cells indicated in (c). Arrows in images indicate the positions of dye switches within the protein fiber. Fluorescence line profiles of JF585and JF635are shown below each confocal image, (e) Statistical analysis (left panel) of fluorescence line profiles from the experiments described in (b), and interpolation between the spatial axis along fiber and the time axis (right panel), using the timestamps from left panel. Time axis recovery via linear curve fitting of timestamps and fixation point. Each raw trace on the left was normalized to its peak to show relative changes before averaging. Thick centerline, mean; darker boundary in the close vicinity of the thick centerline, s.e.m.; lighter boundary, s.d.; light gray thin lines, data from individual CytoTapes. (f) Schematic of the constructs transfected into cultured neurons and (g) expected dye distribution along the CytoTape. (h), (j), and (1) Timestamps for different temporal scales with varying temporal resolutions. First row, time points of JF585and JF635addition; second row, images of CytoTape at timescales of 5 days, 9 days, and 15 days; third row, enlarged view of CytoTape; fourth row, fluorescence line profiles. Scale bars, 10 pm. CytoTape shown in (1) extended into the initial segment of a neurite from the soma, (i), (k), and (m) Top panel, statistical analysis of fluorescence line profiles from the experiments described in (h) n = 8 CytoTapes from 8 neurons from two cultures, (k) n = 10 CytoTapes from 10 neurons from two cultures, and (m) n = 18 CytoTapes from 18 neurons from two cultures. Bottom panel, interpolation between the spatial axis along fiber and the time axis using the timestamps from top panel. Time axis recovery via B-spline curve fitting of timestamps and fixation point. Each raw trace was normalized to its peak to show relative changes before averaging. Thick centerline, mean; darker boundary in the close vicinity of the thick centerline, s.e.m.; lighter boundary, s.d.; light gray thin lines, data from individual CytoTapes. Normalized position along CytoTape iscalculated as dividing the distance along the half fiber starting from the optimal split point by the total length of this half fiber. The details of the interpolation between the spatial axis along fiber and the time axis using timestamps are described in Methods. CytoTape shows minutes-scale temporal resolution, (n) Schematic of the constructs transfected into HEK cells, (o) Time points of JF585, JF635, and JF503addition and cell fixation, (p) Confocal images of timestamped fibers labeled with different dye-switching intervals. The dashed lines indicate the transient dye switching. The confocal images were taken using a spinning disk confocal microscope with a 60X objective
[0017] FIG. 4 shows CytoTape enables modular design of transcriptional recorders for tracking gene regulation dynamics, (a) Schematic of the constructs transfected into cultured neurons and (b) the experimental timeline. CytoTape-V5, the signal monomer, is driven under an activitydependent promoter of interest, (c) Expected HA tag and V5 tag distribution along the CytoTape. (d), (f), (h), (j), and (1) Representative images of cultured neurons expressing the constructs shown in (a), c-fos, Egrl (also known as zif / 268 ), SARE-ArcMin, N-RAM, and 6xCRE-CMVMin promoters that are responsive to transcriptional activities of c-fos, Egrl, and Arc genes and transcription factor activities of Npas4 and CREB proteins, respectively, were used to drive the signal monomer expression. Images were captured after fixation, Nissl staining, and immunostaining for HA and V5 tags. Neurons were stimulated with 55 mM KC1 for 3 h for c-fos, 30 mM KC1 for 2 h for Egrl, 55 mM KC1 for 3 h for Arc, 55 mM KC1 for 3 h for Npas4, and 10 pM forskolin (FSK) for 1 h for CREB. Enlarged views of the CytoTape in the top-row panels are shown in the three rows of rectangular panels below. Scale bars, 10 pm. (e), (g), (i), (k), and (m) Profiles of HA and V5 signal intensities along CytoTape, based on the experiment in (b). First row, HA intensity profile; second row, V5 intensity profile; third row, recovered V5 signal, calculated from the intensity profiles, plotted as a function of the fraction of the HA intensity line integral; fourth row, V5 signal relative to baseline (calculated as the ratio of V5 signal to the center V5 signal) plotted as a function of the fraction of the HA intensity line integral. In the first three rows, raw traces were normalized to their peaks to highlight relative changes before averaging. Data were from c-fos, n = 13 CytoTapes (13 neurons, two cultures); Egrl, n = 29 CytoTapes (29 neurons, two cultures); Arc, n = 26 CytoTapes (26 neurons, three cultures);Npas4, n = 14 CytoTapes (14 neurons, two culture); CREB, n = 11 CytoTapes (11 neurons, two cultures). Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary,s.d.; thin light lines, intensity profiles from all individual CytoTapes; thin magenta lines, three representative intensity profiles for each group, (n), (o), (p), (q) and (r) Top panel, V5 signal relative to baseline with different KC1 or FSK stimulations. Centerline, mean; shaded boundary, s.e.m. The sample size (n) is listed below as (X, Y, Z), which denotes n = X protein assemblies from Y neurons from Z cultures, (n) c-fos: “55 mM KC1, 3 h”, (13, 13, 2); “55 mM KC1, 1 h”, (8, 8, 2), “55 mM KC1, 30 min”, (26, 26, 4), “55 mM KC1, 10 min”, (20, 20, 3), “No Stim”: (13, 13, 2). (o) Egrl: “55 mM KC1, 3 h”, (29, 29, 2); “55 mM KC1, 1 h”, (14, 14, 3); “55 mM KC1, 30 min”, (23, 23, 2); “55 mM KC1, 10 min”, (8, 8, 2); “No Stim”, (12, 12, 2). (p) Arc: “30 mM KC1, 3 h”, (26, 26, 3); “55 mM KC1, 2 h”, (36, 36, 2); “55 mM KC1, 1 h”, (20, 20, 2); “55 mM KC1, 30 min”, (15, 15, 2); “55 mM KC1, 10 min”, (27, 27, 3); “No Stim”, (24, 24, 2). (q) Npas4 activity: “55 mM KC1, 3 h”, (14, 14, 2); “55 mM KC1, 2 h”, (11, 11, 2); “55 mM KC1, 1 h”, (10, 10, 2); “55 mM KC1, 30 min”, (10, 10, 2); “No Stim”, (11, 11, 2). (r) CREB activity: “25 pM FSK, 1 h”, (21, 21, 3); “20 pMFSK, 1 h”, (27, 27, 2); “15 pMFSK, 1 h”, (26, 26, 3); “10 pMFSK, 1 h”, (26, 26, 3); “5 pM FSK, 1 h”, (11, 11, 2); “No Stim”: (9, 9, 2). Bottom panel, box plots comparing (top panel) peak relative change in V5 signal. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant; Kruskal-Wallis analysis of variance followed by Dunn’s post hoc tests. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points. See FIG. 38 for details of statistical analysis.
[0018] FIG. 5 shows CytoTape enables multiplexed, weeks-long recording of gene regulation dynamics, (a) Schematic of the constructs transfected into cultured neurons, (b) the experimental timeline (top panel), and the expected dye distribution along the CytoTape (bottom panel).CytoTape-V5 refers to CytoTape fused to the V5 tag. (c) Images of neurons expressing the constructs shown in (a). Images were captured after fixation, Nissl staining, and immunostaining for V5 tag. Neurons were stimulated with 55 mM KC1 for 1 h on day 18 and day 20. First row, a composite image of all imaged channels showing the CytoTape in the cell; second row, the image in the timestamp channels; third row, the image in the c-fos signal channel. Scale bar, 10 pm. CytoTape shown in (c) extended into the initial segment of a neurite from the soma, (d) Top panel, c-fos signal (from (c)) relative change from baseline plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection. Bottom panel, statistical analysis of c-fos signal relative change from baseline plotted against recovered time after calcium phosphate transfection. Thick centerline, mean; darker boundary near thecenterline, s.e.rn.; lighter boundary, s.d.; thin gray lines, individual CytoTape data, (e) Statistical analysis of the peak amplitudes (left panel) and widths (full width at half maximum, FWHM) (right panel) between the sequential V5 signals, n.s., not significant; Wilcoxon signed-rank test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum, not indicated in the box plot; black dots, individual data points, (f) Schematic of the constructs transfected into cultured neurons, (g) the experimental timeline (top panel), and the expected dye distribution along the CytoTape (bottom panel). CytoTape-V5 and CytoTape-OLLAS refers to CytoTape fused to the V5 tag and the OLLAS tag, respectively, as signal monomers, (h) Images of neurons expressing the constructs shown in (f). Images were captured after fixation, Nissl staining, and immunostaining for V5 and OLLAS tags. Neurons were stimulated with 10 pM FSK for 1 h on day 6. First row, a composite image of all imaged channels showing the CytoTape in the cell; second row, the image in the timestamp channels; third row, the image in the c-fos signal channel; fourth row, the image in the Arc signal channel. Scale bar, 10 pm. (i) Top panel, c-fos and Arc signal (from (h)) relative change from baseline plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection. Bottom panel, statistical analysis of c-fos and Arc signals relative change from baseline plotted against recovered time after calcium phosphate transfection. Thick centerline, mean; darker boundary near the centerline, s.e.rn.; lighter boundary, s.d.; thin light lines, individual CytoTape data, (j) Statistical analysis of the onset time (left panel) and the time to peak (right panel) between the c-fos and Arc signals. ***, P < 0.001; n.s., not significant; Wilcoxon signed-rank test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points, (k) Schematic of the constructs transfected into HEK cells, (1) the experimental timeline (top panel), and the expected dye distribution along the CytoTape (bottom panel). CytoTape-HA refers to CytoTape fused to the HA tag, CytoTape-Etag refers to CytoTape fused to the Etag tag, CytoTape-OLLAS refers to CytoTape fused to the OLLAS tag, CytoTape-V5 refers to CytoTape fused to the V5 tag, and CytoTape-FLAG refers to CytoTape fused to the FLAG tag. (m) Images of a representative HEK cell expressing the constructs shown in (k). Images were captured after three rounds of processing: first, imaging of JF dyes and the HA tag followed by fixation and immunostaining for HA tag; second, photobleaching of JF dye signals followed by immunostaining for HA, Etag, OLLAS, V5, and FLAG tags (with the HA tag used for alignment of CytoTape between the tworounds of immunostaining); third, Nissl staining. HEK cells were stimulated with 50 pM FSK for 1 h on day 3. Left, first row, the CytoTape within the cell; left, second row, JF635dye; left, third row, JF503dye; left, fourth row, JF585dye; left, fifth row, merge of JF635, JF503, and JF585dyes. Right, first row, CREB signal; right, second row, c-fos signal; right, third row, Egrl signal; right, fourth row, Arc signal; right, fifth row, Npas4 signal. Scale bar, 10 pm. (n) HA (left, first row), OLLAS (right, first row), Etag (left, second row), V5 (right, second row), and FLAG (left, third row) signal relative change from baseline plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection. Right, third row, comparison of c-fos, Egrl, Arc, CREB activity, and Npas4 activity. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d.; thin gray lines, individual CytoTape data. See FIG. 38 for details of statistical analysis.
[0019] FIG. 6 shows CytoTape reveals nonlinear waveform correlations between CREB and Fos activities in single HEK cells, (a) Schematic of the constructs transfected into HEK cells, (b) the experimental timeline (top panel), and the expected JF dyes distribution along the CytoTape (bottom panel). 6xCRE-CMVMin promoter and F-RAM promoter were used to couple CREB activity and Fos activity, respectively, to the expression of CytoTape signal monomers, (c) Images of HEK cells expressing the constructs shown in (a). Images were captured after fixation, Nissl staining, and immunostaining for HA and OLLAS tags. HEK cells were stimulated with 50 pM FSK for 1 h at day 2.25 (6 h after day 2). Left panel, the CytoTape in the HEK cells. First row, timestamps; second row, CREB activity and Fos activity. Scale bar, 10 pm. (d) UMAP plot based on time-lagged correlations between CREB activity and Fos activity across single cells, (e) Heatmaps illustrate time lagged correlations between CREB and Fos signals for Type 1 (left panel, n = 35 CytoTapes from 35 HEK cells) and Type 2 (right panel, n = 42 CytoTapes from 42 HEK cells) HEK cells, x-axis represents a time-lagged shift window of ±0.4 days (1 / 10 of the entire recording duration) (both left and right panels), y-axis represents HEK cells, (f) Type 1 and (g) Type 2, single traces of CREB (left panel) and Fos (middle panel) signals relative change from baseline, plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection in two responsive types. Right panel, averaged curve of CREB and Fos signals relative change from baseline plotted against recovered time after calcium phosphate transfection. Thick centerline, mean; darker boundary near the centerline, s.e.m. (h) Quantification of the degree of baseline fluctuations in CREB and Fos signals prior tostimulation for Type 1 and Type 2 cells. The degree of baseline fluctuation is quantified by line length, which is calculated by summing the absolute differences between consecutive points, between day 1.5 and day 2.25. (i) Average post-stimulation signal of Fos in Type 1 and Type 2 cells. *, P < 0.05; **, P < 0.01; n.s., not significant; Mann-Whitney U test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points. See FIG. 38 for details of statistical analysis.
[0020] FIG. 7 shows protein assembly design screening and characterization in cultured neurons, (a) Atomic structures used in monomer designs. First row, five artificial scaffolds (artificial ticker tapes (ATTs); used in designs Al-1 to Al-5) generated by CPDiffusion for replacing 1POK(E239Y). The table shows the sequence identity (SI) and root mean square deviation (RMSD) between each pair of scaffolds. The CPDiffusion-generated structures share a similar conformation with 1POK(E239Y), but vary in the amino acid sequences. Second row, natural scaffold for replacing 1POK(E239Y) (used in designs A3-1 to A3-5). Third row, linker length optimization (used in designs B-l and C-4); fourth row, MBP homologs identified via BLAST search and their engineered variants. Note that the 2MBPs shown in the third row represent a direct fusion of two MBPs (366 AAs) (used in designs C-l to C-5). All the atomic structures are predicted by AlphaFold3. (b) Confocal images of cultured mouse hippocampal neurons expressing design variants fused to the HA tag, and after fixation on day 7, Nissl staining, and immunostaining against the HA tag. (c) Statistical analysis of protein assembly width for C-4 and B-l (left panel) and C6 and CytoTape (right panel). Left panel, A total of 31 fibers from B 1 and 29 fibers from C4 were analyzed. Right panel, A total of 20 fibers from Cl and 16 fibers from CytpTape were analyzed. *, P < 0.05; Mann-Whitney U test. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points. The constructs transfected into neurons are listed in FIG. 18. Scale bars, 10 pm.
[0021] FIG. 8 shows Analysis of iPAK4 and CytoTape formation in cultured neurons, HEK, and HeLa cells. Representative confocal images of (a) cultured mouse hippocampal neurons, as well as (b) HEK and HeLa cells expressing iPAK4 with iPAK4-HaloTag. Cells were labeled with JF585dye added to the culture, fixed at different time points, and subsequently stained with Nissl. Scale bars, 10 pm. (c) Left panel, the HSPAlA-promoter-driven expression experiment timeline. Middle panel, the constructs transfected into HeLa cells. Right panel, confocal image ofHeLa cell expressing CytoTape-based constructs, taken after fixation on day 4, Nissl staining and immunostaining against the HA tag and the V5 tag. Scale bar, 10 pm. The three rows of rectangular panels on the right are enlarged views of the regions marked by white rectangles in the left column of square panels. The growth kinetics of CytoTape in (d) HEK cell and (e) HeLa cell. 20 CytoTapes from two cell cultures were analyzed for length calculations. Shaded boundary, s.d. (f) Histogram of the number of CytoTapes located in the neuron soma, partially soma and partially extended to neurites, and neurites (n = 50 neurons from five cultures), (g) Histogram of the number of soma-localized CytoTapes per neuron (n = 47 neurons from four cultures). ‘> 95%’ with an arrow, > 95% of the neurons have CytoTape(s) rather than puncta. Histogram of the number of CytoTapes per (h) HEK cell or (i) HeLa cell (n = 69 HEK cells from six cultures, n = 40 HeLa cells from two cultures). ‘> 90%’ with an arrow, > 90% of the cells have CytoTape(s) rather than puncta.
[0022] FIG. 9 shows CytoTape encodes temporal information in HeLa cells, HEK cells, and cultured neurons, (a) Schematic of the constructs transfected into HeLa cells, (b) Top panel, time points of JF585and JF635addition and fixation. Bottom panel, expected dye distribution along the CytoTape. The JF585and JF635dyes were used for labeling time within the CytoTape. (c) A representative confocal image of CytoTapes with timestamps in HeLa cells, which is taken after fixation on day 4 and Nissl staining. The middle row and bottom row show the CytoTape with timestamps and fluorescence line profiles, respectively. Scale bar, 10 pm. (d) Top panel, statistical analysis of fluorescence line profiles from the experiments described in (b) n = 8 CytoTapes from 8 HeLa cells from two cultures Bottom panel, interpolation between the spatial axis along fiber and the time axis using the timestamps from top panel. Time axis recovery via B-spline curve fitting of timestamps and fixation point. Each raw trace was normalized to its peak to show relative changes before averaging. Thick centerline, mean; darker boundary in the close vicinity of the thick centerline, s.e.m.; lighter boundary, s.d.; lighter thin lines, data from individual CytoTapes. (e) and (g) Time points of dye addition and fixation and expected dye distribution along the CytoTape. (e) JF585and JF635and (g) JF585, JF635, and JF503were used for labeling time within the CytoTape. Images of timestamps with (f) two dye switches and (h) three dye switches. The middle and bottom rows show fluorescence line profiles and fitted curves, respectively. The details of the interpolation between the spatial axis along fiber and the time axis using timestamps are described in Methods, (i) Percentage of CytoTape fibers labeledwith all timestamps in cultured neurons, HEK, and HeLa cells (n = 40 CytoTapes from 40 neurons from five cultures; n = 50 CytoTapes from 50 HEK cells from three cultures; n = 30 CytoTapes from 30 HeLa cells from two cultures).
[0023] FIG. 10 shows Control experiments and cross-validation of transcriptional recorders for tracking gene regulation dynamics with CytoTape. (a) Schematic of the constructs transfected into neuron cultures and (b) the experimental timeline, (c) Expected HA tag and V5 tag distribution along the CytoTape. (d), (f), (h), (j), and (1) Representative images of cultured neurons expressing the constructs shown in (a). Images were captured after fixation, Nissl staining, and immunostaining for HA and V5 tags. Enlarged views of the CytoTape in the toprow panels are shown in the three rows of rectangular panels below. Scale bars, 10 pm. (e), (g), (i), (k), and (m) Profiles of HA and V5 signal intensities along CytoTape, based on the experiment in (b)). First row, HA intensity profile; second row, V5 intensity profile; third row, recovered V5 signal, calculated from the intensity profiles, plotted as a function of the fraction of the HA intensity line integral; fourth row, V5 signal relative to baseline (calculated as the ratio of V5 signal to the center V5 signal) plotted as a function of the fraction of the HA intensity line integral. In the first three rows, raw traces were normalized to their peaks to highlight relative changes before averaging. Data were from c-fos, n = 12 CytoTapes from 12 neurons from two cultures; Egrl, n = 13 CytoTapes from 13 neurons from two cultures; Arc, n = 24 CytoTapes from 24 neurons from three cultures; Npas4 activity, n = 11 CytoTapes from 11 neurons from two cultures; CREB activity, n = 9 CytoTapes from 9 neurons from two cultures. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d.; thin light lines, individual CytoTape data, (n) A confocal image of a neuron showing three fibers. The experimental conditions are the same as in (d). The right panel shows the V5 signal peak position plotted against the HA signal. Each gray sphere represents a neuron (n = 10). The dashed line represents x = y = z. Scale bar, 10 pm.
[0024] FIG. 11 shows time courses of Arc-promoter-driven expression and CREB activity in cultured neurons measured by timelapse imaging of GFP reporter, (a) Construct schematic of GFP driven under Arc-promoter and representative confocal images of live cultured mouse hippocampal neurons in the GFP channel 2-7 days (2d-7d) after plasmid transfection, without (upper row) and with (lower row) 55 mM KC1 stimulation for 1 hour on 4 d. All images were captured under the same imaging condition. Scale bar, 10 pm. (b) GFP fluorescence at soma(normalized by the average GFP fluorescence at soma over days 2-4) versus time (n = 10 neurons from 2 cultures for “No stim” group; n = 10 neurons from 2 cultures for “KC1 stim” group). Thick centerline, mean; lighter boundary, s.d.; thin light lines, individual data for stimulation group. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant; Mann-Whitney U test. See FIG. 38 for details of statistical analysis, (c) Construct schematic of GFP driven under CREB-promoter and representative confocal images of live cultured mouse hippocampal neurons in the GFP channel 2-7 days (2d-7d) after plasmid transfection, without (upper row) and with (lower row) 15 pM FSK stimulation for 1 hour on 4 d. All images were captured under the same imaging condition. Scale bar, 10 pm. (d) GFP fluorescence at soma (normalized by the average GFP fluorescence at soma over days 2-4) versus time (n = 10 neurons from 2 cultures for “No stim” group; n = 10 neurons from 2 cultures for “FSK stim” group). Thick centerline, mean; lighter boundary, s.d.; thin light lines, individual data for stimulation group. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant; Mann-Whitney U test. See FIG. 38 for details of statistical analysis.
[0025] FIG. 12 shows CytoTape enables waveform recording of c-fos-, Egrl-, and Arc-promoter-driven expression in cultured mouse hippocampal glial cells under chemical stimulation, (a), (c), and (e) Schematic of the constructs transfected into cultured mouse hippocampal glial cells. CytoTape-HA refers to CytoTape fused to the HA tag, and CytoTape-V5 refers to CytoTape fused to the V5 tag. (b), (d), and (f) Representative images of cultured mouse hippocampal glial cells expressing the constructs shown in (a), (c), and (e). Images were captured after fixation, Nissl staining, and immunostaining for HA and V5 tags. Glial cells were stimulated with 55 mM KC1 for 1 h and fixed on day 7. Enlarged views of the white-marked regions in the top-row panels are shown in the three rows of rectangular panels below. The bottom row shows the fluorescence line profiles of HA and V5 tags. Scale bars, 10 pm
[0026] FIG. 13 shows CytoTape enables recording of c-fos- and HSPAlA-promoter-driven expression histories in HEK cells, (a) Schematic of the constructs transfected into HEK cells, (b) Top panel, time points of JF585and JF635dyes addition and stimulation (10 pM FSK for 1 h). Bottom panel, expected dye distribution along the protein fiber. The JF585and JF635dyes were added to the HEK cell culture on day 0 and day 2, and fixation was performed on day 3. (c) Left panel, low magnification images of CytoTape in HEK cells, which is taken after fixation on day 3, and Nissl staining and immunostaining against the V5 tag. Scale bar, 100 pm. Right panel,enlarged confocal images of CytoTapes indicated in left panel. Arrows indicate the positions of dye switches within the protein fiber, (d) c-fos signal (from (c)) relative change from baseline plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection, (e) and (h) Schematic of the constructs transfected into HEK cells and the experimental timeline. The JF585and JF635dyes were added to the HEK cell culture on day 0 and day 2, and fixation was performed on day 3. (g) and (j) Images of HEK cells expressing the constructs shown in (e) and (h) after stimulation with FSK for 1 h at different time points (left panels) and without stimulation (right panels). Images were captured after fixation, Nissl staining, and immunostaining for V5 tag. Enlarged views of the CytoTape in the top-row panels are shown in the two rows of rectangular panels below. The second-row and third-row panels show the timestamps and activity-dependent-promoter-driven expression, respectively. The third-row panel shows statistical analysis of V5 signal relative change from baseline plotted against recovered time after calcium phosphate transfection. Stimulation group, data are from n = 10 CytoTapes for c-fos from 10 HEK cells from two cultures; n = 13 CytoTapes for HSPA1A from 13 HEK cells from two cultures. Control group, data are from n = 10 CytoTapes for c-fos from 10 HEK cells from two cultures; n = 10 CytoTapes for HSPA1A from 10 HEK cells from two cultures. The dashed gray lines indicate the timestamps, marking the points after which the recovered time is accurate. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d.; thin light lines, individual CytoTape data. Scale bars, 10 pm.
[0027] FIG. 14 shows CytoTape enables recording of c-fos-, Arc-, and Egrl-promoter driven expression and Npas4 activity in cultured neurons, (a), (f), (k), and (p) Schematic of the constructs transfected into cultured mouse hippocampal neurons and (b), (g), (1), and (q) the experimental timeline. The JF585and JF635dyes were added to neuron cultures on day 0 and day 5, respectively, and fixation was performed on day 7. Neurons were stimulated with 55 mM KC1 for 1 h on day 5 for c-fos, Arc, Egrl and day 6 for Npas4. CytoTape-HA refers to CytoTape fused to the HA tag and CytoTape-V5 refers to CytoTape fused to the V5 tag. (c), (h), (m), and (r) Images of cultured neurons expressing the constructs shown in (a), (f), (k), and (p) following stimulation with 55 mM KC1 for 1 h. Images were captured after fixation, Nissl staining, and immunostaining for HA and V5 tags. Enlarged views of the CytoTape in the top-row panels are shown in the two rows of rectangular panels below. The second-row and third-row panels show the timestamps and activity -dependent-promoter-driven gene expression, respectively. Scalebars, 10 pm. (e) c-fos, (j) Egrl, (o) Arc, and (t) Npas4 signal relative change from baseline plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection. The dashed gray lines indicate the timestamps, marking the points after which the recovered time is accurate
[0028] FIG. 15 shows pCREB and Fos exhibit complex expression kinetics following FSK stimulation, as revealed by protein immunostaining, (a) Averaged curve of pCREB and Fos signals relative change from baseline plotted against recovered time after calcium phosphate transfection. Thick centerline, mean; darker boundary near the centerline, s.e.m. Confocal images of pCREB and Fos protein immunostaining in cells fixed at (b) 1 hour and (c) 24 hours after a 1-hour stimulation with 50 pM FSK. pCREB and Fos intensities were quantified in 30 cells from 2 wells. Each dot represents a single HEK cell. Scale bar: 50 pm.
[0029] FIG. 16 shows CytoTape reveals nonlinear waveform correlations between Multiplexed recording and temporal analysis of Arc- and Egrl -promoter-driven expression histories in single neurons, (a) Schematic of the constructs transfected into cultured neurons, (b) the experimental timeline (top panel), and the expected dye distribution along the CytoTape (bottom panel), (c) Representative single traces of Arc and Egrl signals relative change from baseline, plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection in three responsive types under KC1 stimulation, (d) Averaged Arc and Egrl signals relative change from baseline plotted against recovered time after calcium phosphate transfection. Data are from n = 16 CytoTapes from 16 neurons from three cultures. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d.; thin light lines, individual CytoTape data, (e) Comparison of Arc (left panel) and Egrl (right panel) signals across three responsive cell types, (f) Representative single traces of Arc and Egrl signals relative change from baseline, plotted against recovered time (interpolated with timestamps and fixation time) after calcium phosphate transfection in three responsive types under FSK stimulation, (g) Averaged Arc and Egrl signals relative change from baseline plotted against recovered time after calcium phosphate transfection. Data are from n = 21 CytoTapes from 21 neurons from three cultures. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d.; thin light lines, individual CytoTape data, (h) Comparison of Arc (left panel) and Egrl (right panel) signals across three responsive cell types. Thick centerline, mean; darker boundary near the centerline, s.e.m.; lighter boundary, s.d. *, P < 0.05; **, P < 0.01; n.s.,not significant; Kruskal-Wallis analysis of variance followed by Dunn’s post hoc tests. See FIG.38 for details of statistical analysis
[0030] FIG. 17 shows temporal analysis of multiplexed recording of Arc- and Egrl -promoter-driven expression histories with CytoTape in cultured neurons, (a) Examples of single traces of Arc and Egrl signals under KC1 (left panel) and FSK stimulation (right panel) recorded in separate CytoTapes without multiplexing, (b) Scatter plots showing the time between stimulation point (day 17) and the first peak maximum amplitude point of Arc signal (left panel, only Type 1 and Type 2 data are shown as Type 3 has no peak), the rising slope of the Egrl signal (middle panel), and the falling slope of the Egrl signal (right panel) across three neuronal subtypes under KC1 stimulation. Data are from n = 16 CytoTapes from 16 neurons from three cultures, (c) Scatter plots showing the time between stimulation point (day 17) and the peak maximum amplitude point of Arc signal (left panel), the time between stimulation point (day 17) and peaks’ returning to baseline point for Arc signal (middle panel), and the peak maximum intensity of the Egrl signal (right panel) across three neuronal subtypes under FSK stimulation. Data are from n = 21 CytoTapes from 21 neurons from three cultures. Middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points. *, P < 0.05; **, P < 0.01; n.s., not significant; Kruskal-Wallis analysis of variance followed by Dunn’s post hoc tests. See FIG. 38 for details of statistical analysis
[0031] FIG. 18 shows the name and configuration of constructs of structural monomers tested in cultured neurons described herein.
[0032] FIG. 19 shows a comparison of XRI, iPAK4, and CytoTape in multiple cell types.
[0033] FIG. 20 shows the name and amino acid sequences of protein motifs described herein.
[0034] FIG. 21 shows the name and configuration of constructs of structural monomers tested in cultured neurons described herein.
[0035] FIG. 22 shows the configuration of constructs of single monomer tested in neurons described herein.
[0036] FIG. 23 shows the configuration of constructs of single monomer tested in HEK293 cells described herein.
[0037] FIG. 24 shows the configuration of constructs of single monomer tested in HeLa cells described herein.
[0038] FIG. 25 shows the configuration of constructs of timestamp monomer described herein, and includes a list of references cited in FIGS. 20-25.
[0039] FIG. 26 shows a schematic of structural monomer binding kinetics in XRI and CytoTape during long-term recording. Dark and light rectangles represent previously incorporated and newly expressed structural monomers, respectively.
[0040] FIG. 27 shows quantification of protein fiber width. The fiber was segmented and skeletonized using the algorithms described in Methods. The gray, tubular-shaped structure represents the fiber mask in 3D space, with the line in the center indicating the extracted skeleton. Dots mark representative points that are evenly distributed along the skeleton at intervals of 1.5 voxels. Di denotes the minimum distance from each skeleton point (dot) to the nearest boundary of the segmented fiber, illustrated by a dark arrowed line.
[0041] FIG. 28 shows confidence analysis of AlphaFold3-predicted models for CytoTape and XRI monomers. The dashed black rectangle highlights the interaction (amino acid structure) between the two domains. Lower panels represent the PAE heatmap of CytoTape monomer (left panel) and XRI monomer (right panel). The linker25, HA epitope tag, and linker3 are located at positions 391 to 427 in the XRI monomer. Overall iPTM of CytoTape monomer and XRI monomer is 0.7 and 0.55, respectively. All the panels are visualized by the AF3 online system.
[0042] FIG. 29 shows CytoTape does not alter cell morphology. CytoTape was expressed in neurons (left panel) and HEK cells (right panel) for 14 days and 3 days, respectively. CytoTape was visualized by HA tag immunostaining (bright), and CellMask staining (dark) was used to label cell morphology.
[0043] FIG. 30 shows a schematic of signal monomer binding kinetics of XRI and CytoTape during long-term recording. Inner and outer rectangles represent structural monomers and signal monomers, respectively.
[0044] FIG. 31 shows iPAK4 alters cell morphology, whereas CytoTape preserves it in HEK cells, (a) iPAK4 (cyan) and (b) CytoTape (cyan) were expressed for 3 days. Nissl and CellMask staining were used to label cell morphology. The right panel shows an enlarged view of the dashed rectangle in the left panel. iPAK4 was visualized using the JF585dye, and CytoTape was visualized using HA tag antibody immunostaining. Scale bar: 50 pm.
[0045] FIG. 32 shows scalable temporal labeling readout of CytoTape. (a) Schematic of the constructs transfected into HEK cells, (b) Time points of JF585and JF635addition and fixation.The JF585and JF635dyes were used for labeling time within the CytoTape. Images of CytoTape labeled with JF585and JF635in HEK cells, taken after fixation on day 3. The scale bar in (c) represents 500 pm, and the scale bars in (d-e) represent 50 pm. The objective lenses used for (c), (d), (e), and (f) were 4×, 10×, 20×, and 40×, respectively. Some fibers do not display clear timestamp transitions in these low-magnification images because the optimal image contrast for each color channel varies across individual cells.
[0046] FIG. 33 shows time encoding performance of XRI in HEK for 3 days and cultured neuron for 15 days. Left panel: JF585and JF635were added to HEK cultures on day 0 and day 2, respectively, and cells were fixed on day 3 after transfection. Scale bar: 50 pm. Right panel: JF585and JF635were added to neuronal cultures on day 5 and day 10, respectively, and cells were fixed on day 15 after transfection.
[0047] FIG. 34 shows a comparison of pCREB activity following forskolin stimulation recorded by live GFP imaging and CytoTape. (a) Schematic of the constructs transfected into HEK cells (left panel) and time points of stimulation (30 pM FSK for 1 h) (right panel), (b) Confocal images of live imaging of GFP driven by the pCREB promoter. Scale bar: 100 pm. (c) Schematic of the constructs transfected into HEK cells (left panel) and time points of JF585and JF635addition and fixation and stimulation (30 pM FSK for 1 h) (right panel). The JF585and JF635dyes were used for labeling time within the CytoTape. (d) Low magnification images of CytoTape in HEK cells, which is taken after fixation on day 3, and immunostaining against the V5 tag. The objective lenses used for the left panel, middle panel, and right panel were 10×, 20×, and 40×, respectively. Some fibers in these low-magnification images do not display clear timestamp transitions or pCREB signals because the optimal image contrast to visualize these fluorescence features in each color channel varies across individual cells. Scale bar: 50 pm.
[0048] FIG. 35 shows spontaneous Fos signals increase in GFP recording without stimulation. (a) Confocal images of live imaging of GFP driven by the F-RAM promoter. Scale bar: 100 pm. (b) Confocal images of Fos protein immunostaining in cells fixed at (a) 24 hours and (b) 48 hours after plasmid transfection. Scale bar: 50 pm.
[0049] FIG. 36 shows CytoTape captures dual pCREB stimulation undetectable by time-lapse GFP imaging under low dose forskolin treatments. 10 pM FSK was added to the culture at 50 and 62 hours after transfection, with each stimulation lasting 1 hour. GFP images were captured every 2 hours.
[0050] FIG. 37 shows confocal images of JF585and JF635before and after photobleaching. The same field of view was imaged under identical conditions before (left) and after (right) photobleaching by white LED light for 50 minutes. The image contrast is identical between the two images. Scale bar: 50 pm.
[0051] FIG. 38 shows no optical crosstalk was observed between the Alexa Fluor 546 dye in the 561 nm channel and the Alexa Fluor 594 dye in the 594 nm channel under the imaging conditions used. Two fields of view (left and right) were imaged under confocal microscopy. The imaging conditions and image contrast in each channel are identical between the two fields of view.
[0052] FIG. 39 shows statistical methods described and utilized herein, in particular those used for data presented in FIGS. Id, li, 2c, 4n-4r, 5, 6h, and 6i.
[0053] FIG. 40 provides a list of reagents and resources utilized for experiments conducted during development of embodiments of the disclosure.
[0054] FIG. 41 depicts the design, name and configuration of CytoTape-vivo constructs generated and tested in embodiments of the disclosure.
[0055] FIG. 42 shows the design of the GLOBE (sinGle-cell spatiotemporaL recording Brain-widE) recording system, (a) Schematic of the GLOBE system. Constitutively expressed structural monomers, activity -dependent signal monomers, and Dox-inducible timestamp monomers self-assemble into bidirectionally elongating intracellular protein fibers. Temporal patterns of cellular activation and Dox administration are encoded as spatially resolved signals along the fiber, (b) Experimental and computational pipeline for GLOBE recording: brain-wide AAV delivery, followed by recovery, an experimental paradigm, tissue fixation, sectioning, and immunostaining. Brain sections are scanned and registered to a reference brain atlas, followed by high-magnification confocal imaging, computational fiber segmentation, and readout of singlecell signals with spatial coordinates, to generate a brain-wide single-cell activity atlas.
[0056] FIG. 43 shows characterization and validation of the GLOBE recording system, (a, b) Construct schematics (a) and experimental timeline (b) for characterization of Dox-based timestamps via time-series brain sampling. AAVs were injected into hippocampus on Day 0; Dox was administered in drinking water during a defined ON period from approximately Day 10 to approximately Day 11, followed by withdrawal. Mice were perfused and brains were collected at indicated time points, (c) Expected Dox-dependent timestamp signal distribution along thefibers (left), and representative confocal images of single fibers stained for HA (cyan) and FLAG (magenta) from brain sections collected at indicated sampling time points (Day 10.5, 11, 11.5, 12, 13, 14, and 15, top to bottom), (d, e) Quantification of the fraction of fibers displaying a Dox-dependent signal during Dox-ON (d) and Dox-OFF (e) periods, as a function of brain sampling time. The median latency between Dox administration and the appearance of the Dox-ON timestamp on the fiber is approximately 17.8 hours, and the median latency between Dox removal and the appearance of the Dox-OFF timestamp on the fiber is approximately 20.9 hours; after global temporal alignment, the residual single-fiber latency errors are approximately ±6.2 hours and approximately ±12.2 hours, respectively, (f, g) Schematics of AAV constructs (f) and experimental design (g) for validation of activity-dependent recording using a Fos-driven GFP reporter. AAVs were injected into hippocampus on Day 0, contextual fear conditioning was performed on Day 10, and fixation was performed on Day 11, with immunostaining for HA (cyan) and V5 (magenta), (h) Schematic and representative images of neurons exhibiting weak versus strong Fos activation, as indicated by GFP fluorescence intensity. Fibers in weakly activated neurons display minimal V5 signal at fiber ends; fibers in strongly activated neurons display high V5 signal at both ends of the fiber, (i) Correlation between GLOBE-recorded Fos signal intensity at the fiber end and end-point Fos-GFP intensity in the same neuron. Each dot represents one neuron and the corresponding fiber, (j) Correlation between GLOBE-recorded Fos signal intensity at the fiber center and end-point Fos-GFP intensity in the same neurons; no comparable correlation is observed at the fiber center.
[0057] FIG. 44 shows brain-wide recording coverage of the GLOBE recording system, (a) Serial coronal sections showing the spatial distribution of XRI structural -monomer expression within a single mouse brain. Sections are arranged from anterior to posterior at approximately 0.18 mm intervals. The brain was sectioned coronally at approximately 30 pm thickness, with one section shown per six consecutive slices. Enlarged views and additional details are shown in FIG. 47. (b) Number of neurons successfully encoding Dox-based timestamps, grouped by major anatomical division, for a single mouse brain. A total of 219,703 neurons were recorded from one mouse, distributed across major anatomical divisions including, without limitation, isocortex, olfactory areas, cortical subplate, hippocampus, pallidum, striatum, thalamus, hypothalamus, and midbrain.
[0058] FIG. 45 shows brain-wide single-cell activity temporal modes revealed by GLOBE recording, (a) Schematic of the AAV constructs comprising the GLOBE recording system as exemplified herein, including: a structural monomer expression cassette (UbC promoter operably linked to XRI-HA); a timestamp monomer expression cassette (TRE promoter operably linked to XRI-FLAG); a transactivator expression cassette (hSyn promoter operably linked to rtTA3G); and a signal monomer expression cassette (Fos promoter operably linked to XRI-V5). (b) Experimental timeline of brain-wide AAV delivery on Day 0; contextual fear conditioning (CFC) on Day 10; recall on Day 14; and fixation on Day 15. The bottom timeline shows the doxycycline-in-drinking-water schedule, with doxycycline-OFF from Day 0 to Day 10, doxycycline-ON from approximately Day 10 to approximately Day 11, and doxycycline-OFF from approximately Day 11 to Day 15. (c) Heatmaps of per-cell GLOBE-fos signal changes along recovered time (Day 10 to Day 15) for cells classified into a plurality of non-limiting temporal modes, including, without limitation, no-response, inhibition, weak first peak, strong first peak, sustained response, dual peak, second peak, and complex modes. Within each temporal-mode sub-panel, cells are further partitioned by anatomical brain region, including, without limitation, cortical subplate (CTXsp), hippocampal formation (HPF), hypothalamus (HY), isocortex, olfactory areas (OLF), pallidum (PAL), striatum (STR), and thalamus (TH). Recovered activity is shown as a normalized GLOBE-fos signal change index, with values ranging from approximately -1.0 (suppression relative to baseline) to approximately +1.5 (elevation above baseline).
[0059] FIG. 46 shows brain-wide expression following intravenous AAV delivery, (a) Coronal section image showing XRI structural-monomer expression following intravenous retro-orbital delivery of AAV-PHP.eB-CAG-XRI-HA, with representative high-magnification images showing XRI fiber morphologies in selected brain regions, (b) Coronal section image showing XRI structural-monomer expression following intravenous retro-orbital delivery of AAV.CAP-B10-CAG-XRI-HA, with representative high-magnification images showing XRI fiber morphologies in selected brain regions. Scale bars, 20 pm.
[0060] FIG. 47 shows brain-wide expression of XRI by multi -site, multi-depth intracranial AAV9 injection. Coronal sections from a single mouse brain show widespread XRI expression across the brain. Sections are arranged from anterior to posterior at approximately 0.18 mm intervals. Anterior-posterior (AP) coordinates are indicated relative to bregma based on theAllen CCFv3 atlas. The brain was sectioned coronally at approximately 30 pm thickness, and one section is shown for every six consecutive slices. Scale bars, 1000 pm.[0611 FIG. 48 shows expression of XRI in selected brain regions following multi-site, multidepth intracranial AAV9 injection. Representative fluorescence images show XRI fiber expression across multiple brain regions, including, without limitation, striatum (ACB), thalamus (AV, CM), hippocampus (CA1sp), isocortex (PL2 / 3), and hypothalamus (LHA). Scale bars, 50 pm.
[0062] FIG. 49 shows validation of single-cell temporal encoding in multiple brain regions using a tamoxifen-inducible iCreERT2 paradigm, (a, b) Schematic of the AAV constructs (a) and experimental pipeline (b) for XRI structural monomer expression (XRI-HA), 4-OHT-inducible labeling of XRI-FLAG, and iCreERT2. AAVs were injected at multiple sites into the mouse brain on Day 0, followed by 4-OHT intraperitoneal injection on Day 10. (c) Representative coronal sections showing XRI expression across the brain, (d) Representative images showing 4-OHT -induced signals along XRI fibers in multiple brain regions, including prelimbic cortex (PL), primary somatosensory cortex (SSp), hippocampal (CAI), dentate gyrus (DG), dorsal peduncular cortex (DP), medial amygdala (MEA), paraventricular thalamus (PVT), and basolateral amygdala (BLA). Scale bars, 10 pm.
[0063] FIG. 50 shows subcellular localization of XRI fibers, (a) Schematic of AAV constructs (top) and experimental pipeline (bottom) for XRI structural monomer expression (XRI-HA), Dox-inducible labeling of XRI-FLAG under TRE, and rtTA3G expression. AAVs were injected into mouse hippocampus on Day 0, and Dox was administered to the mouse via drinking water from Day 10 to Day 11. (b) Confocal images of representative neurons exhibiting (i) both soma-localized cytosolic fibers and nucleus-localized fibers, (ii) soma-localized cytosolic fibers only, (iii) nucleus-localized fibers only, or (iv) no fibers. Scale bars, 5 pm. (c) Quantification of the percentage of neurons in each of the foregoing categories, (d) Quantification of the percentage of fibers displaying Dox-induced signal at both ends of the fiber, separately for soma-localized cytosolic fibers and nucleus-localized fibers.
[0064] FIG. 51 shows temporal characterization of Dox-dependent signals following Dox administration, (a, b) Representative confocal images of brain sections collected at Day 10.5 (a) and Day 11 (b) during the Dox-ON period. XRI fibers are stained for HA (cyan) and Dox-dependent FLAG signal (magenta), with Nissl stain shown in blue. Yellow boxes indicate regions of interest, with corresponding enlarged views shown on the right. Scale bars, 20 pm.[0651 FIG. 52 shows temporal characterization of Dox-dependent signals following Dox withdrawal, (a-e) Representative confocal images of brain sections collected at Day 11.5 (a), Day 12 (b), Day 13 (c), Day 14 (d), and Day 15 (e) during the Dox-OFF period. XRI fibers are stained for HA (cyan) and Dox-dependent FLAG signal (magenta), with nuclei counterstained in blue. Boxes indicate regions of interest, with corresponding enlarged views shown on the right. Insets display representative fibers illustrating progressive decay of Dox-dependent signals along the fiber axis over time. Scale bars, 20 pm.
[0066] FIG. 53 shows multiple temporally distinct timestamps resolved by expansion microscopy of GLOBE-recorded fibers, (a, b) Schematics of AAV constructs (a) and experimental design (b) with two Dox-ON periods separated by an intervening Dox-OFF interval. AAVs were delivered into hippocampus on Day 0, followed by alternating Dox-OFF and Dox-ON periods in drinking water at defined time periods, and fixation on Day 15. (c) Expansion microscopy images showing XRI fibers stained for HA (green) and Dox-dependent FLAG signal (magenta). Distinct, spatially separated bands corresponding to multiple Dox-ON / Dox-OFF switching events are resolved along individual fibers. Bottom panels are enlarged views of representative fibers from this field of view. Scale bars, 20 pm.
[0067] FIG. 54 shows validation of activity-dependent expression of an AAV-Fos-GFP reporter, (a) Schematic of AAV construct and experimental design. AAVs were delivered to hippocampus on Day 0, followed by contextual fear conditioning (CFC) or kainic acid (KA) intraperitoneal injection on Day 10 and fixation on Day 11. (b) Representative confocal images of hippocampal sections from mice under home cage, KA, and CFC conditions. Scale bars, 100 pm. (c) Quantification of the percentage of GFP -positive neurons among Nissl-positive cells across conditions (home cage, KA, and CFC). Each point represents one brain section. *P < 0.05; a two-sided Mann-Whitney U test was used.
[0068] FIG. 55 shows that the global manifold structure of brain-wide GLOBE recordings may be preserved across a plurality of temporal binning schemes.
[0069] FIG. 56 shows a table of GLOBE construct sequences for tUBC-XRI-HA (structural monomer), fos-XRI-V5-P1N4 (signal monomer), hSyn-TRE3G, and TRE-XRI-FLAG(timestamp monomer). Shading shows sequence promoter (light shade), coding region (dark shade), and 3’UTR regions (medium shade).[0701 FIG. 57 shows electrophysiological properties, synaptic transmission, and calcium dynamics of cultured neurons expressing CytoTape, demonstrating that CytoTape expression does not detectably alter cellular physiology of cultured neurons. Scatter plots of electrophysiological properties of cultured neurons with or without CytoTape expression are shown for (a) resting potential, (b) membrane capacitance, (c) membrane resistance, (d) holding current at -65 mV, and (e) action potential amplitude; middle line, median; error bar, interquartile range; black dots, individual data points; n = 9 neurons for the control group (expressing CAG-mEGFP for 8–11 days); n = 10 neurons for the CytoTape group (expressing UbC-CytoTape-P2A-mEGFP for 8–11 days). Scatter plots of synaptic transmission properties, including (f) EPSC amplitude and (g) EPSC inter-event interval, are shown for cultured neurons in the control (no gene delivery) and CytoTape (expressing GZ> C-CytoTape for 3-7 days) groups; middle line, mean; error bar, interquartile range; black dots, individual data points; (f) n = 8 neurons for the control group, n = 8 neurons for the CytoTape group; (g) n = 8 neurons for the control group, n = 7 neurons for the CytoTape group. Single traces of calcium dynamics of cultured neurons (h) with or (i) without CytoTape expression are shown. Scatter plots of calcium imaging-based network activity metrics in control (no gene delivery; n = 201 neurons from 9 fields of view from 3 cultures) and CytoTape (expressing UbC-CytoTape for 11 days; n = 163 neurons from 8 fields of view from 3 cultures) groups, including (j) amplitude of calcium spikes, (k) frequency of calcium spikes, (1) synchronous firing rate, and (m) coefficient of variation. Middle line, median; error bars, interquartile range; dots, individual neurons or fields of view. Throughout this figure: n.s., not significant; two-sided Mann–Whitney U test.
[0071] FIG. 58 shows that CytoTape expression does not alter cellular, physiological, transcriptional, or signaling markers in HEK cells, (a) Representative confocal images of HEK cells expressing CytoTape for 3 days, demonstrating that the majority of HEK cells express CytoTape fibers. HEK cells were stained either by antibodies against cellular or physiological markers (b-e), fluorescent chemical dyes (f, g), or antibodies against transcriptional and signaling activity markers (h l). Mean fluorescence intensities for panels (b, e, h l) were quantified in ImageJ as the averaged signal of the fluorescent secondary antibodies over imaged fields of view. Scale bars, 50 pm. (b— 1, top) Representative confocal images of HEK cellstransfected with pUC19 (Ctrl) or expressing CytoTape, stained with the indicated antibodies or imaged with the indicated fluorescent dyes together with DAPI; scale bars, 50 pm. (b-1, bottom) Scatter plots of the quantifications for each marker between control and CytoTape-expressing groups (n = 10 fields of view from 2 cultures); middle line, median; whiskers, 95% CI; black dots, individual data points; n.s., not significant; two-sided Mann-Whitney U test. The markers are: (b) cleaved Caspase-3 (apoptotic marker); (c) GRP78 / BiP (endoplasmic reticulum stress marker); (d) Ki-67 (cell proliferation marker); (e) TOMM20 (mitochondrial integrity marker); (f) ethidium homodimer- 1 (membrane permeability and DNA damage marker); (g) calcein-AM (live cell marker); (h) EGR1 (EGR1 expression marker); (i) pElk-1 (Elk-1 activity marker); (j) pCREB (CREB activity marker); (k) FOS (FOS expression marker); (1) pERKl / 2 (ERK activity marker).
[0072] FIG. 59 shows that CytoTape resolves CREB-FOS decoupling under MEK-ERK pathway perturbations in single HEK cells, demonstrating that ERK signaling is necessary but not sufficient for robust FOS induction in response to CREB activation, (a) Schematics of the constructs transfected into HEK cells, comprising C7> C-CytoTape, (7Z> C-CytoTape-HaloTag, pCREB-CytoTape-HA, and Fos-CytoTape-OLLAS. (b) Experimental timelines (left) and expected JF dye distributions along CytoTape (right) for the JF525, JF552, and JF635sequential dye-switching protocol with stimulation by 50 pM FSK + 10 pM U0126, 1 hour, or 50 pM FSK + 20 pM EGF, 1 hour, (c, d) Averaged curve of pCREB and FOS signal relative change from baseline plotted against recovered time under (c) 50 pM FSK + 10 pM U0126 and (d) 50 pM FSK + 20 pM EGF stimulation; thick centerline, mean; boundary, s.e.m. (e, f) Confocal images of pCREB and FOS protein immunostaining in cells fixed at 1 hour (left) and 24 hours (right) after the completion of a 1-hour stimulation with (e) 50 pM FSK + 10 pM U0126 stimulation and (f) 50 pM FSK + 20 pM EGF; scale bar, 50 pm. (g) UMAP plot of time-lagged correlations between pCREB and FOS signals across single cells under 50 pM FSK (n = 77 CytoTapes from 77 cells, 5 cultures), 50 pM FSK + 10 pM U0126 (n = 30 CytoTapes from 30 cells, 2 cultures), and 50 pM FSK + 20 pM EGF (n = 29 CytoTapes from 29 cells, 2 cultures), (h) Heatmaps showing time-lagged correlations between pCREB and FOS signals for decoupled (upper) and coupled (lower) HEK cells under 50 pM FSK (left), 50 pM FSK + 10 pM U0126 (middle), and 50 pM FSK + 20 pM EGF (right) stimulation; x-axis represents a time-lagged shift window of ±0.4 days; y-axis represents HEK cell numbers.
[0073] FIG. 60 shows CytoTape-vivo screening, characterization, and weeks-long recording across large neuron populations in vivo, (a) A confocal image of CytoTape fibers in dentate gyrus neurons of mouse brain 14 days after AAV injection; scale bar, 10 pm. (b) Fiber width of CytoTape, XRI, and CytoTape-vivo variants in the soma of dentate gyrus neurons in mouse brains 14 days after AAV injection; n = 312 CytoTape fibers, 358 XRI fibers, 364 CytoTape-vivo variant 1 (linker8) fibers, 374 CytoTape-vivo variant 2 (linker12) fibers, 460 CytoTape-vivovariant 3 (linker18) fibers, and 501 CytoTape-vivo fibers; each group is from one mouse; *, P < 0.05; ***, P < 0.001; Kruskal-Wallis analysis with Dunn's post-hoc tests; middle line, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points, (c) Histogram of the number of soma-localized CytoTape fibers per neuron; n = 156 dentate gyrus neurons from one mouse, (d) Histogram of the number of soma-localized CytoTape-vivo fibers per neuron; n = 173 dentate gyrus neurons from one mouse, (e, f) For the experiment described in 14-day recording (FIG. 63g— j): (e) Dox signals (left) and F s promoter signals (right) in the control group (first row, “Ctrl”; no Dox, no kainic acid; n = 718 dentate gyrus neurons from one mouse) and the experimental group (second row, “Exp”; Dox and kainic acid administered; n = 4,692 dentate gyrus neurons from one mouse); (f) recorded relative change in Dox signal monomer intensity from baseline in the experimental group (n = 4,692 neurons from one mouse), (g-i) For the experiment described in 18-day recording (FIG. 63k-m): (g) representative confocal images of CytoTape-vivo; (h) recorded relative change in Dox signal monomer intensity from baseline; (i) recorded Fos signal monomer intensity relative change from baseline (enlarged views of FIG. 631); n = 14,123 CA1 neurons from one mouse.
[0074] FIG. 61 shows immunohistochemical characterization of cellular and synaptic physiology markers in mouse brains expressing CytoTape-vivo, demonstrating that weeks-long expression of CytoTape-vivo in the mouse brain does not detectably alter cellular physiology and synaptic state markers in the hippocampus, (a) Representative confocal images of brain slices from adult mice expressing CytoTape-vivo in the hippocampus of the right cerebral hemisphere for 14 days following AAV injection; scale bars, 500 pm. (b-j, top) Representative confocal images of the hippocampus region in the non-injected hemisphere (Ctrl) and CytoTape-vivo-injected hemisphere (CytoTape-vivo) in the brain slices stained with antibodies against each of the cellular and synaptic markers indicated, and DAPI; scale bars, 50 pm. (b-j, bottom) Box plots of the quantifications for each of the cellular and synaptic markers between the non-injectedhemisphere (Ctrl) and CytoTape-vivo-injected hemisphere (CytoTape-vivo); for each marker in each hemisphere, n = 10 fields of view from 3 mice; middle line in box plot, median; box boundary, interquartile range; whiskers, minimum and maximum; black dots, individual data points; n.s., not significant; two-sided Wilcoxon signed-rank test. The markers are: (b) NeuN (a neuronal marker); (c) cleaved Caspase-3 (an apoptotic marker); (d) GFAP (an astrocyte marker); (e) Synaptophysin (a synaptic protein marker); (f) Ibal (a microglial marker); (g) γH2AX (a DNA damage marker); (h, i) Hsp70 and Hsp27 (cell physiological stress markers); (j) FOS protein (a cellular activity marker).
[0075] FIG. 62 shows behavioral characterizations of mice with and without CytoTape-vivo expression, under contextual fear conditioning, open field test, and novel object recognition, demonstrating that hippocampus-wide, weeks-long CytoTape-vivo expression in both hemispheres does not detectably alter hippocampal -dependent behavior in vivo. The behavioral assays disclosed in this figure are used herein as physiological -compatibility controls, not as recording paradigms, (a) Representative confocal images of brain slices from adult mice expressing CytoTape-vivo over weeks in the hippocampi of both the left and the right cerebral hemispheres following AAV injection; scale bars, 500 pm. (b) Experimental pipeline of contextual fear conditioning experiment for mice with or without CytoTape-vivo expression for 12 days, (c) Freezing rate during contextual fear recall (n = 8 mice per group); n.s., not significant; two-sided Mann-Whitney U test; middle line, median; whiskers, interquartile range; black dots, data from individual mice, (d, e) Representative movement traces of mice with or without CytoTape-vivo expression for 10 days in the open-field arena. Quantification of locomotor parameters, including (f) total travel distance, (g) mean speed, (h) time spent in the center, (i) distance traveled in the center, and (j) average speed in the center, comparing the control and CytoTape-vivo groups (n = 10 mice per group); n.s., not significant; two-sided Mann-Whitney U test; middle line, median; whiskers, interquartile range; black dots, data from individual mice, (k) Representative exploration heatmaps of mice with or without CytoTape-vivo expression for 17 days during the training (left) and testing (right) phases of the novel object recognition task; dashed outlines indicate predefined object zones. Quantification of novel object recognition performance, including (1) percentage of total exploration time during familiarization of object 1 (FO1) and object 2 (FO2); (m) percentage of exploration time for familiar (FO1) and novel (NO) objects during the test phase; and (n) discrimination index comparing between thecontrol and CytoTape-vivo groups (n = 10 mice per group). In (1), n.s., not significant, two-sided Wilcoxon signed-rank test. In (m), *, P < 0.05; **, P < 0.01; two-sided Wilcoxon signed-rank test. In (n), n.s., not significant, two-sided Mann-Whitney U test. Middle line in bar plots, median; whiskers, interquartile range; black dots, data from individual mice.
[0076] FIG. 63 shows that CytoTape-vivo simultaneously records doxycycline (Dox)-dependent and Fos signal monomer expression histories over weeks in single cells across multiple brain regions in vivo, (a) Schematic of the CytoTape-vivo system for multiplexed, scalable recording of cellular signals in living mouse brains, comprising a structural monomer (CytoTape-vivo-HA), a Dox-dependent monomer (XRI-FLAG), and a Fos-promoter signal monomer (CytoTape-V5). (b) Experimental pipeline for in vivo application (left); low-magnification coronal-view confocal images from a mouse brain expressing CytoTape-vivo (middle); and computational segmentation of neuronal soma and CytoTape-vivo fibers from high-magnification dentate gyrus volumes (right), (c) Experimental timeline for multiplexing in vivo: AAV delivery on day 0; concurrent administration of Dox-containing drinking water and intraperitoneal kainic acid (KA) injection on day 10; perfusion and brain fixation on day 11. (d) Low-magnification image of a representative brain slice (left; scale bar, 500 pm); a 3.2-pm-thick maximum-intensity projection in the dentate gyrus (DG) (middle; scale bars, 50 pm); and confocal images showing Fos-promoter-driven and Dox-dependent signal monomer expression in DG neurons (right). Both Dox-dependent (FLAG) signal monomers and / ’as-promoter-driven (V5) signal monomers were observed to accumulate at fiber termini, indicating successful simultaneous in vivo recording, (e) Dox and Fos-promoter signals in the posterior parietal cortex (left), hippocampal CAI (middle), and hippocampal DG (right); n = 605, 1,835, and 11,206 fibers from 600, 1,697, and 6,342 neurons, respectively, from one mouse, (f) Fos promoter signal amplitudes from panel (e); PPC, posterior parietal cortex; dentate gyrus neurons displayed higher Fos promoter signal amplitudes than CAI or posterior parietal cortex neurons, (g) Experimental timeline for 14-day Fos promoter signal recording in vivo: AAV delivery on day 0; Dox administered on day 10 concurrent with intraperitoneal kainic acid; Dox replaced with regular drinking water on day 12; perfusion and brain fixation on day 14. (h) Dox signal changes over 14 days in the DG in control (no Dox and no KA; n = 718 neurons from one mouse) and experimental (n = 4,692 neurons from one mouse) mice (left), where the center line indicates the mean and the shaded area denotes the interquartile range; Dox signal amplitude change in control and experimental mice(right), (i) Averaged Fos promoter signal changes in control and experimental mice from panel (h). (j) Recorded Fos promoter signal changes in DG neurons under a kainic acid-induced seizure in the experimental mice from panel (h); the dashed line indicates seizure induction, (k) Experimental timeline for 18-day Fos promoter signal recording in vivo: AAV delivery on day 0; Dox administered on day 10 concurrent with intraperitoneal kainic acid; Dox replaced with regular drinking water on day 13; perfusion and brain fixation on day 18. (1) Recorded Fos promoter signal intensity changes in CAI neurons under kainic acid-induced seizure (described in panel (k)); n = 14,123 neurons from one mouse; the dashed line indicates seizure induction, (m) Spatiotemporal mapping of Fos-promoter signals over weeks from the recording in panel (1); the red color intensity represents the Fos promoter signal intensity, spatially mapped across time. For the boxplots in panels (f, h, i), the middle line indicates the median, the box boundary shows the interquartile range, and the whiskers denote the 10th-90th percentile. Throughout this figure, ***, p < 0.001; Kruskal-Wallis analysis with Dunn's post-hoc tests.
[0077] These and other features, aspects, and advantages of the present disclosure will become better understood with regard to the following description and accompanying drawings.DETAILED DESCRIPTIONDefinitions
[0078] For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. In the event that any definition set forth below conflicts with any document incorporated herein by reference, the definition set forth below shall control.
[0079] As used herein the terms “disease” and “pathologic condition” are used interchangeably, unless indicated otherwise herein, to describe a deviation from the condition regarded as normal or average for members of a species or group (e.g., humans), and which is detrimental to an affected individual under conditions that are not inimical to the majority of individuals of that species or group. Such a deviation can manifest as a state, signs, and / or symptoms (e.g., diarrhea, nausea, fever, pain, blisters, boils, rash, immune suppression, inflammation, altered transcriptional states etc.) that are associated with any impairment of the normal state of a subject or of any of its organs or tissues that interrupts or modifies the performance of normal functions. A disease or pathological condition may be caused by orresult from contact with a microorganism (e.g., a pathogen or other infective agent (e.g., a virus or bacteria)), may be responsive to environmental factors (e.g., malnutrition, industrial hazards, and / or climate), may be responsive to an inherent or latent defect in the organism (e.g., genetic anomalies) or to combinations of these and other factors.
[0080] The term “solution” refers to an aqueous or non-aqueous mixture.
[0081] A “disorder” is any condition or disease that would benefit from the compositions, methods and / or systems of the disclosure. This includes chronic and acute disorders including those pathological conditions which predispose the mammal to the disorder in question. Nonlimiting examples of disorders to be treated herein include conditions such as cancer.
[0082] As used herein, the terms “cancer” and “tumor” refer to a cell that exhibits a loss of growth control or tissue of uncontrolled growth or proliferation of cells. Cancer and tumor cells generally are characterized by a loss of contact inhibition, may be invasive, and may display the ability to metastasize.
[0083] An “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result.
[0084] As used herein, the terms “purified” or “to purify” refer to the removal of contaminants or undesired compounds from a sample or composition. As used herein, the term “substantially purified” refers to the removal of from about 70 to 90%, up to 100%, of the contaminants or undesired compounds from a sample or composition.
[0085] As used herein, the terms “administration” and “administering” refer to the act of giving a composition of the present disclosure to a subject. Exemplary routes of administration to the subject include, but are not limited to injection (e.g., intravenously, subcutaneously, intraperitoneally, intratumorally, etc.).
[0086] As used herein, the terms “co-administration” and “co-administering” refer to the administration of at least two agent(s) in which one of those agents could be a therapeutic (e.g., CytoTape under a specific promoter of interest, and a therapeutic drug with the purpose of limiting expression of said promoter). In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent / therapy is administered prior to a second agent / therapy. In some embodiments, co-administration can be via the same or different route of administration. Those of skill in the art understand that the formulations and / or routes of administration of the various agents or therapies used may vary.
[0087] The terms “pharmaceutically acceptable” or “pharmacologically acceptable,” as used herein, refer to compositions that do not substantially produce adverse reactions (e.g., toxic, allergic or other immunologic reactions) when administered to a subject.
[0088] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers including, but not limited to, phosphate buffered saline solution, water, and various types of wetting agents (e.g., sodium lauryl sulfate), any and all solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic and absorption delaying agents, disintegrants (e.g., potato starch or sodium starch glycolate), polyethylene glycol, and the like. The compositions also can include stabilizers and preservatives. Examples of carriers, stabilizers and adjuvants have been described and are known in the art (see, e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. (1975), incorporated herein by reference).
[0089] As used herein, the term “kit” refers to any delivery system for delivering materials. In the context of CytoTape, such delivery systems include systems that allow for the storage, transport, or delivery of CytoTape components and / or supporting materials (e.g., written instructions for using the materials, etc.) from one location to another. For example, kits include one or more enclosures (e.g., boxes) containing the relevant CytoTape components (e.g., CytoTape). As used herein, the term “fragmented kit” refers to delivery systems comprising two or more separate containers that each contain a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain a composition comprising CytoTape for a particular measurement, while a second container contains a second form of CytoTape (e.g., a HaloTag labeled form of CytoTape). Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the term “fragmented kit.” In contrast, a “combined kit” refers to a delivery system containing all of the components of an immunogenic agent needed for a particular use in a single container (e.g., in a single box housing each of the desired components). The term “kit” includes both fragmented and combined kits.
[0090] As used herein, the term “gene transfer system” refers to any means of delivering a composition comprising a nucleic acid sequence to a cell or tissue. For example, gene transfer systems include, but are not limited to, vectors (e.g., retroviral, adenoviral, lentiviral, adeno-associated viral, and other nucleic acid-based delivery systems), microinjection of naked nucleicacid, polymer-based delivery systems (e.g., liposome-based and metallic particle-based systems), biolistic injection, and the like. As used herein, the term “viral gene transfer system” refers to gene transfer systems comprising viral elements (e.g., intact viruses, modified viruses and viral components such as nucleic acids or proteins) to facilitate delivery of one or more components of the disclosure to a desired cell or tissue. Non-limiting examples of viral gene transfer systems useful in the compositions and methods of the disclosure are lentiviral- and retroviral-gene transfer systems.
[0091] As used herein, the term “nucleic acid sequence” refers to any nucleic acid sequence containing one or more components of CytoTape for example including, but not limited to, DNA encoding 1POK carrying the E239Y mutation, along with one or more hydrophobic mutations, at least one detectable tag (referred to herein as an epitope tag), and a N-terminal truncated maltose binding protein.
[0092] The term “gene” refers to a nucleic acid (e.g., DNA) sequence encoded into an expression vector that comprises coding sequences necessary for the production of a polypeptide, for example, that encodes for the components of CytoTape. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g. self-assembling filaments) of the full-length gene product or fragment thereof are retained.
[0093] As used herein, the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.
[0094] As used herein, the terms “an oligonucleotide having a nucleotide sequence encoding a gene” and “polynucleotide having a nucleotide sequence encoding a gene,” means a nucleic acid sequence comprising the coding region of a gene or in other words the nucleic acid sequence that encodes a product (e g., CytoTape). The coding region may be present in a cDNA, genomic DNA or RNA form, and may be in an expression vector (e.g., introduced into a cell). When present in a DNA form, the oligonucleotide or polynucleotide may be single-stranded (i.e., the sense strand) or double-stranded. Suitable control elements such as enhancers / promoters, splice junctions, polyadenylation signals, etc. may be placed in close proximity to the codingregion the sequence (e.g., CytoTape) if needed to permit proper initiation of transcription and / or correct processing of the primary RNA transcript (e.g., for measurement of a gene transcript of interest). Alternatively, the coding region utilized in the expression vectors of the present disclosure may contain endogenous enhancers / promoters, splice junctions, intervening sequences, poly adenylation signals, etc. or a combination of both endogenous and exogenous control elements.
[0095] ‘Amino acid sequence” and terms such as “polypeptide” or “protein” are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.
[0096] “Percent "identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the percent "identity" can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared. For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. Alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra). An example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990).Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).[0971 “Sequence identity” refers to the degree two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) have the same sequential composition of monomer subunits. The term “sequence similarity” refers to the degree with which two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) have similar polymer sequences. For example, similar amino acids are those that share the same biophysical characteristics and can be grouped into the families, e.g., acidic (e.g., aspartate, glutamate), basic (e.g., lysine, arginine, histidine), non-polar (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan) and uncharged polar (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). The “percent sequence identity” (or “percent sequence similarity”) is calculated by: (1) comparing two optimally aligned sequences over a window of comparison (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window), (2) determining the number of positions containing identical (or similar) monomers (e.g., same amino acids occurs in both sequences, similar amino acid occurs in both sequences) to yield the number of matched positions, (3) dividing the number of matched positions by the total number of positions in the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window), and (4) multiplying the result by 100 to yield the percent sequence identity or percent sequence similarity. For example, if peptides A and B are both 20 amino acids in length and have identical amino acids at all but 1 position, then peptide A and peptide B have 95% sequence identity. If the amino acids at the non-identical position shared the same biophysical characteristics (e.g., both were acidic), then peptide A and peptide B would have 100% sequence similarity. As another example, if peptide C is 20 amino acids in length and peptide D is 15 amino acids in length, and 14 out of 15 amino acids in peptide D are identical to those of a portion of peptide C, then peptides C and D have 70% sequence identity, but peptide D has 93.3% sequence identity to an optimal comparison window of peptide C. For the purpose of calculating “percent sequence identity” (or “percent sequence similarity”) herein, any gaps in aligned sequences are treated as mismatches at that position.
[0098] The term “isolated” when used in relation to a nucleic acid, as in “an isolated oligonucleotide” or “isolated polynucleotide” refers to a nucleic acid sequence that is identified and separated from at least one component or contaminant with which it is ordinarily associatedin its natural source. Isolated nucleic acid is such present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids as nucleic acids such as DNA and RNA found in the state they exist in nature. For example, a given DNA sequence (e.g., a gene) is found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs that encode a multitude of proteins. However, isolated nucleic acid encoding a given protein includes, by way of example, such nucleic acid in cells ordinarily expressing the given protein where the nucleic acid is in a chromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid, oligonucleotide, or polynucleotide may be present in single-stranded or double-stranded form. When an isolated nucleic acid, oligonucleotide or polynucleotide is to be utilized to express a protein, the oligonucleotide or polynucleotide will contain at a minimum the sense or coding strand (i.e., the oligonucleotide or polynucleotide may be single-stranded), but may contain both the sense and anti-sense strands (i.e., the oligonucleotide or polynucleotide may be double-stranded).
[0099] As used herein, the term “purified” or “to purify” refers to the removal of components (e.g., contaminants) from a sample. For example, antibodies are purified by removal of contaminating non-immunoglobulin proteins; they are also purified by the removal of immunoglobulin that does not bind to the target molecule. The removal of non-immunoglobulin proteins and / or the removal of immunoglobulins that do not bind to the target molecule results in an increase in the percent of target-reactive immunoglobulins in the sample. In another example, recombinant polypeptides are expressed in bacterial host cells and the polypeptides are purified by the removal of host cell proteins; the percent of recombinant polypeptides is thereby increased in the sample.
[0100] As used herein, the term “GLOBE recording” refers to a method or system for single-cell, spatiotemporally resolved recording of cellular activity across the brain of a mammalian subject described herein, the system comprising, for example, in vivo delivery to the subject of a structural monomer, a signal monomer, and a timestamp monomer of a recording substrate as defined herein, application of one or more user-defined temporal references referred to as timestamps, optional behavioral, pharmacological, physiological, environmental, or pathological manipulation of the subject during a recording window, post-mortem fixation, immunostaining,multi-channel volumetric imaging, and computational extraction of per-cell signal traces aligned to an absolute time axis. The acronym GLOBE is used herein to refer to sinGle-cell spatiotemporaL recording Brain-widE. The term “GLOBE recording system” refers to the composition or kit of components used to perform GLOBE recording.
[0101] As used herein, the terms "filament," "fiber," "assembly," "chain," and "tape" — for example, as used in "intracellular protein filament," "intracellular protein fiber," "intracellular protein assembly," "intracellular protein chain," and "intracellular protein tape" — are used interchangeably to refer to a substantially linear, longitudinally elongating polymer of selfassembling protein monomers formed upon expression of one or more recording-substrate monomers in a mammalian cell (e.g., in the cytosol of a mammalian cell), including one or more of a structural monomer, a signal monomer, and a timestamp monomer. In some embodiments, the filament elongates bidirectionally from a central reference position. The term "selfassembling protein," when used to describe a recording-substrate monomer, refers to a protein monomer that, upon expression in a mammalian cell, polymerizes by non-covalent or covalent interactions to form an intracellular protein filament as defined herein, without the addition of an exogenous crosslinking, polymerizing, or template agent.
[0102] As used herein, the term “recording substrate” refers to a self-assembling protein monomer that, upon expression in a mammalian cell in vivo or in vitro, forms an intracellular linear self-assembling protein filament, and that, when co-expressed with a signal monomer or a timestamp monomer comprising the same or a related self-assembling protein monomer fused to a different epitope tag, accepts incorporation of the signal monomer or the timestamp monomer into the filament, such that the temporal pattern of expression of the signal monomer or the timestamp monomer is recorded as a corresponding spatial distribution of the signal -monomer or timestamp-monomer epitope tag along the filament. Non-limiting examples of a recording substrate include XRI, CytoTape, and CytoTape-vivo, as further described herein. The term “GLOBE-compatible substrate” refers to a recording substrate that satisfies each of the following functional criteria: (a) the substrate forms an intracellular linear self-assembling protein filament in the cytosol of mammalian neurons in vivo, (b) the substrate accepts incorporation of a signal monomer driven by an activity-dependent regulatory element; (c) the substrate accepts incorporation of a timestamp monomer driven by a small-molecule-inducible regulatory element;and (d) the substrate permits post-fixation immunofluorescence readout of epitope tags fused to the signal and timestamp monomers along the spatial axis of the filament.
[0103] As used herein, the term “structural monomer” refers to a recording-substrate monomer that is operably linked to a constitutive regulatory element and configured, upon expression, to self-assemble into an intracellular protein filament that elongates over time and forms a continuous molecular scaffold along which signal-monomer and timestamp-monomer incorporations may be deposited. In some embodiments, the structural monomer is fused to an epitope tag distinct from the epitope tags fused to the signal and timestamp monomers.
[0104] As used herein, the term “signal monomer” refers to a recording-substrate monomer that is operably linked to an activity-dependent regulatory element, such that the rate of expression and incorporation of the signal monomer along the assembled filament reflects the temporal pattern of activation of the activity -dependent regulatory element. Non-limiting examples of activity-dependent regulatory elements include a c-fos promoter, an Arc promoter (including SARE-ArcMin and N-RAM promoters), an Egrl promoter (also known as a Zrf268 promoter), an Npas4 promoter, a CREB -responsive promoter (including a 6*CRE-CMVMin promoter), an HSPA1A promoter, an F-RAM promoter, and combinations of any of the foregoing. In some embodiments, the signal monomer is fused to an epitope tag distinct from the epitope tags fused to the structural and timestamp monomers.
[0105] As used herein, the term “timestamp monomer” refers to a recording-substrate monomer that is operably linked to an inducible regulatory element, including, without limitation, a tetracycline-responsive promoter (for example, TRE or TRE3G) operating in combination with a tetracycline-controlled transactivator (for example, rtTA or rtTA3G), such that expression, incorporation, or detection of the timestamp monomer along the assembled filament is controlled by administration of a corresponding inducing agent (including, without limitation, a tetracycline-class antibiotic such as doxycycline). The term “timestamp” refers to a spatially localized signal band deposited along the filament as a consequence of an induction event (a “timestamp-ON” event) or the cessation of an induction event (a “timestamp-OFF” event). In some embodiments, the timestamp monomer is fused to an epitope tag distinct from the epitope tags fused to the structural and signal monomers.
[0106] As used herein, the term “CytoTape” refers to a recording substrate comprising a 1POK-derived self-assembling protein monomer comprising at least an E239Y substitution and anL349K substitution, fused to a maltose binding protein (MBP)-derived insulator domain, as further described herein, suitable for in vitro recording applications.
[0107] As used herein, the terms “CytoTape-vivo” and “BrainTape” are used interchangeably to refer to a recording substrate optimized for in vivo recording in mammalian brain tissue, as further described herein.
[0108] As used herein, the term “GLOBE Tape Reader” refers to an artificial-intelligence-powered, parallel-computing-accelerated computational pipeline described herein, for example, for high-throughput automated segmentation, skeletonization, signal extraction, and readout of protein filaments along with cell morphology from multi-channel volumetric microscopy images of mammalian brain tissue, as further described herein. The term encompasses any computational pipeline performing the recited steps regardless of the specific software implementation.
[0109] As used herein, the term “timestamp” refers to a spatially localized signal band deposited along an intracellular protein filament as defined herein, as a consequence of (a) an induction event, in which case the timestamp is referred to as a “timestamp-on” timestamp, or (b) the cessation of an induction event, in which case the timestamp is referred to as a “timestamp-off’ timestamp. The term may additionally refer to the corresponding real-world time point inferred from the spatial position of such a band along the filament, optionally corrected for empirically determined latency between the external induction transition and the corresponding spatial feature.
[0110] As used herein, the term “common anatomical coordinate framework” refers to a three-dimensional reference brain atlas to which the spatial coordinates of cells, tissues, or anatomical features may be registered, providing a common spatial reference frame for cross-subject or cross-experiment comparison. Non-limiting examples of common anatomical coordinate frameworks include the Allen Mouse Brain Common Coordinate Framework version 3 (Allen CCFv3), and other species-specific or species-agnostic three-dimensional brain atlases known in the art.
[0111] As used herein, the term “mammalian subject” refers to a member of any species of mammal, including, without limitation, a human, a non-human primate, a mouse, a rat, a rabbit, a guinea pig, a hamster, a ferret, a cat, a dog, a pig, a sheep, a goat, a horse, or a cow. In some embodiments of methods of GLOBE recording disclosed herein, the mammalian subject is anon-human mammal. The terms “mammalian subject” and “subject,” when used in connection with GLOBE recording, may be used interchangeably.
[0112] As used herein, “brain-wide” refers to recording from multiple anatomically distinct brain regions and does not require recording from every cell, every section, or every anatomical subdivision of a brain. “Local recording density” refers to the fraction of cells in an imaged or recorded region that contain analyzable fibers with timestamp information.
[0113] As used herein, “Dox-ON timestamp” and “Dox-OFF timestamp” refer to spatial features along a protein fiber corresponding to the onset of a doxycycline-dependent timestamp signal rise and the onset of a doxycycline-dependent timestamp signal decay, respectively, optionally corrected for empirically determined latency between an external Dox transition and a corresponding fiber-encoded feature.
[0114] As used herein, “activity manifold” or “memory manifold” refers to a low-dimensional representation of time-resolved activity traces from a plurality of cells, generated using dimensionality reduction, clustering, manifold learning, or another computational analysis. Such terminology is used for convenience and does not require any particular algorithm or final classification scheme unless expressly recited.
[0115] The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
[0116] The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and / or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and / or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0117] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or“and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of’ or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0118] The term “about” as used herein means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to ± 20 %, preferably up to ± 10 %, more preferably up to ± 5 %, and more preferably still up to ± 1 % of a given value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” is implicit and in this context means within an acceptable error range for the particular value.
[0119] Compositions, methods, and practice of the present disclosure employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press; T. E. Creighton, Proteins: Structures and Molecular Properties (W. H. Freeman and Company, 1993);Oligonucleotide Synthesis (M. J. Gait, ed. 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J. E. Cellis, ed., 1989) Academic Press; Animal Cell Culture (R. I. Freshney, ed. 1987); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.);Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds. 1993-8) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds.): Gene TransferVectors for Mammalian Cells (J. M. Miller and M. P. Calos, eds., 1987); Current Protocols in Molecular Biology (F. M. Ausubel, et al. eds. 1987); PCR: The Polymerase Chain Reaction, (Mullis, et al., eds. 1994); Current Protocols in Immunology (J. E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practice approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds. Harwood Academic Publishers, 1995); DNA Cloning: A practical Approach, Volumes I and II (D. N. Glover ed. 1985); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds.(1985»; Transcription and Translation (B. D. Hames & S. J. Higgins, eds. (1984»; Animal Cell Culture (R. I. Freshney, ed. (1986»; Immobilized Cells and Enzymes (IRL Press, (1986»; and B. Perbal, A practical Guide To Molecular Cloning (1984); F. M. Ausubel et al. (eds.).
[0120] The disclosure allows for the simultaneous recording of various cellular physiological information using steadily growing protein chains made from self-assembling proteins that are entirely genetically encoded. The data embedded in these self-assembling proteins can be retrieved via routine immunofluorescence and imaging techniques. The composition of the disclosure includes human-created self-assembling proteins that have been optimized to enable thinner, more flexible assemblies. This design enhances the ability for long-term growth and data recording over a longer duration of time as well as new cell-types such as mitotic cells. The composition of the disclosure comprises one or more optimized self-assembling protein candidates, one or more optimized protein spacers, and one or more detectable tags. When this composition is expressed within a cell, the cell generates a protein complex that can grow in a stable and ordered manner over an extended period. The embodiments of the composition of the disclosure encompass a sequencing encoding CtyoTape.
[0121] It has now been determined that using 1POK, a human engineered fdament forming protein, with mutation E239Y and modifications to hydrophobic residues, N-terminus truncation of Maltose Binding Protein (MBP), removal of a linker domain, and placement of an epitope tag on the C-terminus of CtyoTape creates a thin, flexible filament. This filament grows longitudinally and maintains a specific thickness over a long duration of time, allowing for improved long-term cell visualization that can capture gene expression time course with single-cell precision, across a multitude of cell populations. As CtyoTape grows continuously over time, the disclosure acts as a molecular tape recorder that can preserve temporal information of the cell and capture cell-specific states and changes. For example, one version of CtyoTape might have an epitope tag ‘A’ along with a HaloTag that is consistently expressed, while a second version could feature an epitope tag ‘B’ with a HaloTag under a promoter dependent on serotonin levels. If a drug believed to increase serotonin levels is introduced to the cell, over two months, the growing protein filament will document the intracellular changes. At the end of this two-month period, changes in the expression of the serotonin-dependent promoter can be analyzed through immunostaining against the tags and imaging the cells. This data can then be used to evaluate the effectiveness of the drug in modulating serotonin levels.
[0122] Information disclosed herein defines, provides rationale for, and validates, a calibratable measure of time that makes use of the fractional cumulative expression of detectable tag bearing monomers, to calibrate the time axis onto the information recorded on CtyoTape via ordered epitope tags. A non-limiting example of an embodiment of a method of the disclosure, comprises application of CytoTape to record six different promoter-driven gene expressions in cultured mouse hippocampal neurons following depolarization. This application utilizes six distinct epitope tags, along with a HaloTag to create timestamps. This enables the recovery of the time axis and allows for the calculation of the fractional cumulative expression of the six epitope tags from the information read out from CytoTape via immunostaining and imaging. Studies disclosed herein provide evidence that CtyoTape can preserve the temporal order of protein monomers expressed in a living cell, including but not limited to a cell in culture, a cell in a live subject, for example a cell in the brain of a live subject. Thus, CytoTape is capable of functioning in multiple biological systems, including the cells in culture and cells in a live subject, cells in a live mammalian brain, and methods of the disclosure can use CytoTape to encode cellular physiological signals into a linear, optically readable protein chain.
[0123] Compared to nucleic acid-based systems, which require nucleic acid sequencing methods that are destructive to cells (Kording, K. P. PLOS Comput. Biol. 7, e!002291 15 (2011); Perli, S. D., et al., Science 2016 Sep 9;353(6304):aag0511, doi: 10.1126 / science.aag0511, Epub 2016 Aug 18 (2016); Rodriques, S. G. et al. Nat. Biotechnol. 2020393 39, 320-325 (2020);Farzadfard, F. & Lu, T. K. Science 2014 Nov 14; 346(6211): 1256272; Farzadfard, F. & Lu, T. K. Science. 361, 870-875 (2018); Farzadfard, F. et al. Mol. Cell 75, 769-780.e4 (2019); Sheth,R. U., et al., Science 358, 1457-1461 (2017)), the reading of recorded information using the compositions and methods of this disclosure only requires standard immunofluorescence techniques and conventional microscopes that are widely available in the art, foregoing the need for additional hardware investments. Additionally, the preservation of cellular physiological information within the native environment offered by the protein-based compositions and methods of the disclosure also enable correlation of the recorded biological information with other kinds of structural and molecular information associated with the cellular population, such as the spatial location, cell type, and presence of RNA / protein markers in the recorded cells (Lin, D. et al. Nature 470, 221 (2011); Ceccatelli, S, et al., Proc. Natl. Acad. Sci. U. S. A. 86, 9569-9573 (1989); Guenthner, C. J., et al., Neuron 78, 773-784 (2013), the content of each of which is incorporated by reference herein in its entirety), some of which may be causally involved with the creation of the physiological signals, or that result from the physiological signals. Such multimodal data can enhance the analysis of how specific cellular mechanisms drive physiological stimuli over complex time courses. For instance, the protein-based CytoTape compositions and methods enable the recording of gene expression time courses in individual cells, allowing for investigations into gene expression changes resulting from specific cellular inputs or drug treatments. (Strober, B. J. et al. Science 364, 1287-1290 (2019); Gallo, F. T., et al., Front. Behav. Neurosci. Vol, 12, Article 79 (2018) doi.org / 10.3389 / fnbeh.2018.00079, the content of each of which is incorporated by reference herein in its entirety). Non-limiting examples of the use of compositions and methods of the disclosure, include their use to investigate circadian genes (Zhang, R., et al, Proc. Natl. Acad. Sci. Ill, 16219-16224 (2014), the content of which is incorporated by reference herein in its entirety) and other genes that change in complex ways over time; to record transcription factor activities (Elf, J., et al, Science 316, 1191 (2007), the content of which is incorporated by reference herein in its entirety); and as an information storage platform to externally introduce unique cellular barcodes into single cells for cell identification (Viswanathan, S. et al. Nat. Methods 12, 568-576 (2015), the content of which is incorporated by reference herein in its entirety).
[0124] Composition and Components
[0125] Certain embodiments of the composition of the disclosure comprise a nucleic acid sequence that encodes CytoTape. This composition includes a nucleic acid sequence that encodes at least one 1POK carrying the E239Y mutation, along with one or more hydrophobicmutations, at least one detectable tag (referred to herein as an epitope tag), and a N-terminal truncated maltose binding protein. In some embodiments, the composition may include a sequence that encodes zero, one, or more independently selected detectable tags. The term "independently selected" refers to the selection of each tag independently of the others. For example, in a composition that includes three independently selected epitope tags, these tags are considered "like components," each of which can be selected without regard to the others. This means that in different embodiments, the three encoded tags may be all the same, all different, or a combination where two are the same and one is different.
[0126] Additionally, some embodiments of the composition may include an expressed CytoTape protein. The components of an expressed CytoTape consist of one 1POK protein with the E239Y mutation, zero, one, two or more hydrophobic mutations, zero or more independently selected detectable tags, and a N-terminal truncated maltose binding protein. A non-limiting example of a detectable tag that may be present in certain embodiments is a human influenza hemagglutinin (HA) tag.
[0127] Expression and Use of CytoTape Components
[0128] Certain embodiments of the disclosure include compositions and methods that utilize CytoTape components for recording the physiological histories of living cells. The term CytoTape refers to a specific embodiment in which CytoTape is expressed within a living cell, allowing the determination of the cell's expression history. In certain aspects of the disclosure, CytoTape is used in a cell to determine characteristics such as but not limited to the timing of protein expression and the effect of stimuli on expression in the cell. In various aspects of the disclosure, CytoTape is employed to analyze characteristics such as the timing of protein expression and how different stimuli affect this expression within the cell. One approach includes performing baseline determinations of one or more expression characteristics in a "control" cell using the methods and / or systems described in this disclosure. These baseline determinations can be conducted for the same characteristics being analyzed in similar cells under different conditions. For example, the baseline determination may establish what is considered a "control" characteristic. This control can then be compared to a "test" cell that has been exposed to one or more different stimuli or environmental changes that the control cell was not subjected to. A test cell containing CytoTape can be treated with a candidate stimulus, allowing researchers to compare changes in one or more characteristics in the test cell againstthose in the control cell that was not exposed to the stimulus. Non-limiting examples of candidate stimuli are: electrical stimulus, a chemical stimulus, a biological stimulus, an inhibitory stimulus, an excitatory stimulus, a signaling molecule, a signaling chemical, a pharmaceutical stimulus, a cellular stimulus, a temperature stimulus, a light stimulus, a candidate compound, a pharmaceutical compound, an electrical stimulus, a chemical stimulus, a biological stimulus. Additional stimuli that are suitable for use in embodiments of the disclosure are known and routinely used in the art.
[0129] In certain aspects of the disclosure, a candidate stimulus may be delivered directly to a cell containing CytoTape, or it may be delivered to another cell that is in communication with a cell containing CytoTape. The term "in communication with," when referring to a cell that expresses or encodes CytoTape, includes cells that influence the cell containing CytoTape. This influence can occur through various means. For example, though not intended to be limiting, via a neurotransmitter means, an electrical means, etc. Communication can be direct communication from a cell immediately (directly) upstream from the cell that includes an expressed or encoded CytoTape or can be indirect communication, such as the result of activity of a cell further (indirectly) upstream that impacts the cell in which an expressed or encoded CytoTape.Stimulation of one or more cell directly upstream and a cell indirectly upstream may result in a change in expression in a cell that includes CytoTape, and the presence of the expressed and / or encoded CytoTape permits determination of changes in characteristics of expression in that cell using methods of the disclosure. As used herein a change in expression means any alteration in expression characteristics, such as an increase or decrease in the rate or timing of expression, the initiation of expression, or a delay in the start of expression, among other possibilities.
[0130] In some embodiments, the candidate stimulus delivered to a cell containing CytoTape comprises a depolarization stimulus, including, without limitation, a high-potassium-buffer (KC1) depolarization at a final extracellular K+concentration of from approximately 5 mM to approximately 100 mM, from approximately 20 mM to approximately 70 mM, or approximately 30 mM or approximately 55 mM, applied for a duration of from approximately 1 minute to approximately 24 hours, or from approximately 10 minutes to approximately 3 hours. In further embodiments, the candidate stimulus comprises a cAMP -pathway-activating stimulus, including, without limitation, forskolin at a final concentration of from approximately 0.1 pM to approximately 100 pM, from approximately 1 pM to approximately 50 pM, or approximately 5μM, approximately 10 μM, approximately 20 μM, or approximately 25 μM, applied for a duration of from approximately 1 minute to approximately 24 hours. The foregoing parameters are exemplary and should not be construed as limiting.
[0131] The methods and CytoTape systems described in this disclosure can be used to assess changes in various environments related to cells. Specifically, these changes can occur in: (1) the internal environment of a cell, (2) the external environment of a cell, (3) the internal environment of a neighboring cell, (4) the external environment of a neighboring cell, (5) the internal environment of an upstream cell, (6) the external environment of an upstream cell, (7) the internal environment of a mitotic cell, and (8) the external environment of a mitotic cell. Nonlimiting examples of events and situations that may affect the internal or external environment of a cell, and consequently influence expression in a cell containing an expressed CytoTape system, include the following: an action potential, a disease or injury condition affecting the cell or the subject containing the cell, contact with a candidate stimulus agent or compound, exposure to a pharmaceutical agent or compound, a surgical procedure, and contact with radiation, light, or electrical stimulation. Other types of events and actions that alter the internal or external environment of a cell are known in the art, and can also be assessed using methods of CytoTape.
[0132] Components of CytoTape system are well suited for targeting cells, expression in cells, and for use to detect and assess expression levels and changes associated with stimuli and / or cell activities. In some embodiments, an expressed and / or encoded CytoTape system can be utilized to detect one or more conductance changes across cell membranes, the impact of endogenous signaling pathways (such as calcium dependent signaling, etc.), and the effect of applied candidate stimuli on a cell that includes the expressed CytoTape system. Therefore, certain aspects of this disclosure include methods for using CytoTape to screen potential therapeutic agents, known therapeutic agents, or combinations of two or more independently selected known and potential therapeutic agents. For example, CytoTape could be employed in a cancer screening process to evaluate new therapeutics. It can be expressed in a cancer cell line under a promoter that is upregulated in cancerous cells. The rate of cell division can then be assessed by analyzing the length of the CytoTape in newly divided cells. After introducing a therapeutic agent, researchers can measure changes in CytoTape expression to draw conclusions about the therapeutic's effectiveness and better hypothesize about the mechanism of action in restoring normal cell division rates.
[0133] In certain aspects of the disclosure, a component of the CytoTape system is non-toxic or at least substantially non-toxic to the cells into which it is delivered or expressed. In some embodiments, a component of CytoTape is genetically introduced into a cell, and methods and reagents are provided for genetically targeted expression of these components. Genetic targeting allows for the delivery of one or more CytoTape components to specific cell types, particular cell subtypes, or distinct spatial regions within an organism. Additionally, the targeting can control both the quantity of CytoTape expressed and the timing of its expression. Routine methods can be employed alongside the teachings provided here to express one or more components of the CytoTape system, along with any additional polypeptides, in a desired cell, tissue, or region, either in vitro or within a living subject.
[0134] CytoTape-vivo for in vivo recording in mammalian brain tissue.
[0135] In some embodiments, the present disclosure provides a recording substrate optimized for in vivo recording in mammalian brain tissue, referred to herein as CytoTape-vivo. In some embodiments, CytoTape-vivo comprises a 1POK-derived self-assembling protein monomer comprising at least an E239Y substitution and an L349K substitution, fused to an N-terminally truncated maltose binding protein (MBP)-derived insulator domain through a linker, and further fused to a detectable tag (including, without limitation, an epitope tag such as HA). In some embodiments, the linker comprises from 2 to 25 amino acids; from 4 to 18 amino acids; or 2, 6, 10, 12, or 18 amino acids. In one non-limiting embodiment, the linker comprises 6 amino acids and yields filaments that are substantially thinner than filaments formed by XRI under comparable expression conditions, and that form approximately one to two filaments per neuronal soma in mammalian brain tissue, enabling accurate imaging and quantification using conventional microscopy without a requirement for super-resolution or expansion microscopy. In further embodiments, CytoTape-vivo permits multiplexed in vivo recording of two or more cellular activities in the same neuron, including, without limitation, simultaneous recording of an immediate-early-gene transcriptional event (for example, c-fos promoter activation) and an inducer-driven temporal reference (for example, doxycycline-induced TRE-driven expression), as further described in Example 2.
[0136] In some embodiments, the methods of the present disclosure provide for integration of asynchronous transcriptional responses onto a single intracellular protein filament in a live cellor living mammalian brain, such that two or more transcriptional events occurring at temporally distinct time points are recorded as spatially separated segments along the same filament.
[0137] Vectors, Plasmids, and Molecules
[0138] Some embodiments of the disclosure involve a reagent designed for genetically targeted expression of a component of CytoTape. This reagent consists of a vector that contains the gene for the component. In this context, the term "vector" refers to a nucleic acid molecule that can transport another nucleic acid, to which it is operatively linked, between different genetic environments. The term "vector" may also encompass a virus or organism capable of moving the nucleic acid molecule. One type of vector is an episome, i.e., a nucleic acid molecule capable of extra-chromosomal replication. Some useful vectors are those capable of autonomous replication and / or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors." Other useful vectors, include, but are not limited to viruses such as lentiviruses, retroviruses, bovine papillomavirus type 1 (BPV-1), adenoviruses, and phages. Vectors utilized in some methods of the disclosure can insert CytoTape into both dividing and non-dividing cells, and they can be employed for in vivo, in vitro, or ex vivo applications.
[0139] Vectors that are useful in the methods described in this disclosure may include additional sequences, such as one or more signal sequences, promoter sequences, or a combination of both. Expression vectors and their applications are well established in the art. The Examples provides several non-limiting examples of suitable expression vectors and methods for their use. In certain embodiments of the disclosure, a vector may be a lentivirus that includes the gene for CytoTape. A lentivirus serves as a non-limiting example of a vector that can be utilized to create a stable cell line. The term "cell line," as used herein, refers to an established cell culture that will continue to proliferate when provided with the appropriate growth medium.
[0140] Promoters that can be utilized in the methods and vectors of the disclosure include, but are not limited to, cell-specific promoters and general promoters. The selection and application of these promoters are well-established in the field. A non-limiting example of a general-purpose promoter suitable for expressing CytoTape across a wide range of cell types is a promoter associated with a "housekeeping gene," which is typically expressed in various cell types.Additional examples of general promoters are provided elsewhere in this document, and other suitable alternative promoters are also well recognized in the art. In certain embodiments of thedisclosure, the promoter may be an inducible promoter, with examples including, but not limited to, tetracycline-inducible systems (both tetracycline-on and tetracycline-off) or tamoxifen-inducible Cre-ER systems.
[0141] In some embodiments of the disclosure a reagent for expression of CytoTape is a vector that comprises a gene encoding the component, and optionally a gene encoding one or more additional polypeptides. Vectors useful in methods of the disclosure may include additional sequences including, but not limited to, one or more signal sequences and / or promoter sequences, or a combination thereof. In certain embodiments of the disclosure, a vector may be a lentivirus, adenovirus, adeno-associated virus, or other vector that comprises a gene encoding CytoTape. An adeno-associated virus (AAV) such as AAV8, AAV1, AAV2, AAV4, AAV5, AAV9, are non-limiting examples of vectors that may be used to express a fusion protein of the disclosure in a cell and / or subject. Expression vectors and methods of preparation and use are well known in the art.
[0142] Promoters that may be used in methods and vectors of the disclosure include, but are not limited to, cell-specific promoters or general promoters. Non-limiting examples promoters that can be used in vectors of the disclosure are: ubiquitous promoters, such as, but not limited to: CMV, CAG, CBA, and EFla promoters; and tissue-specific promoters, such as but not limited to: Synapsin, CamKIIa, GFAP, RPE, ALB, TBG, MBP, MCK, TNT, and aMHC promoters. In some embodiments, a promoter included in a method and / or vector of the disclosure is a UBC promoter. Methods to select and use ubiquitous promoters and tissue specific promoters are well known in the art. A non-limiting example of a tissue-specific promoter that can be used to express a component of CytoTape in a cell such as a neuron is a synapsin promoter, which can be used to express the component in certain embodiments of methods of the disclosure.Additional tissue-specific promoters and general promoters are well known in the art and, in addition to those provided herein, may be suitable for use in compositions and methods of the disclosure. Other non-limiting examples of promoters that may be used in certain embodiments of methods of the disclosure are provided in the Examples section.
[0143] Non-limiting examples of detectable label polypeptides that may be included in a composition comprising CytoTape are: green fluorescent protein (GFP); enhanced green fluorescent protein (EGFP), red fluorescent protein (RFP); yellow fluorescent protein (YFP), dtTomato, mCardinal, mCherry, DsRed, cyan fluorescent protein (CFP); far red fluorescentproteins, etc. Numerous fluorescent proteins and their encoding nucleic acid sequences are known in the art and routine methods can be used to include such sequences in fusion proteins and vectors, respectively, of the disclosure.
[0144] Additional sequences that may be included in a fusion protein comprising a component of CytoTape are trafficking sequences, including, but not limited to: Kir2.1 sequences and functional variants thereof, KGC sequences, ER2 sequences, etc. Trafficking polypeptides and their encoding nucleic acid sequences are known in the art and routine methods can be used to include and use such sequences in fusion proteins and vectors, respectively, of the disclosure.
[0145] Cells and Subjects
[0146] Some aspects of the disclosure include cells used in conjunction with CytoTape. Cells in which CytoTape may be expressed, and that can be used in methods of the disclosure, include prokaryotic and eukaryotic cells. Certain embodiments of the disclosure include use of mammalian cells; including but not limited to cells of humans, non-human primates, dogs, cats, horses, rodents, etc. In some embodiments of the disclosure, cells that are used are nonmammalian cells; including but not limited to insect cells, avian cells, fish cells, plant cells, etc. CytoTape may be included in non-excitable cells and in excitable cells, the latter of which include cells able to produce and respond to electrical signals. Examples of excitable cell types include, but are not limited, to neurons, muscle cells, visual system cells, sensory cells, auditory cells, cardiac cells, and secretory cells (such as pancreatic cells, adrenal medulla cells, pituitary cells, etc.), cardiac cells, immune system cells, etc. Cells in which CytoTape can be used include embryonic cells, stem cells, pluripotent cells, mature cells, geriatric cells, mitotic cells, as well as cells in other developmental stages. Non-limiting examples of cells that may be used in methods of the disclosure include neuronal cells, nervous system cells, cardiac cells, circulatory system cells, kidney cells, liver cells, epidermal cells, visual system cells, auditory system cells, secretory cells, endocrine cells, and muscle cells.
[0147] In some embodiments, a cell used in conjunction with methods and CytoTape may be a healthy normal cell that is not known or suspected to have any disease, disorder, or abnormal condition. Alternatively, the cell could be an abnormal cell. Examples of abnormal cells include: (1) cells that have a disorder, disease, or condition; (2) cells obtained from subjects who have, had, or are suspected of having a disorder, disease, or condition; (3) cells known or suspected to be involved in a disorder, disease, or condition; and (4) cells that serve as models for a disorder,disease, or condition, etc. Non-limiting examples of such cells are a degenerative cell, a neurological disease-bearing cell, a cancer cell, a cell model of a disease or condition, an injured cell, a cell downstream from a disease-bearing or injured cell, etc. Additionally, in some embodiments of the disclosure, a cell may be a control cell. A cell that is directly or indirectly upstream or adjacent to a cell in which CytoTape may be included can either be a normal cell or an abnormal cell.
[0148] An embodiment CytoTape may be included in a cell from or in culture, a cell in solution, a cell obtained from a subject, and / or a cell in a subject (in vivo cell). In some embodiments of the disclosure, CytoTape is present in and monitored in cultured cells, cultured tissues (e.g., brain slice preparations, etc.), and in living subjects, etc. As used herein, the term "subject" may refer to a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat, bird, rodent, fish, insect, or other vertebrate or invertebrate organism. In certain embodiments, a subject is a mammal and in certain embodiments, a subject is a human. Additional non-limiting examples of cell types that may be used in certain methods of the disclosure are provided in the Examples section, as are non-limiting examples of organisms that may subjected to certain methods of the disclosure.
[0149] A cell that includes CytoTape can take various forms, such as a single cell, an isolated cell, a cell in culture, an in vitro cell, an in vivo cell, an ex vivo cell, a cell within a tissue, a cell in a subject, a cell in an organ, a cell in a cultured tissue, a cell in a neural network, a cell in a brain slice, or a neuron. It may also refer to a cell that is part of a group of multiple cells, a cell in a network of interconnected cells, a cell communicating with another, or cells that are in physical contact with each other. The methods of the disclosure can be applied to multiple cells, allowing for at least one of those cells to contain CytoTape. Including this system across a group of cells enables monitoring and the assessment of changes in expression across those cells. It will be understood that when assessing expression and history in a plurality of cells, a plurality of cells may be prepared to contain an expressed CytoTape and the status of expression in the plurality of cells can be determined at one or more different time points by obtaining one or more cells from the plurality at the one or more different time points and determining the expression and / or history in the obtained cell or cells. At a different time point, another cell or other cells may be obtained from the plurality of cells and also assessed. Results of two or more assessments done in cells obtained from the plurality at different times can be compared to determine a change inexpression in the plurality of cells. As well as multiplexing multiple different CytoTapes used in the plurality of cells to understand how numerous different cellular processes are intertwined in the plurality of cells. Results using cells obtained at two or more times can be used to assess changes in expression in the plurality of cells over time and under different conditions. For example, one or more cells may be collected from a group containing expressed and / or encoded CytoTape and evaluated for expression. After this initial assessment, the group of cells can be exposed to candidate stimuli, and additional cells can be collected following this exposure. These subsequent cells can then be assessed and compared to the initial or control assessment to determine the expression history of the entire group of cells for various cell signals being tracked.
[0150] The methods described in this disclosure can also be utilized in a single cell, eliminating the need for multiple cells to calculate a timestamp axis. For example, but not limited to the disclosure, CytoTapes can be expressed using a bovine papillomavirus type 1 (BPV-1) in a mitotic cell, such as a neural progenitor cell, to observe asymmetric cell division. One CytoTape contains a C-terminus HaloTag with a UBC promoter, the second has a C-terminus HA tag under Synapsin, and the third includes a C-terminus FLAG tag governed by a nestin promoter. This experiment is conducted over six weeks, with the HaloTag ligand being swapped every week. At the conclusion of the experiment, visualization of the HaloTag allows for the establishment of a time axis based on the temporal resolution provided by the HaloTag ligand swapping, and staining for the HA and FLAG tags is performed. The results of the staining are multiplexed, and the change in expression of the CytoTapes through the expressed protein chain is assessed. This method enables assessments of how long after the division of a neuronal progenitor cell one of the daughter cells matures into a neuron by the increased expression of the HA tag and decreased expression of the FLAG tag.
[0151] Controls
[0152] CytoTape and the methods for using CytoTape can be employed to assess changes in cells, tissues, and subjects where the system is applied. Some embodiments of this disclosure involve using CytoTape to identify the effects of candidate stimuli on cells, tissues, and subjects. The results of testing cell expression activity with CytoTape can be effectively compared to a control group. In certain embodiments, CytoTape may be integrated into a cell or cell population, allowing researchers to test the effects of candidate stimuli on that specific cell or population. A"test" cell, tissue, or organism is defined as one in which the activity of CytoTape can be evaluated or measured. Results obtained using assays and tests of a test cell, tissue, or organism may be compared with results obtained from the assays and tests performed in other test cells, tissues, or organisms or assays and tests performed in control cells, tissues, or organisms.
[0153] As used herein a control value refers to a predetermined measurement that may take various forms. It can be a single cutoff value, such as the median or mean. This value can be established using comparative groups, such as cells or tissues that are treated with CytoTape under similar test conditions but are not exposed to a candidate compound. Another non-limiting example of a comparative group includes cells or tissues that have a disorder or condition and groups without the disorder or condition. Another non-limiting example of comparative group includes cells from a subject or subjects with a family history of a disease or condition and cells from a subject or subjects without such family history. A predetermined value can be arranged, for example, where a tested population is divided equally (or unequally) into groups based on results of testing. Those skilled in the art can select appropriate control groups and values for use in comparative methods of the disclosure.
[0154] Administration Means
[0155] Administration of a component of CytoTape may include, but is not limited to: administering to a cell or subject a composition that includes a vector comprising a polynucleotide sequence that encodes for CytoTape, administering to a cell or subject a composition comprising the vector, and administering to a subject a cell in which the vector and / or encoded CytoTape is present. Components of CytoTape can be administered to a cell or subject in a formulation that adheres to pharmaceutically acceptable standards. These formulations may typically contain acceptable concentrations of salts, buffering agents, preservatives, compatible carriers, adjuvants, and other optional ingredients. In some aspects, a pharmaceutical composition comprises one or more CytoTape components and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to the skilled artisan and may be selected and utilized using routine methods. As used herein, a pharmaceutically acceptable carrier means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Pharmaceutically acceptable carriers may include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materialsthat are well known in the art. Exemplary pharmaceutically acceptable carriers are described in U. S. Pat. No. 5,211,657 and others are known by those in the art.
[0156] The terms "delivery into" and "include," as used in this document, refer to actions that result in a component of CytoTape being present within a cell. This encompasses both the direct delivery of the component(s) into the cell and the delivery of a polynucleotide sequence that encodes the component, which is then expressed in the cell. A component of CytoTape may be administered using art-known methods. The absolute amount to be delivered can be determined using routine methods. The delivery may be done in a single administration, a single or multiple deliveries, and if delivered into a subject may be based on individual subject parameters including age, physical condition, size, weight, and the stage of a disease or condition, test parameters to be followed, etc. These factors can be addressed with no more than routine experimentation. Various methods of administration are available to those skilled in the art for effectively delivering one or more components of CytoTape to a desired cell, tissue, organ, or region within a subject. Common methods for administering a composition that contains a CytoTape component may include, but are not limited to, injection, microinjection, perfusion, and electroporation. The disclosure is not restricted to the specific modes of administration described here; other known delivery methods in the art may also be suitable for administering components of CytoTape.
[0157] Other protocols suitable for administration of one or more components that are part of CytoTape are known to those in the art. Embodiments of methods of the disclosure to administer a cell or vector to increase a level of a component of CtyoTape in an animal other than a human; and administration and use of Cytotape for testing purposes or veterinary purposes, are substantially the same as described above. It will be understood by a skilled artisan that this disclosure is applicable to both humans and animals.
[0158] Assessment Methods
[0159] Disorders, conditions, and events that may be assessed using methods of the disclosure to include CytoTape in a cell, tissue, and / or subject and to use the system to determine characteristics of expression in the cell. These methods can help determine expression characteristics in cells and can be applied to evaluate early-stage development, cell and tissue regeneration, cell communication, and diseases, etc.. Diseases that may be examined using methods and systems of the disclosure include, but are not limited to injury, brain damage, spinalcord injury, epilepsy, metabolic disorders, cardiac dysfunction, vision loss, blindness, deafness, hearing loss, cancer, and neurological conditions (e.g., Parkinson's disease, Alzheimer's disease, and seizure), degenerative neurological conditions, drug contact, toxins, etc. In some embodiments, a disorder or condition can be monitored by incorporating CytoTape into at least one cell and observing changes in expression characteristics within those cells. These methods may also be useful for evaluating therapeutic agents and treatments, understanding cell connectivity, studying cells in mitotic states, and exploring expression activity patterns.CytoTape can be specifically targeted to cells to monitor changes in expression. The disclosure includes several aspects, such as preparing nucleic acid sequences that encode components of CytoTape, expressing these components in cells, and monitoring changes in expression by assessing protein levels, determining the amino acid sequences of expressed proteins, and detecting the presence, location, and quantity of CytoTape detectable tags within the cells. The ability to specifically, consistently, reproducibly, and sensitively monitor changes in the CytoTag composition using methods such as multiplex imaging has been demonstrated. The present disclosure enables monitoring of expression changes in in vivo, ex vivo, and in vitro, and CytoTape and CytoTape-vivo use have broad-ranging applications for drug screening, disease assessment, treatment assessment, and research applications, some of which are describe herein.
[0160] One of ordinary skill in the art, based on the present disclosure, can utilize the compositions and methods described to their fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way.
[0161] GLOBE Recording — System, Methods, and Embodiments.
[0162] GLOBE recording system overview.
[0163] In one aspect, the present disclosure provides a system for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject in vivo, referred to herein as a “GLOBE recording system” and the corresponding methods as “GLOBE recording” (sinGle-cell spatiotemporaL recording Brain-widE). In some embodiments, the GLOBE recording system comprises three modular, genetically encoded protein components, each delivered to single cells of a mammalian subject through brain- wide gene transduction: (a) a structural monomer expressed under the control of a constitutive regulatory element, the structural monomer being configured to self-assemble into an intracellular protein filament that elongates over time; (b) asignal monomer expressed under the control of an activity-dependent regulatory element and configured to be incorporated into the elongating filament, such that a temporal pattern of activitydependent expression is encoded as a corresponding spatial pattern of signal-monomer incorporation along the filament; and (c) a timestamp monomer expressed under the control of a small-molecule-inducible regulatory element and configured to be incorporated into the elongating filament, such that one or more user-defined induction events are encoded as one or more spatially detectable timestamps along the filament. In some embodiments, the structural monomer, signal monomer, and timestamp monomer are each fused to a distinct epitope tag, enabling reconstruction of their relative spatial location along the filament by post-fixation immunofluorescence and providing a time-resolved readout of cellular activity within individual cells (see FIG. 42 and Example 3 for non-limiting embodiments).
[0164] In some embodiments, the filament elongates bidirectionally, such that signal-monomer and timestamp-monomer incorporation events deposited prior to fixation are recorded on each of two halves of the filament flanking a central reference position. In some such embodiments, the inherent bilateral symmetry of bidirectional fiber growth is exploited to determine an optimal split point dividing the filament into two symmetric halves, as further described in connection with the GLOBE Tape Reader pipeline herein.
[0165] Modularity of the GLOBE recording system.
[0166] The GLOBE recording system is modular with respect to (a) the choice of recording substrate; (b) the choice of activity -dependent regulatory element driving the signal monomer; (c) the choice of small-molecule-inducible regulatory element driving the timestamp monomer; (d) the choice of epitope tag fused to each monomer; (e) the choice of behavioral, pharmacological, physiological, environmental, or pathological manipulation of the subject; (f) the choice of dimensionality reduction or temporal-mode-classification technique applied to the recorded data; and (g) the choice of common anatomical coordinate framework to which spatial coordinates are registered. Combinations of any one or more of the foregoing are within the scope of the present disclosure.
[0167] In some embodiments, the recording substrate is a self-assembling protein monomer that satisfies each of the following functional criteria: (a) the substrate forms an intracellular linear selfassembling protein filament in the cytosol of a mammalian cell upon expression in vivo or in vitro, (b) the substrate accepts incorporation of a signal monomer driven by an activity-dependentregulatory element, such that the signal monomer is co-assembled into the filament in a manner reflective of the temporal pattern of activity-dependent regulatory-element activation; (c) the substrate accepts incorporation of a timestamp monomer driven by a small-molecule-inducible regulatory element, such that the timestamp monomer is co-assembled into the filament in a manner that creates a spatially detectable reference reflecting the timing of inducer presence and absence; and (d) the substrate permits post-fixation immunofluorescence readout of epitope tags fused to the signal and timestamp monomers along the spatial axis of the filament. A recording substrate satisfying each of the foregoing criteria is referred to herein as a “GLOBE-compatible substrate.”
[0168] In some embodiments, the GLOBE-compatible substrate comprises a 1POK-derived selfassembling protein. In some embodiments, the GLOBE-compatible substrate comprises a 1POK-derived self-assembling protein comprising one or more amino acid substitutions selected from E239Y and L349K, and combinations of any of the foregoing. In some embodiments, the GLOBE-compatible substrate further comprises an N-terminally truncated maltose binding protein insulator domain or homologous insulator domain. In further embodiments, the GLOBE-compatible substrate comprises XRI as described in Linghu et al., Nat. Biotechnol. 41:640-651 (2023). In further embodiments, the GLOBE-compatible substrate comprises CytoTape or CytoTape-vivo (also referred to herein as BrainTape), as described in detail herein, and as described in Zheng et al., Nature 652:1038-1048 (2026). The foregoing examples of GLOBE-compatible substrates are non-limiting; further variants and homologs satisfying the functional criteria above are within the scope of the present disclosure.
[0169] Activity-dependent regulatory elements.
[0170] In some embodiments, the activity-dependent regulatory element driving the signal monomer is a regulatory element responsive to one or more cellular activities selected from, without limitation, neuronal activity, neuronal depolarization, calcium signaling, cAMP signaling, immediate early gene expression, transcription factor activation, heat shock, drug exposure, pathogen exposure, exposure to a candidate therapeutic agent, exposure to a developmental cue, exposure to a stress stimulus, exposure to an inflammatory stimulus, and combinations of any of the foregoing. Non-limiting examples of activity-dependent regulatory elements include a c-fos promoter, an Arc promoter (including SARE-ArcMin and N-RAM promoters), an Egr1 promoter (also known as a Zif268 promoter), an Npas4 promoter, an HSPA1 A promoter, a CREB -responsivepromoter (including, without limitation, a 6*CRE-CMVMin promoter), an F-RAM promoter, and combinations of any of the foregoing. In some embodiments, the signal monomer further comprises one or more elements that enhance temporal specificity of activity-dependent expression, including, without limitation, a protein-destabilizing PEST sequence fused in-frame to the C-terminus of the coding sequence, an mRNA-destabilizing element inserted downstream of the stop codon, or both. In some embodiments, the destabilization elements are referred to in the present specification as P1N4.
[0171] In some embodiments, two, three, four, five, or more signal monomers, each driven by a distinct activity-dependent regulatory element, are co-expressed in the same cell to enable simultaneous, multiplexed recording of multiple cellular activities.
[0172] Small-molecule -inducible regulatory elements and timestamp signals.
[0173] In some embodiments, the small-molecule-inducible regulatory element driving the timestamp monomer is a tetracycline-responsive regulatory element. In some such embodiments, the tetracycline-responsive regulatory element comprises a tetracycline-responsive element (TRE), a TRE3G regulatory element, or a homolog or variant thereof. In some such embodiments, the tetracycline-responsive regulatory element is operated in combination with a tetracycline-controlled transactivator. In some such embodiments, the tetracycline-controlled transactivator is a reverse tetracycline-controlled transactivator (rtTA), and is optionally rtTA3G. In some such embodiments, the tetracycline-controlled transactivator is itself expressed under the control of a tissue-selective promoter, including, without limitation, a human synapsin 1 (hSyn) promoter for neuronal expression. The corresponding inducing agent is a tetracycline-class antibiotic, including, without limitation, doxycycline, minocycline, tetracycline, anhydrotetracycline, or a combination of any of the foregoing. In some embodiments, the inducing agent is doxycycline.
[0174] In some embodiments, the inducing agent is administered to the subject by oral administration in drinking water (e.g., in a home cage), by intraperitoneal injection, by intravenous injection, by subcutaneous injection, by intranasal administration, by feeding in a chow formulation, by direct intracranial administration, or by any combination of the foregoing. In some embodiments, the inducing agent is administered by oral administration in drinking water in a home cage, in which case the non-invasive, subject-spontaneous mode of administration may avoid potential confounding effects associated with injection -based administration, including,without limitation, stress- or handling-induced Fos activity that may otherwise contaminate signal-monomer recordings.
[0175] In some embodiments, ON / OFF transitions of inducer exposure produce reversible, in vivo temporal references along the fdament, referred to herein as Dox-ON and Dox-OFF timestamps when the inducer is doxycycline. In some embodiments, the appearance of a timestamp signal along the filament is delayed relative to an external induction transition by a latency reflecting the kinetics of inducer delivery, transcription, translation, and / or monomer incorporation. In some embodiments, this latency is empirically characterized via a time-series sampling experiment, and the median latency is used to globally align timestamp positions to a real-world time axis, as further described in Example 3 (see also FIG. 43). In some embodiments, the median latency between inducer administration and the appearance of an ON timestamp is from approximately 1 hour to approximately 48 hours; from approximately 6 hours to approximately 36 hours; from approximately 12 hours to approximately 24 hours; or approximately 15, 16, 17, 18, 19 or 20 hours. In some embodiments, the median latency between inducer administration and the appearance of an ON timestamp is approximately 18 hours. In some embodiments, the median latency between inducer withdrawal and the appearance of an OFF timestamp is from approximately 1 hour to approximately 72 hours; from approximately 6 hours to approximately 48 hours; from approximately 12 hours to approximately 36 hours; or approximately 18, 19, 20, 21, 22, 23, or 24 hours. In some embodiments, the median latency between inducer withdrawal and the appearance of an OFF timestamp is approximately 21 hours. In some embodiments, the residual single-fiber timing accuracy after global temporal alignment is from approximately ±1 hour to approximately ±24 hours; from approximately ±3 hours to approximately ±18 hours; from approximately ±6 hours to approximately ±12 hours; or approximately ±6.2 hours and approximately ±12.2 hours for ON and OFF timestamps, respectively. The foregoing ranges are non-limiting.
[0176] In some embodiments, the timestamp monomer is induced and withdrawn one, two, three, four, five, or more times during a recording window, thereby depositing a corresponding plurality of spatially separated bands along the filament. In some such embodiments, the resulting plurality of bands is resolved by expansion microscopy under a customized expansion protocol disclosed herein (see FIG. 53 and Example 3).
[0177] Brain-wide AA V delivery architecture.
[0178] In some embodiments, the structural monomer, signal monomer, timestamp monomer, and tetracycline-controlled transactivator are each delivered to cells of the subject by adeno-associated virus (AAV)-mediated gene transduction. In some embodiments, each component is delivered as a separate AAV viral particle, such that the relative AAV genome copy numbers of the four components in a delivered cocktail can be independently varied. In some embodiments, the AAV cocktail is prepared at defined viral -genome-copy ratios such that the final viral genome copy number of the structural monomer AAV is greater than the final viral genome copy numbers of the timestamp monomer AAV and the signal monomer AAV. In some embodiments, the final viral genome copy number of the structural monomer AAV is at least approximately two-fold greater, at least approximately five-fold greater, at least approximately ten-fold greater, at least approximately fifty-fold greater, at least approximately one-hundred-fold greater, or more, than the final viral genome copy number of the timestamp monomer AAV, the signal monomer AAV, or both. In one non-limiting embodiment, the final viral genome copy number of the structural monomer AAV is approximately ten-fold greater than that of the timestamp monomer AAV and approximately one-hundred-fold greater than that of the signal monomer AAV (e.g., ensuring that resultant filaments are predominantly composed of structural monomers).
[0179] In some embodiments, the AAV cocktail is delivered systemically by intravenous administration. In some such embodiments, an AAV serotype having blood-brain-barrier-crossing capability is used, including, without limitation, AAV-PHP.eB, AAV. CAP-B10, or homologs or variants thereof. In some embodiments, however, intravenous AAV-PHP.eB or AAV. CAP-B10 delivery at conventional dosages may produce predominantly puncta or short, non-elongating filaments in some brain regions, indicating insufficient per-cell expression to support robust filament elongation for brain-wide recording (see FIG. 46). Accordingly, in some embodiments, the AAV cocktail is delivered by multi-site, multi-depth intracranial AAV injection, providing broad expression coverage and robust filament formation across the mammalian brain (see FIG.47, FIG. 48). In some such embodiments, the AAV serotype is AAV9, AAV1, AAV2, AAV5, AAV6, AAV8, AAV. PHP. S, AAV. PHP.eB, AAV. CAP-B10, or a homolog or variant of any of the foregoing. In one non-limiting embodiment, the AAV serotype is AAV9.
[0180] In some embodiments, the multi-site, multi-depth intracranial injection comprises injections at two, three, four, five, six, seven, eight, nine, ten, or more distinct stereotactic coordinates per hemisphere, defined relative to bregma and brain surface, with one or more depthsper coordinate. Non-limiting representative coordinates are provided in Example 3. In some embodiments, each injection site receives from approximately 50 nL to approximately 5 pL of AAV mixture; from approximately 100 nL to approximately 1 pL of AAV mixture; or approximately 350 nL of AAV mixture. In some embodiments, AAV is delivered at a rate from approximately 10 nL / min to approximately 1 pL / min, or approximately 100 nL / min, with a hold time at the target site of from approximately 1 min to approximately 30 min, or approximately 5 min, following injection.
[0181] In some embodiments, the total AAV dosage delivered to the subject is from approximately 1 × 109to approximately 1 × 1013viral genome copies (GC) per subject; from approximately 1 × 1010to approximately 1 × 1012GC per subject; or approximately 6.8 * 10’° GC per mouse subject. In some embodiments, the total AAV9 dosage delivered by multi -site, multi-depth intracranial injection is less than approximately 50%, less than approximately 41%, or less than approximately 30% of the per-subject dosage typically used for intravenous AAV-PHP.eB or AAV. CAP-B10 delivery to the same species, while providing greater per-cell expression and more robust filament formation.
[0182] Scalable brain-wide single-cell recording capacity.
[0183] In some embodiments, the GLOBE recording system enables single-cell recording of cellular activity from at least approximately 1,000; at least approximately 10,000; at least approximately 100,000; at least approximately 200,000; at least approximately 300,000; at least approximately 400,000; at least approximately 500,000; or more cells per subject. In one nonlimiting embodiment exemplified herein, GLOBE recording achieved single-cell recording of up to 219,703 neurons in a single mouse brain (see FIG. 44 and Example 3). In some embodiments, the GLOBE recording system enables single-cell recording at a local recording density, defined as the fraction of Nissl-positive neurons within a recorded brain region from which a successfully recorded fiber is obtained, of at least approximately 10%, at least approximately 25%, at least approximately 50%, at least approximately 60%, at least approximately 70%, at least approximately 80%, or at least approximately 90%; or from approximately 50% to approximately 95%; or from approximately 69% to approximately 90%.
[0184] In some embodiments, single-cell recording is achieved across at least two; at least three; at least five; at least ten; or at least twenty distinct anatomically defined brain regions of the same subject. Non-limiting examples of recorded brain regions include isocortex, olfactory areas,cortical subplate, hippocampal formation, pallidum, striatum, thalamus, hypothalamus, and midbrain, and sub-regions of any of the foregoing. In some embodiments, the recorded brain regions include one or more regions selected from prelimbic cortex (PL), primary somatosensory cortex (SSp), hippocampal CAI, dentate gyrus (DG), dorsal peduncular cortex (DP), medial amygdala (MEA), paraventricular thalamus (PVT), and basolateral amygdala (BLA).
[0185] In some embodiments, the recording window during which the GLOBE recording system records cellular activity is from approximately 1 day to approximately 30 days; from approximately 3 days to approximately 14 days; from approximately 5 days to approximately 7 days; or approximately 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. In further embodiments using a recording substrate having extended-duration capacity, including, without limitation, CytoTape or CytoTape-vivo, the recording window is from approximately 1 week to approximately 20 weeks, from approximately 2 weeks to approximately 10 weeks, or from approximately 2 weeks to approximately 4 weeks. The foregoing ranges are non-limiting.
[0186] In some embodiments, an imaging readout is performed at an average imaging readout speed of from approximately 0.1 to approximately 10 seconds per cell per microscope; from approximately 1 to approximately 5 seconds per cell per microscope; or approximately 1.9 seconds per cell per microscope. In some embodiments, a downstream computational readout is performed at an average computational readout speed of from approximately 0.1 to approximately 10 seconds per cell per graphics processing unit (GPU); from approximately 0.5 to approximately 2 seconds per cell per GPU; or approximately 1.0 seconds per cell per GPU. In some embodiments, brainwide readout from sectioned tissue is parallelized through one or more of: (a) imaging multiple sectioned tissues in parallel using a plurality of microscopes; (b) processing images concurrently using a plurality of GPUs; (c) processing images simultaneously while imaging; or any combination of the foregoing, such that brain-wide readout time scales down proportionally with the degree of parallelization.
[0187] Histology, immunostaining, and imaging readout.
[0188] In some embodiments, the subject is fixed by transcranial perfusion with phosphate-buffered saline followed by paraformaldehyde, and the brain is post-fixed by immersion in paraformaldehyde. In some embodiments, brain tissue is sectioned coronally, sagittally, or horizontally, at a thickness of from approximately 10 pm to approximately 200 pm; from approximately 20 pm to approximately 50 pm; or approximately 30 pm. In some embodiments,sections are subjected to immunofluorescence staining against the epitope tags fused to the structural monomer, signal monomer, and timestamp monomer, in combination with a cytosol -selective stain (including, without limitation, a Nissl stain such as a NeuroTrace Blue Fluorescent Nissl Stain), under blocking, washing, and staining conditions disclosed herein. In some embodiments, primary antibodies are used at a dilution of approximately 1:500 and fluorescent secondary antibodies are used at a dilution of approximately 1:500.
[0189] In some embodiments, fluorescence microscopy is performed using a confocal microscope, including, without limitation, a spinning disk confocal microscope, equipped with one or more high-numerical-aperture water-immersion objectives, lower-magnification objectives, an sCMOS camera, and laser / filter sets compatible with the epitope-tag fluorophores employed. In some embodiments, automated multi-channel, multi-location volumetric imaging is conducted at a Z-step of from approximately 0.1 pm to approximately 2 pm, or approximately 0.4 pm, under a high-magnification objective. In some embodiments, four imaging channels are acquired, corresponding to (i) a cytosol-selective stain channel, (ii) a structural-monomer channel, (iii) a signal -monomer channel, and (iv) a timestamp-monomer channel.
[0190] High-throughput computational pipeline (GLOBE Tape Reader).
[0191] In some embodiments, the present disclosure provides an artificial -intelligence-powered, parallel-computing-accelerated, high-throughput computational pipeline forbrain-wide automated segmentation, skeletonization, signal extraction, and readout of protein filaments along with cell morphology from multi-channel volumetric microscopy images of mammalian brain tissue, referred to herein as “GLOBE Tape Reader.” In some embodiments, the GLOBE Tape Reader pipeline takes as input multi-tile multi-channel volumetric images comprising a cytosol-selective stain channel, a structural-monomer channel, a signal -monomer channel, and a timestamp-monomer channel, and produces per-fiber intensity profiles, cell assignments, quality metrics, and / or time-aligned signal traces.
[0192] In some embodiments, the pipeline comprises one or more of the following steps: (a) instance segmentation of protein filaments from the structural-monomer channel; (b) instance segmentation of cell soma boundaries from the cytosol-selective-stain channel; (c) point-cloud representation, principal-component-analysis-based axis determination, cubic spline fitting through the central portion of each filament, and resampling of the resulting centerline to a standardized number of equidistant points; (d) trilinear-interpolation-based extraction ofcontinuous channel intensity signals along the standardized centerline; (e) optimal split-point determination dividing each filament into two symmetric halves based on bilateral symmetry of the timestamp-monomer signal; (f) quality control filtering by geodesic length, principalcomponent morphological criterion, and Nissl-overlap; and (g) time-axis recovery by piecewise-linear curve fitting between timestamp positions along the filament and the corresponding real-world time points. In some embodiments, additional intermediate or downstream steps are included.
[0193] In some embodiments, instance segmentation of protein filaments employs a three-dimensional convolutional neural network architecture, including, without limitation, a MedNeXt architecture, a U-Net architecture, a 3D-Unet architecture, or a homolog or variant thereof, optionally with a backbone provided by a deep-learning library such as PyTorch Connectomics. In some embodiments, the network predicts a binary foreground mask, an instance contour map, and / or a skeleton-aware Euclidean distance transform, and instance segmentations are generated by application of a marker-based watershed algorithm to these intermediate representations. In some embodiments, instance segmentation of cell soma boundaries employs a Segment Anything for Microscopy (pSAM) framework, applied in an automatic instance-segmentation mode, with pretrained weights. In some embodiments, hyperparameter optimization is performed using a Tree-structured Parzen Estimator (TPE) sampler, including, without limitation, an Optuna-based implementation thereof.
[0194] In some embodiments, optimal split-point determination is performed in a two-pass procedure: a first coarse grid search over a plurality of candidate midpoints maximizing Pearson correlation between left and right halves of the timestamp-monomer signal, followed by a second refinement step using a TPE sampler within a defined interval around the coarse optimum. In some embodiments, time-axis recovery is performed by curve-fitting the spatial location coordinates of two, three, four, or more timestamps along the filament, together with one or more reference real-world time points (including, without limitation, an inducer-on time, an inducer-off time, and a fixation endpoint), to a piecewise-linear function, a higher-order spline, or another monotonically increasing function. In some embodiments, quality-control filtering excludes (i) segmented structures located outside neuronal soma as detected by cytosol -selective staining; (ii) segmented structures with geodesic length below approximately 8 pm or with a first-principal-component explained variance below approximately 0.8; and (iii) filaments without detected timestamps.
[0195] In some embodiments, the end-to-end pipeline is orchestrated as a multi-stage parallelcomputing job array (including, without limitation, a SLURM job array) with inter-stage dependencies, where stages corresponding to fiber segmentation, cell segmentation, and fiber analysis are parallelized across imaging tiles. In some embodiments, the pipeline processes from approximately 100 GB to approximately 50 TB of multi-channel volumetric image data per subject; from approximately 1 TB to approximately 20 TB per subject; or up to approximately 7.5 TB per subject. In some embodiments, the pipeline produces, for each filament, an output data record including one or more of: a fiber identifier, a parent cell identifier, a fiber length, fiber centroid coordinates, an optimal midpoint position, one or more Pearson correlation coefficients quantifying timestamp symmetry, and per-channel intensity profiles sampled at a standardized number of equidistant points along the filament.
[0196] Brain-wide spatiotemporal functional atlas of cellular activity.
[0197] In further embodiments, the present disclosure provides methods for generating a brainwide spatiotemporal functional atlas of cellular activity in a mammalian subject. In some such embodiments, the methods comprise the following steps, (a) Brain-wide single-cell recording of cellular activity is performed using a GLOBE recording system as disclosed herein, over a recording window during which the subject is subjected to a defined behavioral, pharmacological, physiological, environmental, or pathological manipulation, or a combination thereof, (b) For each recorded cell, a per-cell signal trace is extracted from the recorded filament and aligned to an absolute time axis using one or more inducer-defined timestamps and a fixation endpoint, as described herein, (c) Each per-cell signal trace is summarized as a vector of activity values within a plurality of time bins aligned to the manipulation paradigm, (d) The resulting per-cell time-binned activity vectors are subjected to dimensionality reduction (for example, by Uniform Manifold Approximation and Projection (UMAP), t-distributed Stochastic Neighbor Embedding (t-SNE), Principal Component Analysis (PCA), Diffusion Maps, or another suitable dimensionality reduction technique) to generate a low-dimensional embedding referred to herein as a “memory manifold” when the manipulation comprises a learning-and-recall paradigm, or more generally as an “activity manifold.” (e) Each cell is assigned a temporal-mode classification based on the per-cell time-binned activity vector, (f) The spatial coordinates of each cell are registered to a common anatomical coordinate framework (for example, the AllenMouse Brain Common Coordinate Framework version 3, Allen CCFv3) to provide a brain-wide, single-cell spatiotemporal functional atlas of cellular activity in the subject.
[0198] In some embodiments, the temporal modes comprise two or more categories selected from: (i) a no-response mode, in which the per-cell signal trace does not exhibit a detectable elevation above baseline within the recording window; (ii) an early-peak mode, in which the per-cell signal trace exhibits a detectable elevation above baseline preferentially at an early time bin within the recording window (e.g., including, without limitation, a weak first peak mode and a strong first peak mode reflecting respective magnitudes of the early elevation); (iii) a late-peak mode, in which the per-cell signal trace exhibits a detectable elevation above baseline preferentially at a late time bin within the recording window (e.g., including, without limitation, a second peak mode in which the late elevation occurs at or about the time of a behavioral recall, sensory, or pharmacological event delivered during the recording window); (iv) a dual-peak mode, in which the per-cell signal trace exhibits two or more discrete temporal peaks within the recording window; (v) a wide-peak mode, in which the per-cell signal trace exhibits a sustained elevation above baseline spanning a majority of the recording window (e.g., including, without limitation, a sustained response mode); (vi) a decay mode, in which the per-cell signal trace exhibits a decrease relative to a baseline established prior to the manipulation (e.g., including, without limitation, an inhibition mode in which the per-cell signal trace is suppressed below baseline across a majority of the recording window); and (vii) a complex mode comprising two or more features of the foregoing modes or other features of the per-cell signal trace (e.g., including, without limitation, heterogeneous combinations of activation, suppression, and timing features). The foregoing categories are non-limiting; additional or alternative temporal-mode classifications may be defined based on features including peak amplitude, peak time, full width at half maximum, decay constant, baseline fluctuation, and time-lagged correlation between time bins, as appropriate to a desired recording window and / or manipulation paradigm. In some embodiments, the temporal modes are visualized as per-cell heatmaps of recovered activity along an absolute or recovered time axis, with cells partitioned by temporal-mode classification, by brain region, or by both, as further described herein and exemplified in FIG. 45.
[0199] In some embodiments, the resulting low-dimensional embedding exhibits a continuous organization rather than clearly separated groups, with cells from different major brain areas distributed across the embedding. In some embodiments, when cells are annotated by theiraverage response strength, the resulting annotated embedding exhibits a gradient, with a subset of strongly activated cells forming a distinct region of the embedding (referred to in some embodiments as a “tail-like” region of the activity manifold). In further embodiments, when cells are annotated by the temporal centroid of their per-cell signal traces, the resulting annotated embedding exhibits a smooth temporal progression along the manifold, illustrating the temporal structure of cell activities across the recording window. In some embodiments, the methods of the present disclosure provide that brain-wide activity-dependent transcriptional activity, including, without limitation, Fos-promoter-driven transcriptional activity, forms a robust lowdimensional structure that reflects both response magnitude and response timing of recorded cellular activity in cells distributed across one or more brain regions of the subject.
[0200] In some embodiments, the methods further comprise identifying, by reference to the registered atlas, brain region-dependent spatial distributions of one or more temporal modes within the subject. In further embodiments, the methods comprise comparing the brain regiondependent spatial distributions of temporal modes between (a) a subject subjected to a first manipulation, condition, or genetic background and (b) a subject subjected to a second manipulation, condition, or genetic background, thereby identifying differentially active brain regions, differentially active temporal modes, or both, between the first and second conditions. In further embodiments, the methods comprise determining whether an individual cell’s recorded activity has increased (activation), decreased (inhibition), or remained substantially unchanged (persistence) between two or more time points within the recording window.
[0201] In some embodiments, the manipulation comprises a learning paradigm, a memory paradigm, a learning-and-recall paradigm, contextual fear conditioning, contextual fear memory recall, sensory stimulation, social interaction, drug exposure, seizure induction, exposure to a candidate therapeutic agent, exposure to a pathological condition or model thereof, exposure to a developmental cue, exposure to a stress stimulus, or any combination of the foregoing. In some embodiments, the methods identify a brain-wide memory manifold or activity manifold whose low-dimensional structure reflects response magnitude, response timing, or both, of activitydependent transcriptional activity, with cells from different brain regions distributed across the manifold. In some embodiments, the methods identify cells or cell populations exhibiting increased activity, decreased activity, persistent activity, early-peaking activity, late-peaking activity, dual-peaking activity, wide or sustained activity, mildly suppressed activity, or anycombination of the foregoing, relative to a baseline established before, during, or after the recording window. By providing analog signal amplitudes that are directly comparable across a continuous time axis, methods of the present disclosure enable detection and quantification of cells exhibiting mild suppression relative to baseline, a feature that may be difficult to detect using snapshot-based labeling systems that rely on distinct fluorescent reporters or chemical dyes for each time point.
[0202] In some such embodiments, the manipulation comprises contextual fear conditioning, and the methods identify a population of cells exhibiting mildly suppressed activity relative to a baseline established prior to fear conditioning, a feature that may be difficult to detect using snapshot-based labeling systems.
[0203] In further embodiments, robustness of the global low-dimensional structure of the activity manifold to different temporal binning schemes may be assessed. In some embodiments, the percell time-binned activity vectors are computed using time bins of approximately 0.25 days, approximately 0.5 days, approximately 1 day, approximately 2 days, or other intervals; in further embodiments, the resulting embeddings may be compared across binning schemes to determine whether overall geometry is preserved as the binning interval is decreased, with decreasing binning interval refining local structure but not necessarily altering the overall geometry of the embedding (see FIG. 55 and Example 3).
[0204] Compatibility with downstream cell-type and molecular readouts.
[0205] Methods of the present disclosure are compatible with downstream cell-type and molecular readouts. In some embodiments, GLOBE-recorded samples are compatible with conventional immunohistochemistry (IHC) for endogenous proteins, including, without limitation, Fos, phospho-CREB, Arc, Egrl, Npas4, and other cellular markers, in addition to IHC for visualizing the recorded filament monomers via their respective epitope tags. In further embodiments, GLOBE-recorded samples are compatible with multi-round, spatially resolved cell-typing using rolling-circle-amplification (RCA)-based RNA fluorescence in situ hybridization (FISH) under a GLOBE-customized protocol disclosed herein. In further embodiments, GLOBE-recorded samples are compatible with expansion microscopy (ExM) under a GLOBE-customized expansion protocol disclosed herein. In further embodiments, GLOBE-recorded samples are compatible with combined, sequential, or simultaneous use of two or more of IHC, RNA FISH, and ExM in the same recorded tissue.
[0206] Such combined single-cell spatial readout of protein-tape recordings, RNA transcripts, and end-point protein markers in the same tissue enables correlation of GLOBE-recorded cellular activity histories with cell-type identity, RNA transcript levels, end-point protein abundance, and other end-point cellular state features in the same cells. In some embodiments, the methods of the present disclosure further comprise the steps of: (a) performing GLOBE recording in the subject; (b) fixing the subject’s tissue; (c) reading out the protein-filament-encoded recording by post-fixation immunofluorescence; and (d) in the same tissue, performing one or more of conventional IHC, RCA-based RNA FISH, and expansion microscopy, to correlate recorded single-cell activity histories with end-point cellular state.
[0207] In some embodiments of the methods disclosed herein, the combined single-cell spatial readout comprises readout of protein-tape recordings and one or more RNAs in the same tissue, thereby enabling correlation of GLOBE recordings with cell-type identity, RNA transcript levels, and other end-point cellular state features in the same cells.
[0208] Whole-brain registration.
[0209] In some embodiments, serial coronal whole-brain sections of approximately 30 pm thickness are collected. In some such embodiments, for every six consecutive sections, one section is imaged at a low magnification (for example, approximately 4×) across the whole brain and registered to a reference brain atlas (for example, the Allen CCFv3 atlas), and each brain section is further imaged at high magnification (for example, approximately 40×) in units of approximately 5 × 5 fields of view, with each unit aligned to the atlas based on anatomical landmarks, including, without limitation, nuclear density, ventricles, and tissue boundaries, thereby generating a brainregion mapping for each field of view. The foregoing imaging and registration scheme is nonlimiting and may be modified, including by changing the section thickness, sampling interval, magnifications, field-of-view tiling scheme, or atlas, while remaining within the scope of the present disclosure.
[0210] Behavioral, pharmacological, and other paradigms in non-human mammals.
[0211] In some embodiments, the subject is subjected to one or more behavioral, pharmacological, physiological, environmental, or pathological manipulations during the recording window prior to fixation. In some embodiments, the manipulation comprises contextual fear conditioning. In one non-limiting example, contextual fear conditioning is performed in a chamber of approximately 64 x 36 x 79 cm with a grid floor, neutral white lighting, and 1% acetic acid scent. Conditioningcomprises an exploration phase of approximately 180 s, followed by three foot shocks of approximately 0.8 mA × 1 s delivered at approximately 180 s, 240 s, and 300 s, each separated by approximately 60 s of rest, followed by an approximately 120 s post-shock period. Recall is performed in a separate session in the same chamber under the same conditions, comprising approximately 420 s of exploration without foot shock. Freezing behavior is assessed using a freezing-detection software (for example, VFreeze software). The foregoing parameters are nonlimiting; alternative chamber dimensions, lighting, scent, exploration durations, shock current, shock duration, shock count, inter-shock-interval, and post-shock period are within the scope of the present disclosure.
[0212] In another non-limiting embodiment, the manipulation comprises seizure induction by intraperitoneal administration of kainic acid, and the GLOBE recording system captures kainic-acid-induced, Fos-promoter-driven transcriptional events as spatially localized signal bands along individual filaments in neurons across multiple brain regions.
[0213] In further non-limiting embodiments, the manipulation comprises one or more of: a learning paradigm; a memory paradigm; a learning-and-recall paradigm; sensory stimulation; social interaction; drug exposure; pharmacological treatment; exposure to a candidate therapeutic agent; exposure to a pathological condition or model thereof, including without limitation a neurodegenerative disease model, an epilepsy model, a stroke model, a tumor model, a neuropsychiatric disease model, a neurodevel opmental disease model, a chronic pain model, an addiction model, an autoimmune-disease model, or an infection model; exposure to a developmental cue; exposure to a stress stimulus; exposure to an inflammatory stimulus; circadian or sleep-wake manipulation; dietary manipulation; or any combination of the foregoing.
[0214] Modular extensions and contemplated embodiments.
[0215] Methods of the present disclosure are modular with respect to the recording substrate. In some embodiments, the recording substrate comprises XRI as the structural monomer, providing days-scale recording durations. In further embodiments, the recording substrate comprises CytoTape or CytoTape-vivo, as described herein. In further embodiments, the recording substrate comprises CytoTape or CytoTape-vivo, as described herein. In such further embodiments, methods of the present disclosure contemplate longer recording durations, including, without limitation, weeks-long (e.g., one, two, three, four, five or more weeks-long) recording durations, simultaneous recording of two or more cellular activities in the same cells, or both, beyond therecording window and signal multiplicity demonstrated using XRT as the recording substrate. In some such embodiments, two, three, four, five, or more signal monomers are co-expressed in the same cell, each driven by a distinct activity-dependent regulatory element selected from, without limitation, a c-fos promoter, an Arc promoter, an Egr1 promoter (also known as a Zif268 promoter), anNpas4 promoter, an HSPA1A promoter, a CREB-responsive promoter, and any combination of the foregoing.
[0216] In further embodiments, GLOBE recording is combined with tools for large-scale, singlecell activation or silencing of cell ensembles with spatiotemporal precision, to dissect causal relationships between cellular activity and a behavioral or pathological output. In further embodiments, GLOBE recording is combined with in situ molecular and connectomics analyses to correlate spatiotemporal signatures of cell activity with one or more of: genetic, epigenetic, transcriptomic, proteomic, circuit, spatial molecular, cellular, or subcellular structural features in the same cells. In further embodiments, GLOBE recording is performed in a non-human mammalian subject other than a mouse, including, without limitation, a rat, a rabbit, a non-human primate, a guinea pig, a hamster, a ferret, a cat, a dog, a pig, a sheep, a goat, a horse, or a cow. In further embodiments, GLOBE recording is performed in an ex vivo preparation of mammalian brain tissue. In further embodiments, GLOBE recording is performed in mammalian organoid or assembloid models.
[0217] N on-perturbation of cellular physiology and behavior.
[0218] In some embodiments, recording substrates of the present disclosure are selected to be substantially non-perturbing to cellular physiology and behavior. Without limitation, mutation-induced filaments of folded proteins, including the structural monomers disclosed herein, have been described as inert and non-toxic in cellular systems (Levin et al., Mol. Syst. Biol. 21:1306-1324 (2025)), and XRI and CytoTape recording substrates have been used to record cellular activity without detectable alteration of key physiological signatures or behavioral functions of recorded cells (See, e.g., Examples 1-2; Linghu et al., Nat. Biotechnol. 41:640-651 (2023); Zheng et al., Nature 652: 1038-1048 (2026)). No reference cited herein is admitted to be prior art. In some embodiments, GLOBE recording employs 1POK -based self-assembling protein tape recorders that retain cellular physiology and function in vitro or in vivo and that have been demonstrated to preserve intact brain functions in behaving non-human mammals, including, without limitation, behaving mice.
[0219] Kits comprising components of the GLOBE recording system.
[0220] In further aspects, the present disclosure provides kits comprising one or more components of a GLOBE recording system. In some embodiments, a kit comprises (a) one or more nucleic acid molecules encoding a structural monomer, a signal monomer, a timestamp monomer, and a tetracycline-controlled transactivator, or (b) one or more recombinant viral vectors comprising the foregoing nucleic acid molecules, or (c) one or more pharmaceutical compositions comprising the foregoing recombinant viral vectors. In some embodiments, the recombinant viral vectors are AAV vectors, optionally AAV9 vectors. In some embodiments, a kit further comprises one or more of a tetracycline-class antibiotic inducer (for example, doxycycline); one or more antibodies directed against the epitope tags fused to the structural, signal, and timestamp monomers; one or more fluorescent secondary antibodies; a cytosol-selective stain; reagents for expansion microscopy under a GLOBE-customized expansion protocol disclosed herein; reagents for RCA-based RNA FISH under a GLOBE-customized protocol disclosed herein; instructions for use; or any combination of the foregoing.
[0221] Diagnostic, therapeutic-screening, and research uses.
[0222] In further aspects, the present disclosure provides methods of using a GLOBE recording system to identify, characterize, or quantify the effect of a candidate agent or candidate manipulation on cellular activity in the brain of a mammalian subject. In some embodiments, the methods comprise: (a) administering a candidate agent or applying a candidate manipulation to the subject during a recording window; (b) performing GLOBE recording during the recording window; (c) extracting per-cell signal traces and registering cell coordinates to a common anatomical coordinate framework; and (d) comparing the resulting brain-wide spatiotemporal functional atlas to (i) a corresponding atlas obtained from a control subject not receiving the candidate agent or manipulation, (ii) a corresponding atlas obtained from a subject receiving a different agent or manipulation, or (iii) a reference atlas, thereby identifying brain regions, cell populations, temporal modes, or any combination thereof, that are differentially affected by the candidate agent or manipulation. In some embodiments, the candidate agent is a small molecule, a biologic, a nucleic acid therapeutic, a cell therapy, a gene therapy, or a combination of any of the foregoing. In some embodiments, the candidate manipulation is a behavioral, environmental, surgical, electrophysiological, or genetic manipulation, or a combination of any of the foregoing.
[0223] In further embodiments, the methods of the present disclosure are used to identify, characterize, or screen therapeutic candidates or therapeutic targets relevant to one or more disorders or conditions of the mammalian brain, including, without limitation, neurodegenerative disorders, neuropsychiatric disorders, neurodevelopmental disorders, epilepsy, traumatic brain injury, stroke, brain tumors, chronic pain, addiction, learning and memory disorders, sleep disorders, and combinations of any of the foregoing. In further embodiments, the methods of the present disclosure are used to characterize cell-type-specific or brain-region-specific responses to candidate therapeutic agents or candidate manipulations, to support drug discovery, target validation, or mechanism-of-action studies.
[0224] All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein. From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions.
[0225] For reasons of completeness, various aspects of the disclosure are set out in the following numbered clauses. The clauses are numbered for ease of reference only and numbering does not indicate any priority, preference, or required order of the embodiments described.
[0226] Clause 1. An isolated nucleic acid encoding a self-assembling protein monomer, the selfassembling protein monomer comprising:
[0227] (a) a self-assembling scaffold domain comprising a 1POK -derived amino acid sequence comprising:
[0228] (i) a glutamic acid-to-tyrosine substitution at a position corresponding to E239Y of a 1POK scaffold sequence; and
[0229] (ii) a hydrophobic amino acid-to-hydrophilic amino acid substitution at a lateral interface of the self-assembling scaffold domain;
[0230] (b) a maltose binding protein-derived insulator domain fused to the self-assembling scaffold domain; and
[0231] (c) a detectable tag;
[0232] wherein expression of the self-assembling protein monomer in a mammalian cell produces an intracellular protein filament.
[0233] Clause 2. The isolated nucleic acid of Clause 1, wherein the hydrophobic amino acid-to-hydrophilic amino acid substitution comprises a leucine-to-lysine substitution.
[0234] Clause 3. The isolated nucleic acid of Clause 1 or 2, wherein the hydrophobic amino acid-to-hydrophilic amino acid substitution is L349K or a substitution at a corresponding position.
[0235] Clause 4. The isolated nucleic acid of any one of Clauses 1-3, wherein the self-assembling scaffold domain comprises 1POK(E239Y, L349K) or an amino acid sequence at least 80%, 85%, 90%>, 95%, 97%, 98%>, or 99% identical thereto that retains the ability to form an intracellular protein filament.
[0236] Clause 5. The isolated nucleic acid of any one of Clauses 1-4, wherein the maltose binding protein-derived insulator domain comprises an E. coli maltose binding protein sequence.
[0237] Clause 6. The isolated nucleic acid of any one of Clauses 1-5, wherein the maltose binding protein-derived insulator domain comprises an N-terminally truncated maltose binding protein.
[0238] Clause 7. The isolated nucleic acid of Clause 6, wherein the N-terminally truncated maltose binding protein comprises dMBP.
[0239] Clause 8. The isolated nucleic acid of any one of Clauses 1-7, wherein the self-assembling scaffold domain is directly fused to the maltose binding protein-derived insulator domain without an intervening linker.
[0240] Clause 9. The isolated nucleic acid of any one of Clauses 1-7, wherein the self-assembling scaffold domain is fused to the maltose binding protein-derived insulator domain through a linker comprising 2 to 25 amino acids.
[0241] Clause 10. The isolated nucleic acid of Clause 9, wherein the linker comprises 2, 6, 10, 12, or 18 amino acids.
[0242] Clause 11. The isolated nucleic acid of any one of Clauses 1-10, wherein the detectable tag is C-terminal to the maltose binding protein-derived insulator domain.
[0243] Clause 12. The isolated nucleic acid of any one of Clauses 1-11, wherein the detectable tag is selected from HA, V5, E-tag, OLLAS, FLAG, HaloTag, a fluorescent protein, an enzymatic tag, and combinations thereof.
[0244] Clause 13. The isolated nucleic acid of any one of Clauses 1-12, wherein the intracellular protein filament is thinner than an intracellular filament formed by an otherwise corresponding monomer lacking the hydrophobic amino acid-to-hydrophilic amino acid substitution.
[0245] Clause 14. The isolated nucleic acid of any one of Clauses 1-13, wherein the intracellular protein filament maintains substantially constant lateral width over at least 7 days, at least 14 days, at least 18 days, or at least 21 days in a live mammalian cell.
[0246] Clause 15. The isolated nucleic acid of any one of Clauses 1-14, wherein the intracellular protein filament is flexible and curls within a cytoplasm of the mammalian cell without detectably deforming a plasma membrane of the mammalian cell.
[0247] Clause 16. A self-assembling protein monomer encoded by the isolated nucleic acid of any one of Clauses 1-15.
[0248] Clause 17. A vector comprising the isolated nucleic acid of any one of Clauses 1-15.
[0249] Clause 18. The vector of Clause 17, wherein the vector is a plasmid, lentiviral vector, retroviral vector, adenoviral vector, or adeno-associated viral vector.
[0250] Clause 19. The vector of Clause 17 or 18, wherein expression of the isolated nucleic acid is controlled by a constitutive promoter, tissue-specific promoter, cell-type-specific promoter, inducible promoter, or activity -responsive promoter.
[0251] Clause 20. A cell comprising the isolated nucleic acid of any one of Clauses 1-15, the selfassembling protein monomer of Clause 16, or the vector of any one of Clauses 17-19.
[0252] Clause 21. The cell of Clause 20, wherein the cell is a mammalian cell, neuron, glial cell, HEK cell, HeLa cell, stem cell, progenitor cell, mitotic cell, cancer cell, immune cell, muscle cell, cardiac cell, or secretory cell.
[0253] Clause 22. A genetically encoded intracellular recording system comprising:
[0254] (a) a structural expression cassette encoding a structural monomer comprising a selfassembling scaffold domain and a structural detectable tag;
[0255] (b) a timestamp expression cassette encoding a timestamp monomer comprising the selfassembling scaffold domain and a time-labelable tag; and
[0256] (c) a signal expression cassette encoding a signal monomer comprising the self-assembling scaffold domain and a signal detectable tag, wherein expression of the signal monomer is controlled by an activity -responsive promoter;
[0257] wherein the structural monomer, timestamp monomer, and signal monomer co-assemble in a live cell into a common intracellular protein filament.
[0258] Clause 23. The genetically encoded intracellular recording system of Clause 22, wherein the self-assembling scaffold domain of each of the structural monomer, timestamp monomer, andsignal monomer comprises a 1POK-derived scaffold comprising E239Y and L349K, or substitutions at corresponding positions.
[0259] Clause 24. The genetically encoded intracellular recording system of Clause 22 or 23, wherein each of the structural monomer, timestamp monomer, and signal monomer further comprises a maltose binding protein-derived insulator domain.
[0260] Clause 25. The genetically encoded intracellular recording system of Clause 24, wherein the maltose binding protein-derived insulator domain comprises dMBP.
[0261] Clause 26. The genetically encoded intracellular recording system of any one of Clauses 22-25, wherein the time-labelable tag comprises HaloTag.
[0262] Clause 27. The genetically encoded intracellular recording system of Clause 26, wherein the timestamp monomer is labelable by two or more spectrally distinguishable HaloTag ligands.
[0263] Clause 28. The genetically encoded intracellular recording system of any one of Clauses 22-27, wherein the activity-responsive promoter is responsive to transcription factor activity, gene promoter activity, cellular stress, neuronal activity, depolarization, cAMP signaling, calcium signaling, heat shock, drug exposure, or disease-associated signaling.
[0264] Clause 29. The genetically encoded intracellular recording system of any one of Clauses 22-28, wherein the activity-responsive promoter comprises a c-fos promoter, Egrl promoter, SARE-ArcMin promoter, N-RAM promoter, F-RAM promoter, 6xCRE-CMVMin promoter, HSPA1A promoter, Npas4 promoter, or a functional variant thereof.
[0265] Clause 30. The genetically encoded intracellular recording system of any one of Clauses 22-29, comprising at least two signal expression cassettes encoding at least two signal monomers.
[0266] Clause 31. The genetically encoded intracellular recording system of Clause 30, wherein the at least two signal monomers comprise different detectable tags and are controlled by different activity-responsive promoters.
[0267] Clause 32. The genetically encoded intracellular recording system of Clause 30 or 31, comprising at least three, at least four, or at least five signal expression cassettes encoding signal monomers comprising mutually distinguishable detectable tags.
[0268] Clause 33. The genetically encoded intracellular recording system of Clause 32, wherein the signal monomers are configured to record at least two activities selected from CREB activity, Fos activity, c-fos promoter activity, Egrl promoter activity, Arc promoter activity, Npas4 activity, HSPA1A promoter activity, and inducible TRE promoter activity.
[0269] Clause 34. The genetically encoded intracellular recording system of any one of Clauses 22-33, wherein the common intracellular protein filament stores a time-resolved record of cellular activity as a spatial distribution of signal detectable tags along the common intracellular protein filament.
[0270] Clause 35. A method of recording a cellular activity history in a live cell, comprising:
[0271] (a) introducing into the live cell the genetically encoded intracellular recording system of any one of Clauses 22-34;
[0272] (b) expressing the structural monomer, timestamp monomer, and signal monomer in the live cell such that the monomers co-assemble into a common intracellular protein filament;
[0273] (c) exposing the live cell to a first timestamp label at a first defined time;
[0274] (d) detecting a spatial distribution of the timestamp monomer and a spatial distribution of the signal monomer along the common intracellular protein filament; and
[0275] (e) reconstructing a time-resolved cellular activity history from the spatial distributions.
[0276] Clause 36. The method of Clause 35, further comprising exposing the live cell to a second timestamp label at a second defined time.
[0277] Clause 37. The method of Clause 36, wherein the first timestamp label and the second timestamp label are spectrally distinguishable HaloTag ligands.
[0278] Clause 38. The method of Clause 36 or 37, wherein the first defined time and the second defined time are separated by at least 0.5 hours, at least 1 hour, at least 3 hours, at least 12 hours, at least 1 day, at least 3 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, at least 18 days, or at least 21 days.
[0279] Clause 39. The method of any one of Clauses 35-38, further comprising fixing the live cell, wherein fixation defines a terminal timestamp corresponding to a terminus of the common intracellular protein filament.
[0280] Clause 40. The method of any one of Clauses 35-39, wherein detecting comprises immunostaining one or more epitope tags on the common intracellular protein filament.
[0281] Clause 41. The method of any one of Clauses 35-40, wherein detecting comprises fluorescence microscopy, confocal microscopy, spinning disk confocal microscopy, superresolution microscopy, expansion microscopy, or multiplexed immunofluorescence imaging.
[0282] Clause 42. The method of any one of Clauses 35-41, wherein reconstructing comprises fitting a transfer function between spatial position along the common intracellular protein filament and real time.
[0283] Clause 43. The method of Clause 42, wherein the transfer function is generated using a dye-switch point, an inducer-on point, an inducer-off point, a fixation endpoint, or any combination thereof.
[0284] Clause 44. The method of Clause 42 or 43, wherein the transfer function comprises a linear fit, polynomial fit, B-spline fit, power fit, or other interpolation.
[0285] Clause 45. The method of any one of Clauses 35-44, wherein reconstructing comprises converting signal-tag intensity along the common intracellular protein filament into a time-resolved waveform.
[0286] Clause 46. The method of Clause 45, wherein the time-resolved waveform identifies onset, amplitude, peak time, duration, full width at half maximum, decay, oscillation, frequency, baseline fluctuation, or time-lagged correlation of the cellular activity.
[0287] Clause 47. The method of any one of Clauses 35-46, wherein the cellular activity history is recorded for at least 1 day, at least 3 days, at least 5 days, at least 7 days, at least 14 days, at least 18 days, or at least 21 days.
[0288] Clause 48. The method of any one of Clauses 35-47, wherein the cellular activity history comprises two or more discrete cellular activity events occurring in the same live cell.
[0289] Clause 49. The method of Clause 48, wherein the two or more discrete cellular activity events are separated by at least 0.5 hours, at least 1 hour, at least 12 hours, at least 1 day, or at least 3 days.
[0290] Clause 50. The method of any one of Clauses 35-49, wherein the live cell is a neuron, glial cell, HEK cell, HeLa cell, mitotic cell, cancer cell, immune cell, cardiac cell, muscle cell, or secretory cell.
[0291] Clause 51. A method of multiplexed recording of cellular activities in a live cell, comprising:
[0292] (a) expressing in the live cell:
[0293] (i) a structural monomer comprising a self-assembling scaffold domain and a structural detectable tag;
[0294] (ii) a timestamp monomer comprising the self-assembling scaffold domain and a time-labelable tag; and
[0295] (iii) at least two signal monomers, each signal monomer comprising the self-assembling scaffold domain, a distinct signal detectable tag, and an activity-responsive promoter different from the activity-responsive promoter of another signal monomer;
[0296] (b) co-assembling the structural monomer, timestamp monomer, and at least two signal monomers into the same intracellular protein filament;
[0297] (c) detecting spatial distributions of the distinct signal detectable tags along the same intracellular protein filament; and
[0298] (d) determining time-resolved histories of at least two cellular activities in the live cell.
[0299] Clause 52. The method of Clause 51, wherein the at least two cellular activities comprise promoter activities of c-fos and Arc.
[0300] Clause 53. The method of Clause 51, wherein the at least two cellular activities comprise promoter activities of Arc and Egrl.
[0301] Clause 54. The method of Clause 51, wherein the at least two cellular activities comprise CREB activity and Fos activity.
[0302] Clause 55. The method of any one of Clauses 51-54, wherein at least five cellular activities are recorded from the same intracellular protein filament.
[0303] Clause 56. The method of Clause 55, wherein the at least five cellular activities comprise CREB activity, c-fos promoter activity, Egrl promoter activity, Arc promoter activity, and Npas4 activity.
[0304] Clause 57. The method of any one of Clauses 51-56, wherein determining comprises comparing onset times, peak times, amplitudes, durations, oscillations, or time-lagged correlations of the at least two cellular activities.
[0305] Clause 58. An isolated nucleic acid encoding a CytoTape-vivo monomer, the CytoTape-vivo monomer comprising:
[0306] (a) a 1POK-derived self-assembling scaffold comprising E239Y and L349K, or substitutions at corresponding positions;
[0307] (b) a maltose binding protein-derived insulator domain;
[0308] (c) a linker positioned between the 1POK-derived self-assembling scaffold and the maltose binding protein-derived insulator domain; and
[0309] (d) a detectable tag;
[0310] wherein expression of the CytoTape-vivo monomer in a neuron forms one or more intracellular protein filaments suitable for optical readout in brain tissue.
[0311] Clause 59. The isolated nucleic acid of Clause 58, wherein the linker comprises 6 amino acids.
[0312] Clause 60. The isolated nucleic acid of Clause 58 or 59, wherein the CytoTape-vivo monomer comprises 1POK(E239Y,L349K)-linker6-MBP-HA.
[0313] Clause 61. A viral vector comprising the isolated nucleic acid of any one of Clauses 58-60.
[0314] Clause 62. The viral vector of Clause 61, wherein the viral vector is an adeno-associated viral vector.
[0315] Clause 63. The viral vector of Clause 62, wherein the adeno-associated viral vector is AAV9.
[0316] Clause 64. A method of recording neuronal activity in vivo in a non-human mammal, comprising:
[0317] (a) delivering to neurons in a brain region one or more viral vectors encoding:
[0318] (i) a CytoTape-vivo structural monomer;
[0319] (ii) a CytoTape-vivo timestamp monomer controlled by an inducible promoter; and
[0320] (iii) a CytoTape-vivo signal monomer controlled by an immediate early gene promoter;
[0321] (b) administering an inducer to the non-human mammal to induce expression of the CytoTape-vivo timestamp monomer;
[0322] (c) exposing the non-human mammal to a neuronal stimulus;
[0323] (d) detecting spatial distributions of a timestamp tag and a signal tag along CytoTape-vivo filaments in brain tissue; and
[0324] (e) reconstructing a time-resolved neuronal activity history from the spatial distributions.
[0325] Clause 65. The method of Clause 64, wherein the brain region comprises hippocampus.
[0326] Clause 66. The method of Clause 64 or 65, wherein the brain region comprises dorsal CA1.
[0327] Clause 67. The method of any one of Clauses 64-66, wherein the inducible promoter comprises a TRE promoter or TRE3G promoter.
[0328] Clause 68. The method of any one of Clauses 64-67, wherein the inducer comprises doxycycline.
[0329] Clause 69. The method of Clause 68, wherein doxycycline is administered orally.
[0330] Clause 70. The method of any one of Clauses 64-69, wherein the immediate early gene promoter comprises a c-fos promoter.
[0331] Clause 71. The method of any one of Clauses 64-70, wherein the neuronal stimulus comprises kainic acid administration, seizure induction, sensory stimulation, behavioral stimulation, pharmacological stimulation, electrical stimulation, or optogenetic stimulation.
[0332] Clause 72. The method of any one of Clauses 64-71, wherein reconstructing comprises using an inducer-on time point, an inducer-off time point, and a tissue fixation or perfusion time point to convert spatial position along a CytoTape-vivo filament into real time.
[0333] Clause 73. The method of any one of Clauses 64-72, further comprising determining spatial heterogeneity of neuronal activity across the brain region.
[0334] Clause 74. A method of identifying an effect of a candidate agent or candidate stimulus on a cellular activity, comprising:
[0335] (a) expressing, in a plurality of cells, the genetically encoded intracellular recording system of any one of Clauses 22-34;
[0336] (b) contacting a test population of the plurality of cells with the candidate agent or candidate stimulus;
[0337] (c) detecting spatial signal-tag distributions along intracellular protein filaments in the test population and in a control population; and
[0338] (d) determining whether the candidate agent or candidate stimulus alters a time-resolved waveform of the cellular activity relative to the control population.
[0339] Clause 75. The method of Clause 74, wherein the candidate agent or candidate stimulus comprises a pharmaceutical compound, signaling molecule, neurotransmitter, toxin, inflammatory stimulus, electrical stimulus, light stimulus, temperature stimulus, biological stimulus, inhibitory stimulus, excitatory stimulus, or cellular stimulus.
[0340] Clause 76. The method of Clause 74 or 75, wherein the time-resolved waveform comprises onset, amplitude, peak time, duration, full width at half maximum, decay, oscillation, frequency, baseline fluctuation, or time-lagged correlation.
[0341] Clause 77. The method of any one of Clauses 74-76, wherein the plurality of cells comprises neurons, glial cells, cancer cells, immune cells, stem cells, progenitor cells, HEK cells, HeLa cells, or mitotic cells.
[0342] Clause 78. The method of any one of Clauses 74-77, wherein the cellular activity comprises gene expression, transcription factor activity, stress response, neuronal activity, calciumdependent signaling, cAMP signaling, disease-associated signaling, or drug response.
[0343] Clause 79. A kit comprising:
[0344] (a) one or more nucleic acids or vectors encoding the genetically encoded intracellular recording system of any one of Clauses 22-34; and
[0345] (b) one or more reagents for detecting timestamp monomers, structural monomers, signal monomers, or combinations thereof.
[0346] Clause 80. The kit of Clause 79, wherein the one or more reagents comprise one or more HaloTag ligands, antibodies to epitope tags, fluorescent secondary antibodies, fixation reagents, staining reagents, or instructions for reconstructing a time-resolved cellular activity history from spatial tag distributions along an intracellular protein filament.
[0347] Clause 81. A genetically encoded system for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject, the system comprising:
[0348] (a) a structural expression cassette encoding a structural monomer comprising a selfassembling recording substrate and a first detectable tag, wherein expression of the structural monomer is controlled by a constitutive regulatory element;
[0349] (b) a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element; and
[0350] (c) a timestamp expression cassette encoding a timestamp monomer comprising the selfassembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element;
[0351] wherein the structural monomer, signal monomer, and timestamp monomer are configured to co-assemble in cells of the mammalian subject into a common intracellular protein filament, such that cellular activity and timestamp information are encoded as spatial distributions of the second and third detectable tags along the common intracellular protein filament.
[0352] Clause 82. The system of Clause 81, further comprising a transactivator expression cassette encoding a transactivator that activates the inducible regulatory element in response to an inducing agent.
[0353] Clause 83. The system of Clause 81 or 82, wherein the common intracellular protein filament elongates bidirectionally from a central reference position.
[0354] Clause 84. The system of any one of Clauses 81-83, wherein the self-assembling recording substrate is a GLOBE-compatible substrate that:
[0355] (a) forms an intracellular linear self-assembling protein filament in the cytosol of a mammalian neuron in vivo;
[0356] (b) accepts incorporation of the signal monomer driven by the activity-dependent regulatory element;
[0357] (c) accepts incorporation of the timestamp monomer driven by the inducible regulatory element; and
[0358] (d) permits post-fixation immunofluorescence readout of the second and third detectable tags along a spatial axis of the filament.
[0359] Clause 85. The system of any one of Clauses 81-84, wherein the self-assembling recording substrate comprises XRI, CytoTape, CytoTape-vivo, or a functional variant of any of the foregoing.
[0360] Clause 86. The system of any one of Clauses 81-85, wherein the self-assembling recording substrate comprises a 1POK-derived self-assembling scaffold.
[0361] Clause 87. The system of Clause 86, wherein the IPOK-derived self-assembling scaffold comprises an E239Y substitution, an L349K substitution, or a combination thereof.
[0362] Clause 88. The system of any one of Clauses 81-87, wherein the self-assembling recording substrate further comprises a maltose binding protein-derived insulator domain.
[0363] Clause 89. The system of any one of Clauses 81-88, wherein the first, second, and third detectable tags are mutually distinguishable epitope tags.
[0364] Clause 90. The system of Clause 89, wherein the mutually distinguishable epitope tags comprise HA, V5, FLAG, E-tag, OLLAS, or combinations thereof.
[0365] Clause 91. The system of any one of Clauses 81-90, wherein the constitutive regulatory element comprises a UbC promoter, CAG promoter, CMV promoter, CBA promoter, or EFla promoter.
[0366] Clause 92. The system of any one of Clauses 81-91, wherein the activity-dependent regulatory element comprises a Fos promoter, c-fos promoter, Arc promoter, SARE-ArcMinpromoter, N-RAM promoter, Egrl promoter, Npas4 promoter, HSPA1A promoter, CREB-responsive promoter, F-RAM promoter, or 6xCRE-CMVMin promoter.
[0367] Clause 93. The system of any one of Clauses 81-92, wherein the activity-dependent regulatory element comprises aFos promoter.
[0368] Clause 94. The system of any one of Clauses 81-93, wherein the signal monomer comprises a protein-destabilizing sequence, an mRNA-destabilizing element, or both.
[0369] Clause 95. The system of Clause 94, wherein the protein-destabilizing sequence comprises a PEST sequence.
[0370] Clause 96. The system of Clause 94 or 95, wherein the signal monomer comprises XRI-V5-P1N4.
[0371] Clause 97. The system of any one of Clauses 81-96, wherein the inducible regulatory element comprises a tetracycline-responsive element.
[0372] Clause 98. The system of Clause 97, wherein the tetracycline-responsive element comprises TRE or TRE3G.
[0373] Clause 99. The system of Clause 98, wherein the transactivator comprises rtTA or rtTA3G.
[0374] Clause 100. The system of Clause 99, wherein expression of rtTA or rtTA3G is controlled by a neuronal promoter.
[0375] Clause 101. The system of Clause 100, wherein the neuronal promoter comprises an hSyn promoter.
[0376] Clause 102. A recombinant viral vector composition for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject, the composition comprising:
[0377] (a) a first recombinant viral vector comprising a structural expression cassette encoding a structural monomer comprising a self-assembling recording substrate and a first detectable tag;
[0378] (b) a second recombinant viral vector comprising a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element;
[0379] (c) a third recombinant viral vector comprising a timestamp expression cassette encoding a timestamp monomer comprising the self-assembling recording substrate and a third detectabletag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element; and
[0380] (d) a fourth recombinant viral vector comprising a transactivator expression cassette encoding a transactivator configured to activate the inducible regulatory element in response to an inducing agent.
[0381] Clause 103. The recombinant viral vector composition of Clause 102, wherein the first, second, third, and fourth recombinant viral vectors are adeno-associated viral vectors.
[0382] Clause 104. The recombinant viral vector composition of Clause 103, wherein the adeno-associated viral vectors are AAV9 vectors.
[0383] Clause 105. The recombinant viral vector composition of Clause 103, wherein at least one adeno-associated viral vector comprises AAV-PHP.eB or AAV. CAP-B10.
[0384] Clause 106. The recombinant viral vector composition of any one of Clauses 102-105, wherein the first recombinant viral vector is present at a greater viral-genome-copy number than the second recombinant viral vector, the third recombinant viral vector, or both.
[0385] Clause 107. The recombinant viral vector composition of Clause 106, wherein the viral-genome-copy ratio of the first recombinant viral vector to the second recombinant viral vector to the third recombinant viral vector is about 100: 1: 10.
[0386] Clause 108. The recombinant viral vector composition of any one of Clauses 102-107, wherein:
[0387] (a) the first recombinant viral vector comprises AAV9-UbC-XRI-HA;
[0388] (b) the second recombinant viral vector comprises AAV9-c-fos-XRI-V5-P1N4;
[0389] (c) the third recombinant viral vector comprises AAV9-TRE3G-XRI-FLAG; and
[0390] (d) the fourth recombinant viral vector comprises AAV9-hSyn-rtTA3G.
[0391] Clause 109. The recombinant viral vector composition of any one of Clauses 102-108, wherein the self-assembling recording substrate comprises XRI.
[0392] Clause 110. The recombinant viral vector composition of any one of Clauses 102-108, wherein the self-assembling recording substrate comprises CytoTape or CytoTape-vivo.
[0393] Clause 111. The recombinant viral vector composition of any one of Clauses 102-110, formulated for multi-site, multi -depth intracranial administration.
[0394] Clause 112. The recombinant viral vector composition of any one of Clauses 102-110, formulated for intravenous administration.
[0395] Clause 113. A method of brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a non-human mammalian subject, the method comprising:
[0396] (a) delivering to cells in a brain of the non-human mammalian subject a genetically encoded recording system comprising:
[0397] (i) a structural expression cassette encoding a structural monomer comprising a selfassembling recording substrate and a first detectable tag;
[0398] (ii) a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element;
[0399] (iii) a timestamp expression cassette encoding a timestamp monomer comprising the selfassembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element; and
[0400] (iv) optionally, a transactivator expression cassette encoding a transactivator that activates the inducible regulatory element in response to an inducing agent;
[0401] (b) expressing the structural monomer, signal monomer, and timestamp monomer in cells of the brain such that the monomers co-assemble into intracellular protein filaments;
[0402] (c) administering the inducing agent to the non-human mammalian subject during a recording window;
[0403] (d) subjecting the non-human mammalian subject to a behavioral, pharmacological, physiological, environmental, or pathological manipulation during the recording window;
[0404] (e) fixing brain tissue of the non-human mammalian subject;
[0405] (f) detecting spatial distributions of the first, second, and third detectable tags along the intracellular protein filaments; and
[0406] (g) reconstructing, from the spatial distributions, time-resolved cellular activity histories for individual cells across multiple anatomically distinct brain regions.
[0407] Clause 114. The method of Clause 113, wherein delivering comprises multi-site, multidepth intracranial injection of recombinant AAV vectors.
[0408] Clause 115. The method of Clause 114, wherein the recombinant AAV vectors comprise AAV9 vectors.
[0409] Clause 116. The method of Clause 113, wherein delivering comprises intravenous administration of an AAV-PHP.eB vector, an AAV. CAP-B10 vector, or both.
[0410] Clause 117. The method of any one of Clauses 113-116, wherein the cells comprise neurons.
[0411] Clause 118. The method of any one of Clauses 113-117, wherein the multiple anatomically distinct brain regions comprise at least two, at least three, at least five, at least ten, or at least twenty brain regions.
[0412] Clause 119. The method of Clause 118, wherein the brain regions comprise isocortex, olfactory area, cortical subplate, hippocampal formation, pallidum, striatum, thalamus, hypothalamus, midbrain, or any combination thereof.
[0413] Clause 120. The method of any one of Clauses 113-119, wherein the recording window is at least 1 day, at least 3 days, at least 5 days, at least 5.5 days, at least 7 days, at least 14 days, or at least 21 days.
[0414] Clause 121. The method of any one of Clauses 113-120, wherein time-resolved cellular activity histories are reconstructed for at least 1,000, at least 10,000, at least 100,000, or at least 200,000 cells in the brain.
[0415] Clause 122. The method of Clause 121, wherein time-resolved cellular activity histories are reconstructed for about 220,000 neurons in a single mouse brain.
[0416] Clause 123. The method of any one of Clauses 113-122, wherein recording is achieved at a local recording density of at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of Nissl-positive neurons in one or more recorded brain regions.
[0417] Clause 124. The method of any one of Clauses 113-123, wherein the behavioral manipulation comprises contextual fear conditioning, contextual fear memory recall, or both.
[0418] Clause 125. The method of any one of Clauses 113-124, wherein the pharmacological manipulation comprises kainic acid administration.
[0419] Clause 126. The method of any one of Clauses 113-125, wherein the activity-dependent regulatory element comprises a Fos promoter.
[0420] Clause 127. The method of any one of Clauses 113-126, wherein detecting comprises immunostaining the first, second, and third detectable tags in fixed brain tissue and imaging the fixed brain tissue using multi-channel volumetric fluorescence microscopy.
[0421] Clause 128. A method of encoding one or more in vivo timestamps along intracellular protein filaments in brain cells of a non-human mammalian subject, the method comprising:
[0422] (a) delivering to the brain cells a timestamp expression cassette encoding a timestamp monomer comprising a self-assembling recording substrate and a detectable tag, wherein expression of the timestamp monomer is controlled by a tetracycline-responsive regulatory element;
[0423] (b) delivering to the brain cells a transactivator expression cassette encoding a tetracycline-controlled transactivator;
[0424] (c) administering doxycycline to the non-human mammalian subject during a first time interval, thereby inducing expression and incorporation of the timestamp monomer into intracellular protein filaments;
[0425] (d) withdrawing doxycycline from the non-human mammalian subject during a second time interval; and
[0426] (e) detecting, in fixed brain tissue, a spatial distribution of the detectable tag along the intracellular protein filaments, wherein the spatial distribution comprises a Dox-ON timestamp, a Dox-OFF timestamp, or both.
[0427] Clause 129. The method of Clause 128, wherein the tetracycline-responsive regulatory element comprises TRE or TRE3G.
[0428] Clause 130. The method of Clause 128 or 129, wherein the tetracycline-controlled transactivator comprises rtTA3G.
[0429] Clause 131. The method of Clause 130, wherein expression of rtTA3G is controlled by an hSyn promoter.
[0430] Clause 132. The method of any one of Clauses 128-131, wherein doxycycline is administered orally in drinking water.
[0431] Clause 133. The method of Clause 132, wherein the drinking water comprises about 1 mg / mL doxycycline and about 5% sucrose.
[0432] Clause 134. The method of any one of Clauses 128-133, further comprising correcting a spatial position of the Dox-ON timestamp, the Dox-OFF timestamp, or both using an empirically determined latency value.
[0433] Clause 135. The method of Clause 134, wherein the empirically determined latency value comprises a median Dox-ON latency of about 17.8 hours.
[0434] Clause 136. The method of Clause 134 or 135, wherein the empirically determined latency value comprises a median Dox-OFF latency of about 20.9 hours.
[0435] Clause 137. The method of any one of Clauses 128-136, wherein after global temporal alignment, residual single-fiber latency errors are about ±6.2 hours for Dox-ON timestamps and about ±12.2 hours for Dox-OFF timestamps.
[0436] Clause 138. The method of any one of Clauses 128-137, wherein the method comprises two or more cycles of doxycycline administration and withdrawal.
[0437] Clause 139. The method of Clause 138, wherein the two or more cycles produce two or more spatially separated timestamp bands along an individual intracellular protein filament.
[0438] Clause 140. The method of Clause 139, wherein the two or more spatially separated timestamp bands are resolved by expansion microscopy.
[0439] Clause 141. A computer-implemented method for reconstructing time-resolved cellular activity histories from GLOBE-recorded tissue, the method comprising:
[0440] (a) receiving multi-channel volumetric microscopy image data of fixed mammalian brain tissue comprising cells that contain intracellular protein filaments formed by co-assembly of structural monomers, signal monomers, and timestamp monomers;
[0441] (b) segmenting intracellular protein filaments from a structural-monomer image channel;
[0442] (c) segmenting cell bodies from a cytosol-selective stain image channel;
[0443] (d) generating, for each segmented intracellular protein filament, a centerline representation;
[0444] (e) extracting intensity profiles from a signal-monomer image channel and a timestamp-monomer image channel along the centerline representation;
[0445] (f) assigning each segmented intracellular protein filament to a cell body;
[0446] (g) determining spatial positions of one or more timestamps from the timestamp-monomer intensity profile; and
[0447] (h) converting the signal-monomer intensity profile into a time-resolved cellular activity history using the spatial positions of the one or more timestamps.
[0448] Clause 142. The computer-implemented method of Clause 141, wherein segmenting intracellular protein filaments comprises applying a three-dimensional convolutional neural network to the structural-monomer image channel.
[0449] Clause 143. The computer-implemented method of Clause 142, wherein the three-dimensional convolutional neural network comprises a MedNeXt architecture, a U-Net architecture, or a 3D U-Net architecture.
[0450] Clause 144. The computer-implemented method of Clause 142 or 143, wherein the three-dimensional convolutional neural network predicts a binary foreground mask, an instance contour map, and a skeleton-aware Euclidean distance transform.
[0451] Clause 145. The computer-implemented method of any one of Clauses 142-144, wherein segmenting intracellular protein filaments further comprises applying a marker-based watershed algorithm to outputs of the three-dimensional convolutional neural network.
[0452] Clause 146. The computer-implemented method of any one of Clauses 141-145, wherein segmenting cell bodies comprises applying a Segment Anything for Microscopy framework to the cytosol-selective stain image channel.
[0453] Clause 147. The computer-implemented method of any one of Clauses 141-146, wherein generating the centerline representation comprises converting the segmented intracellular protein filament to a point cloud, applying principal component analysis to determine a fiber alignment axis, fitting a cubic B-spline through a central portion of the point cloud, and resampling the cubic B-spline to generate a standardized number of equidistant points.
[0454] Clause 148. The computer-implemented method of Clause 147, wherein the standardized number of equidistant points is 1,000.
[0455] Clause 149. The computer-implemented method of any one of Clauses 141-148, wherein extracting intensity profiles comprises trilinear interpolation of voxel intensities along the centerline representation.
[0456] Clause 150. The computer-implemented method of any one of Clauses 141-149, further comprising determining an optimal split point that divides each intracellular protein filament into two symmetric halves based on bilateral symmetry of the timestamp-monomer intensity profile.
[0457] Clause 151. The computer-implemented method of Clause 150, wherein determining the optimal split point comprises a coarse grid search followed by Tree-structured Parzen Estimator refinement.
[0458] Clause 152. The computer-implemented method of Clause 150 or 151, wherein each symmetric half is resampled to 500 points.
[0459] Clause 153. The computer-implemented method of any one of Clauses 141-152, further comprising excluding segmented structures that:
[0460] (a) are located outside neuronal soma as determined using the cytosol-selective stain;
[0461] (b) have a geodesic length below about 8 pm;
[0462] (c) have a first-principal-component explained variance below about 0.8;
[0463] (d) lack a detected timestamp; or
[0464] (e) any combination thereof.
[0465] Clause 154. The computer-implemented method of any one of Clauses 141-153, wherein converting the signal-monomer intensity profile into the time-resolved cellular activity history comprises fitting timestamp positions and corresponding real-world time points to a piecewise-linear function.
[0466] Clause 155. The computer-implemented method of any one of Clauses 141-154, wherein the multi-channel volumetric microscopy image data comprise a Nissl channel, a structural-monomer channel, a signal-monomer channel, and a timestamp-monomer channel.
[0467] Clause 156. The computer-implemented method of any one of Clauses 141-155, wherein the method produces, for each intracellular protein filament, an output data record comprising a fiber identifier, a parent cell identifier, a fiber length, fiber centroid coordinates, an optimal midpoint position, one or more timestamp-symmetry correlation coefficients, and per-channel intensity profiles.
[0468] Clause 157. A method of generating a brain-wide spatiotemporal functional atlas of cellular activity in a non-human mammalian subject, the method comprising:
[0469] (a) performing the method of any one of Clauses 113-127;
[0470] (b) extracting, for each recorded cell, a per-cell signal trace aligned to an absolute time axis;
[0471] (c) summarizing each per-cell signal trace as a vector of activity values within a plurality of time bins;
[0472] (d) applying dimensionality reduction to the vectors of activity values to generate a lowdimensional activity manifold;
[0473] (e) assigning temporal-mode classifications to recorded cells based on the vectors of activity values; and
[0474] (f) registering spatial coordinates of the recorded cells to a common anatomical coordinate framework, thereby generating the brain-wide spatiotemporal functional atlas.
[0475] Clause 158. The method of Clause 157, wherein the dimensionality reduction comprises UMAP, t-SNE, PC A, Diffusion Maps, or a combination thereof.
[0476] Clause 159. The method of Clause 157 or 158, wherein the common anatomical coordinate framework comprises the Allen Mouse Brain Common Coordinate Framework version 3.
[0477] Clause 160. The method of any one of Clauses 157-159, wherein the temporal-mode classifications comprise two or more of a no-response mode, early-peak mode, late-peak mode, dual-peak mode, wide-peak mode, and decay mode.
[0478] Clause 161. The method of any one of Clauses 157-160, wherein the activity manifold reflects response magnitude, response timing, or both.
[0479] Clause 162. The method of any one of Clauses 157-161, wherein the method identifies cells or cell populations exhibiting increased activity, decreased activity, persistent activity, early-peaking activity, late-peaking activity, dual-peaking activity, sustained activity, mildly suppressed activity, or any combination thereof.
[0480] Clause 163. The method of any one of Clauses 157-162, wherein the non-human mammalian subject is subjected to contextual fear conditioning, contextual fear memory recall, or both during a recording window.
[0481] Clause 164. The method of Clause 163, wherein the low-dimensional activity manifold is a memory manifold.
[0482] Clause 165. The method of any one of Clauses 157-164, further comprising comparing the brain-wide spatiotemporal functional atlas to a corresponding atlas obtained from a control subject or a subject subjected to a different manipulation.
[0483] Clause 166. The method of any one of Clauses 157-165, wherein the plurality of time bins comprises time bins of about 0.25 days, about 0.5 days, about 1 day, about 2 days, or combinations thereof.
[0484] Clause 167. The method of Clause 166, further comprising determining whether a global low-dimensional structure of the activity manifold is preserved across different temporal binning schemes.
[0485] Clause 168. The method of any one of Clauses 113-127 or 157-167, further comprising performing, in the same fixed tissue, immunohistochemistry for one or more endogenous proteins.
[0486] Clause 169. The method of Clause 168, wherein the one or more endogenous proteins comprise Fos, phospho-CREB, Arc, Egrl, Npas4, or a combination thereof.
[0487] Clause 170. The method of any one of Clauses 113-127 or 157-169, further comprising performing RNA fluorescence in situ hybridization in the same fixed tissue.
[0488] Clause 171. The method of Clause 170, wherein the RNA fluorescence in situ hybridization comprises rolling-circle-amplification-based RNA fluorescence in situ hybridization.
[0489] Clause 172. The method of any one of Clauses 113-127 or 157-171, further comprising performing expansion microscopy on the fixed tissue.
[0490] Clause 173. The method of any one of Clauses 168-172, further comprising correlating the time-resolved cellular activity histories with cell-type identity, RNA transcript level, endogenous protein abundance, spatial location, or any combination thereof.
[0491] Clause 174. A method of identifying an effect of a candidate agent or candidate manipulation on brain-wide cellular activity, the method comprising:
[0492] (a) performing GLOBE recording in a test non-human mammalian subject that receives the candidate agent or candidate manipulation;
[0493] (b) performing GLOBE recording in a control non-human mammalian subject that does not receive the candidate agent or candidate manipulation;
[0494] (c) generating a first brain-wide spatiotemporal functional atlas from the test non-human mammalian subject;
[0495] (d) generating a second brain-wide spatiotemporal functional atlas from the control non-human mammalian subject; and
[0496] (e) comparing the first and second brain-wide spatiotemporal functional atlases to identify a brain region, cell population, temporal mode, activity waveform feature, or combination thereof that is altered by the candidate agent or candidate manipulation.
[0497] Clause 175. The method of Clause 174, wherein the candidate agent comprises a small molecule, biologic, nucleic acid therapeutic, cell therapy, gene therapy, or combination thereof.
[0498] Clause 176. The method of Clause 174 or 175, wherein the candidate manipulation comprises a behavioral, environmental, surgical, electrophysiological, optogenetic, chemogenetic, pharmacological, genetic, disease-model, or stress manipulation.
[0499] Clause 177. The method of any one of Clauses 174-176, wherein the altered activity waveform feature comprises onset, amplitude, peak time, duration, full width at half maximum, decay, oscillation, frequency, baseline fluctuation, time-lagged correlation, or temporal centroid.
[0500] Clause 178. A kit for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject, the kit comprising:
[0501] (a) one or more nucleic acids or recombinant viral vectors encoding a structural monomer comprising a self-assembling recording substrate and a first detectable tag;
[0502] (b) one or more nucleic acids or recombinant viral vectors encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element;
[0503] (c) one or more nucleic acids or recombinant viral vectors encoding a timestamp monomer comprising the self-assembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element; and
[0504] (d) optionally, one or more nucleic acids or recombinant viral vectors encoding a transactivator configured to activate the inducible regulatory element in response to an inducing agent.
[0505] Clause 179. The kit of Clause 178, wherein the recombinant viral vectors comprise AAV9 vectors.
[0506] Clause 180. The kit of Clause 178 or 179, further comprising doxycycline, antibodies against the first, second, or third detectable tags, fluorescent secondary antibodies, a cytosol-selective stain, expansion microscopy reagents, RNA fluorescence in situ hybridization reagents, instructions for use, or any combination thereof. 1EXAMPLES
[0507] Examples of specific embodiments for carrying out the present disclosure are provided. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present disclosure in any way.
[0508] Example 1. Generation of CytoTape characterization of expression in cultured neurons and glial cells.
[0509] Materials and Methods.
[0510] Molecular dynamics simulations. The structure of the protein monomer for simulations was predicted by AlphaFold3 (Nature 2024, 630, 493-500) (See FIGS.1g and 1h). A cubic box was filled with one protein monomer. Water molecules were randomly inserted into the box to reach the protein that is fully covered by water molecules in the simulation. Chlorine counter ions were added to keep the system neutral in charge. The CHARMM27 force field was used for the complex and the CHARMM-modified TIP3P model was chosen for water. The simulationswere carried out at 310 K (37 oC). After the 5000-step energy -minimization procedure, the systems were heated and equilibrated for 100 ps in the NVT ensemble and 500 ps in the NPT ensemble. 500 ns production simulations were conducted with a trajectory saving frequency of 10 ps. The final 300 ns (30,000 frames) were extracted for subsequent analysis. The integration step was set to 2 fs, and only the covalent bonds with hydrogen atoms were constrained by the LINCS algorithm. Lennard-Jones interactions were truncated at 12 A with a force-switching function from 10 to 12 A. The electrostatic interactions were calculated using the particle mesh Ewald method with a cutoff of 12 A on an 1 A grid with a fourth-order spline. The temperature and pressure of the system are controlled by the velocity rescaling thermostat and the Parrinello-Rahman algorithm, respectively. All molecular dynamics simulations were performed using GROMACS 2021.1 packages.
[0511] The free energy landscape (FEL) was constructed using the trajectory data from the last 300 ns of the production simulations. Two reaction coordinates — root-mean-square deviation (RMSD) from the initial structure and radius of gyration (Rg) — were used to represent the conformational space of the protein. Trajectory frames were extracted at 10 ps intervals and aligned to the reference structure to remove overall translational and rotational motions. The 2D histogram of RMSD and Rg was computed using bins of 0.05 nm × 0.05 nm, and the corresponding free energy G was calculated using the Boltzmann inversion: G(RMSD, Rg) = -kBT / lnP(RMSD, Rg), where kB is the Boltzmann constant, T is the absolute temperature (310 K), and P(RMSD, Rg) is the normalized probability distribution of the system in the 2D conformational space. The analysis was performed using GROMACS tools (gmx rms, gmx gyrate, and gmx sham), and the FEL was visualized as a contour map using Origin2019b.
[0512] To evaluate the relative motion between two structural domains within the same protein, the center-of-mass (COM) distance between the domains was calculated over the course of the molecular dynamics simulation. The simulation trajectory was preprocessed using gmx trjconv to remove periodic boundary conditions and align the protein to a common reference frame. The interdomain distance at each time point was determined as the Euclidean distance between the COM coordinates. Analysis was performed on the final 300 ns of the production simulation, sampled every 10 ps, and the resulting distance profile was visualized using Origin2019b.
[0513] Molecular cloning. The DNAs encoding the protein motifs used in this work were mammalian-codon optimized and synthesized by Epoch Life Science, and then cloned intomammalian expression backbones, pAAV-UbC (for constitutive expression), pAAV-c-fos (for expression driven by the c-fos promoter), pAAV-Arc (for expression driven by the SARE-ArcMin promoter), pAAV-Egrl (for expression driven by the Egrl promoter), pAAV-Npas4 (for expression driven by the N-RAM promoter), pAAV-Fos (for expression driven by the F-RAM promoter), pAAV-CREB (for 6xCRE-CMVMin-dependent expression) or pAAV-HSPAlA(for expression driven by the HSPA1 A promoter) for DNA transfection in cultured neurons, glial cells, HEK293T clone 17 (referred to as HEK; ATCC CRL-11268) cells, and HeLa cells (ATCC CCL-2). pAAV-hSyn and pAAV-TRE are used for doxycycline-inducible timestamping in in vivo experiments. See FIG. 20, SEQ ID NOs:1-28, for sequences of the motifs, FIG. 18 for all constructs of protein monomer designs, and FIGS. 21-25 for all designed signal constructs.
[0514] Animals and preparation of primary mouse hippocampal neuron-glia co-cultures. All disclosed procedures involving animals at the University of Michigan were conducted in accordance with the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were reviewed and approved by the University of Michigan Institutional Animal Care & Use Committee. Cultured hippocampal neurons with glial cells were prepared from neonatal (postnatal day 0 or 1) Swiss Webster mice (Taconic; both male and female mice were used) as described (See Ref. 38). Briefly, the brains of ice-anesthetized neonatal mice were dissected out, and the hippocampal tissue was further dissected from the brains in an ice-cold dissection buffer (1 mM Kynurenic acid, 10 mM MgC12, 35 mM D-glucose in HBSS). The hippocampal tissue was subsequently treated with papain for 10 min at 37C followed by a 5-minute ovomucoid inhibition. The dissociated tissues were triturated, and a single-cell suspension was prepared using neuronal culture media (Minimum Essential Medium (MEM; Gibco) supplemented with 10 mM HEPES, 10% heat inactivated fetal bovine serum (HI FBS; Corning), 2% B27 supplement (Gibco), 2 mM L-Glutamine, 1 pM transferrin, 25 mM D-glucose; pH adjusted to 7.4). Cells were plated at a density of 40,000 cells per 100 pL on Matrigel (Corning)-coated coverslips (Carolina) and then incubated in a humidified cell culture incubator at 37C with 5% CO2. After the cells had settled and attached to the coverslips, 1 mL of neuronal culture media was added. When glial cells reached approximately 80% confluency (usually two days after plating), 1 mL neuronal culture media supplemented with 4 pM AraC was added to the existing media in each well.
[0515] CytoTape expression in cultured neurons and glial cells. Cultured neurons and glial cells were transfected at 7 days in vitro (DIV 7) for protein assembly design screening (See FIG. 1c, FIG. 7b), CytoTape with timestamps (See FIG. 3), and CytoTape-based transcriptional recorders (See FIG. 4, FIG. 10). For recording the time course of c-fos, Arc, Egrl, Npas4, and CREB-promoter-driven expression (See FIG. 5, FIG. 14 and FIG. 16), cells were transfected at DIV 4. A commercial calcium phosphate transfection kit (Invitrogen) was used as previously described (See 16,38), with the following transfection parameters. For protein assembly design screening (FIG. 1, FIG. 7), each well of a 24-well glass-bottom plate received 50 ng of the structural monomer plasmid and 1450 ng of the pUC19 plasmid (a “dummy” plasmid without a mammalian open reading frame to maintain the optimal mass ratio between DNA and calcium phosphate for the formation of co-precipitates for transfection). In the timestamped CytoTape expression experiment (FIG. 3), each well received 50 ng of the structural monomer plasmid (UbC-CytoTape), 5 ng of the timestamp monomer plasmid (UbC-CytoTape-HaloTag), and 1445 ng of pUC19 plasmid. For the CytoTape-based transcriptional recorder experiment (FIG. 4, FIG.10), each well was transfected with 50 ng of the structural monomer plasmid (UbC-CytoTape), 12.5 ng of CytoTape-HaloTag plasmid (UbC-CytoTape-HaloTag), and 1437.5 ng of pUC19 plasmid. In the single signal recording experiment (FIG. 5, FIG. 14), each well received 300 ng of the structural monomer plasmid (UbC-CytoTape), 30 ng of the timestamp monomer plasmid (UbC-CytoTape-HaloTag), 75 ng of the signal monomer plasmid (c-fos, Egrl, Arc, orNpas4-CytoTape-V5), and 1095 ng of the pUC19 plasmid. For the two-signal recording experiment (FIG. 5, FIG. 16), each well was transfected with 300 ng of the structural monomer plasmid (UbC-CytoTape), 30 ng of the timestamp monomer plasmid (UbC-CytoTape-HaloTag), 2×75 ng of the signal monomer plasmids (c-fos-CytoTape-V5 and Arc-CytoTape-OLLAS), and 1020 ng of pUC19 plasmid. After a 45-min incubation with DNA-calcium phosphate precipitates, cells were washed with a preformulated acidic buffer, HMEM (that is the MEM buffer supplemented with 15 mM HEPES and then adjusted to a final pH of 6.70-6.74 with acetic acid (Millipore Sigma) over the time course of 6 h) to remove residual precipitates. Cells were then placed back to the cell culture incubator.
[0516] GFP expression in cultured neurons. Cultured neurons were transfected at 7 days in vitro (DIV 7) (FIG. 11). A commercial calcium phosphate transfection kit (Invitrogen) was used as previously described (See Ref. 16,38), with the following transfection parameters. Each well of a24-well glass-bottom plate received 50 ng of the structural monomer plasmid and 1450 ng of the pUC19 plasmid (a “dummy” plasmid without a mammalian open reading frame to maintain the optimal mass ratio between DNA and calcium phosphate for the formation of co-precipitates for transfection). After a 45-min incubation with DNA-calcium phosphate precipitates, cells were washed with a preformulated acidic buffer, HMEM (that is the MEM buffer supplemented with 15 mM HEPES and then adjusted to a final pH of 6.70-6.74 with acetic acid (Millipore Sigma) over the time course of 6 h) to remove residual precipitates. Cells were then placed back to the cell culture incubator.
[0517] CytoTape expression in HEK and HeLa cells. HEK and HeLa cells at a low passage number (< 10 passages) were plated at 40% confluence onto a 200-mm tissue culture dish. Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco; containing high glucose, GlutaMAX supplement, and pyruvate) supplemented with 10% HI FBS (Coming) andpenicillin / streptomycin (Gibco) was used as the HEK and HeLa cell culture media. Cells were then grown in a cell culture incubator at 37C with 5% CO2. After reaching 50-70% confluence, cells were transferred to 24-well glass-bottom plates via trypsin treatment. The 24-well glassbottom plates were pre-treated with matrigel at room temperature for 30 min before cell plating.24 h after cell plating, genes were delivered using the TransIT-X2 Dynamic Delivery System kit (Mirus Bio).
[0518] For structural monomer expression experiment (FIG. 2), 100 ng structural monomer plasmid (UbC-CytoTape-HA) and 20 ng pUC19 plasmid were first diluted in 50 pL Opti-MEM medium (Gibco), followed by the addition of 0.9 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the single well. The cells were further incubated at 37C with CO2 for 24 h. For timestamped CytoTape expression experiment (FIG. 3, FIG. 9, FIG. 13, and FIG. 32), 100 ng structural monomer plasmid (UbC-CytoTape-HA), 100 ng timestamp monomer plasmid (UbC-CytoTape-HaloTag), and 190 ng pUC19 plasmid were first diluted in 50 pL Opti-MEM medium, followed by the addition of 0.9 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the single well. The cells were further incubated at 37C with CO2 for 24 h. For single-signal recording experiment (FIG. 13, FIG. 35), 100 ng structural monomer plasmid (UbC-CytoTape-HA), 10 ng timestamp monomer plasmid (UbC-CytoTape-HaloTag), 25 ng signal monomer plasmid (c-fos, CREB, or HSPAlA-CytoTape-V5), and 165 ng pUC19 plasmid were first dilutedin 50 pL Opti-MEM medium, followed by the addition of 0.9 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the single well. The cells were further incubated at 37C with CO2 for 24 h. For two-signal recording experiment (FIG. 6), 100 ng structural monomer plasmid (UbC-CytoTape), 10 ng timestamp monomer plasmid (UbC-CytoTape-HaloTag), 2 * 25 ng signal monomer plasmids (CREB-CytoTape-HA and Fos-CytoTape-OLLAS), and 140 ng pUC19 plasmid were first diluted in 50 pL Opti-MEM medium, followed by the addition of 0.9 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the single well. The cells were further incubated at 37C with CO2 for 24 h. For five-signal recording experiments (FIG. 5), 180 ng structural monomer plasmid (UbC-CytoTape), 20 ng CytoTape-HaloTag plasmid (UbC-CytoTape-HaloTag), and 5 * 25 ng signal monomer plasmid (CREB-CytoTape-HA, Egrl-CytoTape-Etag, c-fos-CytoTape-OLLAS, Arc-CytoTape-V5, and Npas4-CytoTape-FLAG) were first diluted in 50 pL Opti-MEM medium, followed by the addition of 1.5 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the well. The cells were further incubated in the cell culture incubator at 37C with 5% CO2 for 24 h.
[0519] GFP expression in HEK cells. HEK cells at a low passage number (< 10 passages) were plated at 40% confluence onto a 200-mm tissue culture dish. DMEM supplemented with 10% HI FBS and penicillin / streptomycin was used as the HEK cell culture media. Cells were then grown in a cell culture incubator at 37C with 5% CO2. After reaching 50-70% confluence, cells were transferred to 24-well glass-bottom plates via trypsin treatment. The 24-well glass-bottom plates were pre-treated with matrigel at room temperature for 30 min before cell plating. 24 h after cell plating, genes were delivered using the TransIT-X2 Dynamic Delivery System kit. 100 ng plasmid (Fos-GFP or CREB-GFP) and 20 ng pUC19 plasmid were first diluted in 50 pL Opti-MEM medium, followed by the addition of 0.9 pL TransIT-X2 reagent. The mixture was incubated at room temperature for 25 min and then added to the single well. The cells were further incubated at 37C with CO2 for 24 h (FIGS. 35-37).
[0520] CytoTape timestamps labeling. CytoTape was labeled with cell-permeant HaloTag-ligand Janelia Fluor (JF) dyes (Promega) (FIGS. 3, 5, 6, 9, 13, 14, 16, 32, 35 and 37). JF5O3, JF585, and JF635were used in this study for timestamps. The JF dyes were in lyophilized powder form and stored at -20C before use. The JF dye powder was first dissolved in 50 pL dimethyl sulfoxide (DMSO) and then diluted into 10 mL of HEK and HeLa cell culture media (for HEK and HeLacells) or into 10 mL of neuronal culture media (for cultured neurons and glial cells) at a final concentration of 0.1 gM. The dyed medium was filtered using a sterile 0.22 gm syringe filter before being added to the culture. It was then used to replace the original media in cell cultures at designated time points. During the dye-switching process, the medium containing the original dye was fully removed, followed by thorough washes of the cell cultures five times with 37C DMEM for HEK and HeLa cells, and MEM for cultured neurons and glial cells. Finally, the cells in each well of the 24-well plate were cultured in 500 gL of fresh HEK and HeLa cell culture media (for HEK and HeLa cells) or 1 mL neuronal culture media (for cultured neurons and glial cells) supplemented with a new JF dye at 0.1 gM final concentration in the cell culture incubator at 37C with 5% CO2.
[0521] Chemical stimulation of cultured neurons. For KC1 stimulation (FIGS. 4, 5, 16, 17, and 34), a KC1 stock buffer was prepared, containing 170 mM KC1, 2 mM CaC12, 1 mM MgC12, and 10 mM HEPES. Then, a KC1 depolarization medium was prepared by mixing the KC1 stock buffer with fresh neuronal culture medium, ensuring that the final concentration of K+ after mixing was 55 mM or 30 mM (accounting for the K+ already present in the fresh neuronal culture medium). The original culture medium from neuron cultures was transferred into a fresh 24-well plastic-bottom plate, where the medium from different neuron cultures was stored in separate wells and kept in the neuronal incubator until the end of the KCl-induced depolarization treatment. Then, 500 gL of KC1 depolarization medium was added to each well containing neuron cultures. The neuron cultures were placed back into the incubator and incubated for 10 min, 30 min, 1 h, 2 h, or 3 h. Finally, the KC1 depolarization medium was removed, and the original neuronal culture medium was transferred back into the corresponding wells. The neuron cultures were then returned to the cell culture incubator.
[0522] For forskolin (FSK) stimulation (FIG. 4, 5, 16, 17, and 34), FSK powder was dissolved in DMSO and the final concentration of it is 5 mM. Then, a FSK stimulation medium was prepared by mixing the 5 mM FSK solution with a fresh neuronal culture medium, ensuring that the final concentration of FSK after mixing was 5 gM, 10 gM, 20 gM, and 25 gM. The FSK stimulation medium was filtered using a sterile 0.22 gm syringe filter (VWR, Avantor) before being added to neurons. The original culture medium from neuron cultures was transferred into a fresh 24-well plastic-bottom plate, where the medium from different neuron cultures was stored in separate wells and kept in the neuronal incubator until the end of the FSK stimulation. Then, 500 gL ofFSK stimulation medium was added to each well containing neuron cultures. The neuron cultures were placed back into the incubator and incubated for 1 h. Finally, the FSK stimulation medium was removed, and the original neuronal culture medium was transferred back into the corresponding wells. The neuron cultures were then returned to the cell culture incubator.
[0523] Chemical stimulation of cultured mouse hippocampal glial cells. For KC1 stimulation (FIG. 12), a KC1 stock buffer was prepared, containing 170 mM KC1, 2 mM CaC12, 1 mM MgC12, and 10 mM HEPES. Then, a KC1 depolarization medium was prepared by mixing the KC1 stock buffer with fresh neuronal culture medium, ensuring that the final concentration of K+ after mixing was 55 mM (accounting for the K+ already present in the fresh neuronal culture medium). The original culture medium was transferred into a fresh 24-well plastic-bottom plate, where the medium from different cultures was stored in separate wells and kept in the neuronal incubator until the end of the KCl-induced depolarization treatment. Then, 500 pL of KC1 depolarization medium was added to each well containing cultures. The cultures were placed back into the incubator and incubated for 1 h. Finally, the KC1 depolarization medium was removed, and the original culture medium was transferred back into the corresponding wells. The cultures were then returned to the cell culture incubator.
[0524] Chemical stimulation ofHEK cells. For FSK stimulation (FIGS. 5, 6, 13, and 34), FSK powder was dissolved in DMSO to a final concentration of 5 mM. Then, an FSK stimulation medium was prepared by mixing the 5 mM FSK solution with fresh HEK cell culture medium, ensuring that the final concentration of FSK after mixing was 10 pM, 20 pM, and 50 pM. The FSK stimulation medium was filtered using a sterile syringe filter before being added to HEK cells. The original culture medium from HEK cell cultures was removed. Then, 500 pL of FSK stimulation medium was added to each well and incubated for 1 h. Finally, the FSK stimulation medium was removed, and fresh culture medium was transferred into the corresponding wells. The HEK cell cultures were then returned to the cell culture incubator.
[0525] Heat treatments ofHEK and HeLa cells. HEK (FIG. 13) and HeLa cells (FIG. 8) were cultured in cell culture media in a cell culture incubator set to 5% CO2 at 37C. Cells were plated in 24-well glass-bottom plates to achieve 90-100% confluence prior to the heat shock treatment. Then, the plates containing the cells were transferred into a mini-incubator preheated to 42C and incubated there for 1 h. After the heat shock, the plates were returned to the original 37C cell culture incubator for recovery.
[0526] Antibodies, Nissl, DAPI, CellMask stain. Primary antibodies (1:500 for immunofluorescence of cultured cells): anti-Etag (Invitrogen MA5-38276), anti-V5 (Invitrogen R960-25), anti-OLLAS (Invitrogen MA5-16125), anti-FLAG (Invitrogen 740001), and anti-HA (Cell Signaling Technology 11846S; Invitrogen PA5-33243), c-Fos Monoclonal Antibody (Synaptic Systems 226009), and Phospho-CREB (Serl33) Monoclonal Antibody (Cell Signaling Technology 9198).
[0527] Fluorescent secondary antibodies (1:500 for immunofluorescence of cultured cells): Mouse IgGl ATTO 425 conjugated antibody pre-absorbed (Rockland), Goat anti-Mouse IgG2a Alexa Fluor 488 (Invitrogen A-21131), Goat anti-Rat IgG(H+L) Alexa Fluor 546 (Invitrogen A-11081), Goat anti-Rabbit IgG(H+L) Alexa Fluor 594 (Invitrogen A-11012), Goat anti-Chicken IgY(H+L) Alexa Fluor Plus 647 (Invitrogen A32933), Goat anti-Mouse IgG2a Alexa Fluor 546 (Invitrogen A21133), and Goat anti-Rabbit IgG(H+L), Alexa Fluor Plus 488 (Invitrogen A-11008).
[0528] Nissl stain: NeuroTrace 435 / 455 Blue Fluorescent Nissl Stain (Invitrogen N21479, 1: 1000 for immunofluorescence of cultured cells).
[0529] DAPI stain: DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain (Thermo Scientific 62248, 1: 1000 for immunofluorescence of cultured cells).
[0530] CellMask stain: CellMask Plasma Membrane Stain (Thermo Scientific C56129 / C37608, 1: 1000 for immunofluorescence of cultured cells).
[0531] Additional details of primary antibodies, secondary antibodies, Nissl, DAPI, and CellMask used in the disclosure are provided in FIG. 40.
[0532] Immunostaining of epitope tags in cultured cells. Cells (neurons, glial, HEK, and HeLa cells) were fixed in 10% buffered formalin (Fisher Scientific) at room temperature (RT) for 10 min, followed by three 5-minute washes in 1 xPBS at RT. Blocking was performed in MAXBlock blocking medium (Active Motif) supplemented with 0.1% Triton X-100 and 100 mM glycine for 20 min at RT, followed by three additional 5-min washes in MAXwash washing medium (Active Motif) at RT. Cells were then incubated with primary antibodies diluted in MAXbind staining medium (Active Motif) for 1 h at RT. Afterward, cells underwent three 5-min washes in MAXwash washing medium at RT. Secondary antibodies were applied in MAXbind staining medium and incubated for 1 h at RT. Cells were then washed three times with MAXwash washing medium for 5 min each at RT. Finally, cells were incubated with NeuroTrace 435 / 455Blue Fluorescent Nissl Stain (Invitrogen) or CellMask (Thermo Scientific) for 10 min and stored in 1*PBS at 4C until imaging.
[0533] Immunostaining of pCREB and Fos protein in HEK cells. HEK cells were fixed in 10% buffered formalin (Fisher Scientific) at room temperature (RT) for 10 min, followed by three 5-minute washes in 1 xPBS at RT. Blocking was performed in MAXBlock blocking medium (Active Motif) supplemented with 0.1% Triton X-100 and 100 mM glycine for 20 min at RT, followed by three additional 5-min washes in MAXwash washing medium (Active Motif) at RT. Cells were then incubated with primary antibodies diluted in MAXbind staining medium (Active Motif) for 24 h at 4C. Afterward, cells underwent three 5-min washes in MAXwash washing medium at RT. Secondary antibodies were applied in MAXbind staining medium and incubated for 24 h at 4C. Cells were then washed three times with MAXwash washing medium for 5 min each at RT. Finally, cells were incubated with DAPI Nuclear Stain (Thermo Scientific) for 10 min and stored in 1 xPBS at 4C until imaging (FIG. 15).
[0534] Fluorescence microscopy of immunostained cells. Fluorescence microscopy was performed using a spinning disk confocal microscope (Yokogawa CSU-W1 Confocal Scanner Unit on a Nikon Eclipse Ti2 inverted microscope) equipped with a 40X 1.15 numerical aperture water immersion objective (Nikon MRD77410), a 10X objective, a Hamamatsu ORCA-Fusion BT sCMOS camera controlled by the NIS-Elements AR software, and laser / filter sets for 405 nm, 488 nm, 561 nm, 594 nm, and 640 nm optical channels. Multi-channel volumetric imaging was conducted at 0.4 pM per Z-step for each field of view under the 40X objective. The crosstalk between 561 nm and 594 nm is shown in FIG. 38. Imaging parameters remained consistent across all samples within each experimental set.
[0535] Photobleaching of Janelia Fluor dyes. For the experiments described in FIGS 5, 6, and 16, once imaging the Janelia Fluor (JF) dyes in cell samples with confocal microscopy, LED exposures was performed to completely photobleach the fluorescence signals and free up the optical channels for subsequent immunofluorescence staining. Samples in 24-well plates were placed approximately 30 cm away from a broadband white LED light source (ThorLabs, MNWHLP1) to be uniformly exposed to the LED illumination. The fluorescence of JF dyes in the samples was checked after every 10 min of LED exposure and such exposures was continued until the fluorescence of JF dyes dropped below the detection limit of the confocal microscope. The total LED exposure duration typically ranged from 10 to 60 min, depending on the initialfluorescence of JF dyes in the samples before LED exposure. The example of confocal images of JF585and JF635before and after LED bleaching is shown FIG. 37.
[0536] Re-identify the protein fiber after bleaching. To re-identify the same fibers after JF dye photobleaching, stage coordinates recorded during the initial timestamp imaging were used to return to the same locations. Additionally, brightfield images of the same cell were acquired to capture its specific morphological context. After antibody immunostaining, the previously imaged fibers were relocated by combining stage-coordinate guidance with brightfield-based visual matching of cell morphology and the spatial arrangement of nearby cells.
[0537] Animals and mouse surgery. C57BL / 6J mice (2-5 months of age; male; Jackson Laboratory) were anesthetized with 5% isoflurane during induction and placed on a heating pad in a stereotactic frame (RWD Instruments) with 1.5-2% isoflurane throughout surgery to maintain deep anesthesia. Ophthalmic ointment was applied to both eyes. Hair was removed with a hair removal cream and the surgical site was cleaned with ethanol and betadine. Following this, an incision was made to expose the skull. Craniotomy was performed by drilling through the skull above the injection site using a 0.5 mm diameter drill bit. AAV mixture (1.0-1.2 pL) was injected into dorsal CAI (AP, -2.0 mm from bregma; ML, ±1.5 mm; DV, -1.5 mm from brain surface) using a pulled glass capillary with a pressure microinjector (RWD) at a rate of 100 nL / min. Following injection, the needle remained at the target site for 15 min to facilitate AAV diffusion into brain tissue. Mice received carprofen i.p. following surgery and were placed on a heating pad for recovery.
[0538] The AAV mixture for injection was prepared by mixing the AAV stocks (serotype AAV9; UNC NeuroTools) at the following final concentrations: AAV9-UbC-BrainTape-HA (titer:1.58 x 1013 GC / ml, 0.5 pL), AAV9-c-fos-BrainTape-V5 (titer: 1.37 x 1013 GC / ml, dilution with DPBS: 1:10, 0.05 pL), AAV9-hSyn-rtTA3G (titer: 3.56 x 1012 GC / ml, 0.44 pL), AAV9-TRE3G-BrainTape-FLAG (titer: 2.67 x 1012 GC / ml, 0.3 pL).
[0539] Seizure induction in mice. Kainic acid (Sigma) was dissolved in sterile saline (ThermoFisher) at 1 mg / mL and administered intraperitoneally (i.p.) to mice at 15 mg / kg. Mice were observed for the next 3 h to evaluate the seizure level, before putting it back to the home cage. Following injection, mice were continuously monitored for 3 hours to assess seizure severity using the Racine scale. Mice were then returned to their home cages and monitored daily for recovery.
[0540] Doxycycline oral delivery in mice. Doxycycline hyclate (Sigma) was dissolved in sterile drinking water at 1 mg / mL and supplemented with 5% (w / v) sucrose. Standard drinking water in home cages was replaced with this doxycycline water. Following the treatment period, doxycycline water was replaced with standard drinking water to terminate doxycycline delivery.
[0541] Histology. Mice were perfused transcranially with lx PBS followed by 4% paraformaldehyde (Electron Microscopy Sciences) in lx PBS. The brain was gently extracted from the skull and postfixed in 4% paraformaldehyde in 1 x PBS overnight at 4 °C. The brain was then incubated in 100 mM glycine in 1 x PBS for 1 h at RT, and then the brain was transferred into 1 x PBS and stored at 4 °C until slicing. The brain was sectioned coronally at 50-pm thickness using a vibratome (Leica VT1000 S), and then stored in 1 x PBS at 4 °C until immunofluorescence staining.
[0542] Immunofluorescence of brain tissue. Brain tissue sections were blocked overnight at 4 °C in MAXBlock blocking medium, followed by four washes for 30 min each at RT in MAXWash washing medium. Next, tissues were incubated with primary antibodies in MAXbind staining medium overnight at 4 °C, and then washed in MAXWash washing medium four times for 30 min each at RT. Next, tissues were incubated with fluorescently labeled secondary antibodies and NeuroTrace Blue Fluorescent Nissl Stain (Invitrogen) in MAXbind staining medium overnight at 4 °C, and then washed in MAXWash washing medium four times for 15 min each at RT. Tissues were then stored in lx PBS at 4 °C until imaging.
[0543] Software for image analysis. Image analysis was performed in ImageJ (National Institutes of Health) and Python.
[0544] Segmentation and geometrical analysis of fibers in images. To capture precise information from CytoTape and improve data consistency, a computational analysis pipeline was developed in Python to extract information from raw 3D confocal microscopy images. The pipeline included several key steps: image deconvolution (in ImageJ. The rest of the steps were performed in Python); CytoTape fiber segmentation with the adaptive threshold strategy; centerline detection; fiber morphology verification, which involved removing intertangled protein fibers which has been recognized by algorithm as a whole (would result in information ambiguity) and noise-like short objects (mainly caused by excessive monomer nucleation events which not growing into a long fiber); and extraction of object properties, such as fluorescent intensity along the centerline, fiber length, thickness, curvature, and spatial locations in the 3Dspace. The pipeline’s reliability was validated using ground truth datasets from human annotation. With this pipeline, the fluorescent intensity profiles along the fibers were obtained.
[0545] Readout information from intensity profiles. Fluorescence intensity profiles along the fiber were extracted from images as previously described (See Ref. 38).
[0546] Time recovery with HaloTag-based timestamp. Each fiber was divided into two segments based on an optimal split point as previously described (See. Ref. 38). This point was determined by iterating through hypothetical split locations within a window spanning 20% of the total fiber length around its geometrical center point and selecting the one that maximized the Pearson correlation between the left and right halves. It was reasoned that this optimal split best balances the trade-off between the inherent symmetry of CytoTape elongation and the variability in protein assembly introduced by the complex cellular environment.
[0547] For each half fiber (representing a complete time axis), the fluorescent intensities from different HaloTag-based timestamp channels were plotted, and critical points for dye color switching were manually identified that represented real-time events along the fiber, serving as a bridge between fiber growth and real-time events. These critical points included the onset rise point of the second dye color relative to the first dye color for the first timestamp (reflecting when the second dye was actually added), the onset rise point of the next dye color (if present) relative to the second color for the second timestamp (reflecting when the subsequent dye was actually added), and the fiber endpoint (reflecting the actual cell fixation time). The normalized position along the fiber (dividing the distance from the initial point by its total length) were also calculated for each point, and were termed as a fraction of fiber length.
[0548] Time axis recovery was achieved by fitting a polynomial curve between the the actual time points when dyes were added or cells were fixed (e.g., Day 2, Day 5.5, and Day 11) and their corresponding fraction of fiber length values (e.g., 0.5, 0.7, and 1). If there was only one dye switch, resulting in two timestamps (the dye switch and the cell fixation time corresponding to the fiber termini), a linear polynomial (first-degree) fitting is performed. If there were two dye switches, resulting in three timestamps (dye switch 1, dye switch 2, and the cell fixation time), a quadratic polynomial (second-degree) fitting or power fitting is used to best characterize the fiber growth kinetics, which was experimentally characterized in FIG. 3, right panel. After curve fitting, the resulting curve served as a transfer function between the spatial axis along the fiber and the real-world time axis. Fluorescent intensities along the fibers from the signal monomerIllchannel(s) were initially plotted along each of the half fibers with respect to the spatial axis representing the fraction of the fiber length. This fractional fiber position is then converted into the real-world time axis using the fitted curve as the transfer function, thereby establishing the time axis for the recorded signal(s).
[0549] Statistical analysis. Statistical analysis was performed in Prism (GraphPad). All statistical tests were two-sided. Details of the statistical analysis are described in the figure captions and full statistical tables are shown in FIG. 39.
[0550] ProtSSN-based protein mutation prediction. ProtSSNl formulates a zero-shot mutation effect prediction task to suggest favorable modifications on a template protein. It takes the sequence and structure of a template protein (e.g., 1POK(E239Y)) as input and uses a deep learning model to extract residue-wise representations. Based on these representations, it produces a predicted matrix Y G 7?*x33for thetemplate protein with each of 1 residues being one of 33 tokens, including 20 regular residue types and other special tokens defined for training purposes. This matrix can be used to compute mutation fitness scores by comparing the differences between mutants and the template protein at the residue level, thus identifying topranked candidate mutants. In the following sections, we describe the model architecture and scoring procedure in detail.
[0551] The core of ProtSSN consists of a pre-trained BERT-style masked protein language model (PLM) that captures long-range residue dependencies along the sequence, followed by a learnable equivariant graph neural network (EGNN)2 that enhances local spatial interactions of residues. For an arbitrary input protein, we first define it as an undirected graph G=(V, E, W_V, W_E, X_V ) using a k-nearest neighbor (kNN) algorithm. Each node vGV corresponds to a residue. For each central node, undirected edges eGE are added to up to k nearest neighboring residues within a 30 A radius in Euclidean space. Node features W_V are 1024-dimensional hidden embeddings extracted from the frozen ESM2-t33 model3 (checkpoint available at https: / / github.com / facebookresearch / esm). Following graph denoising neural networks4, edge features WEG / ?lElx93capture pairwise relationships between connected residues based on inter-atomic distances, local backbone directions (N-C vectors), and relative sequence positions. Additionally, to maintain roto-translation equivariance and permutation invariance for node attributes during geometric message passing, X V stores the 3D coordinates of residues in Euclidean space.
[0552] The parameters of the EGNN layers are learned through a self-supervised denoising task. For each residue in the input sequence, a random perturbation is applied with probability p using a replacement matrix ©(•), defined by empirical observations. This perturbation updates each residue v to v The frozen protein language model then encodes the perturbed residue sequence and generates the node features Wv= PLMfrozen(y), where V = {vj,..., v is the perturbed sequence. The EGNN layers further process the representation, enhancing local environmental information, and output Wy = EGNN(G). This is subsequently passed to the readout layers ( ) to provide the recovered sequence Y = <p(Wy~) E Rnx33. The training objective is to minimize Loss(Y, P), i.e., the difference between the denoised and the ground-truth residue tokens.
[0553] Once the model is properly trained, it can be used to infer mutation effect scores for mutants by comparing with the template residue types V. In this case, the template sequence and structure are fed into the frozen PLM and trained EGNN layers (without additional perturbation, which is different from the training steps) to output Y. Suppose the mutant of interest has mutated sites T (|T| > 1). Its fitness score is computed as Fx= 2{ter] l°9 ^°9~ log log p(vt), where ytand vtrepresent the mutated and wild-type residues at the tth position, respectively. While the absolute value of these fitness scores does not have a direct physical meaning, when multiple mutants are under consideration, their corresponding fitness scores are effective references for ranking the preference of these mutations. In the case of recommending single-site mutations for 1POK(E239Y) in this study, we employed ProtSSN to score single-site saturation mutations and selected the top 2 mutations for further investigation and validation through wet lab experiments.
[0554] CPDiffusion-based protein sequence generation. CPDiffusior is a discrete diffusion probabilistic model designed for the protein inverse folding task, i.e., recovering the residue sequences Xaa=conditioned on a given protein backbone Xpos= {xos,..., xfos,.... xos}. To meet specific application needs and improve generation quality, the model allows the incorporation of additional conditions during the generation process, such as fixing conserved residue positions, providing reference secondary structure sequences, or including homologous sequences in the training set. In addition, the generated sequences are further refined through a series of structure-based filtering strategies to enhance the success rate of novel protein designs.
[0555] To achieve this generative objective, CPDiffusion establishes a progressive diffusion process over residue types and trains a denoising network to gradually recover the input sequence distribution p(Xaa\XposThe forward diffusion process adds noise step-by-step to one-hot encoded residue types based on a transition probability matrix (e.g., the BLOSUM62 matrix) until time T, when q(X“) asymptotically converges to a uniform distribution and becomes independent of the initial state Xaa. In the denoising phase, a multi-layer EGNN is trained to predict Xaafrom the noisy sequence Xtat time t, using the input protein backbone (represented as a ANN undirected graph) and additional conditions (defined in the node attributes, such as secondary structure information). During training, the network parameters 0 in EGNNQ(-) are learned from a joint training set consisting of protein crystal structures in CATH 4.26and homologous sequences of 1POK (z.e., E. coli ladA) along with their structures predicted by AlphaFol d27, with the objective of minimizing the cross-entropy loss between the predicted sequences p(Xaa) = EGNNe(Xt, E, t) and the ground-truth sequences X for each input protein. Optionally, a mask matrix M can be defined to fix conservative sites. In this case, the predicted sequences by EGNN requires an additional step of adjustment p(Xt) = M O p(Xaa) + (1 — M) O p(Xaa|Xt). We fixed tyrosine (Y) at the 293 position of th...
Claims
1. What is claimed is:
1. An isolated nucleic acid encoding a self-assembling protein monomer, the self-assembling protein monomer comprising:(a) a self-assembling scaffold domain comprising a 1POK-derived amino acid sequence comprising:(i) a glutamic acid-to-tyrosine substitution at a position corresponding to E239Y of a 1POK scaffold sequence; and(ii) a hydrophobic amino acid-to-hydrophilic amino acid substitution at a lateral interface of the self-assembling scaffold domain;(b) a maltose binding protein-derived insulator domain fused to the self-assembling scaffold domain; and(c) a detectable tag;wherein expression of the self-assembling protein monomer in a mammalian cell produces an intracellular protein filament.
2. The isolated nucleic acid of claim 1, wherein the hydrophobic amino acid-to-hydrophilic amino acid substitution comprises a leucine-to-lysine substitution.
3. The isolated nucleic acid of claim 1 or 2, wherein the hydrophobic amino acid-to-hydrophilic amino acid substitution is L349K or a substitution at a corresponding position.
4. The isolated nucleic acid of any one of claims 1-3, wherein the self-assembling scaffold domain comprises 1POK(E239Y, L349K) or an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical thereto that retains the ability to form an intracellular protein filament.
5. The isolated nucleic acid of any one of claims 1-4, wherein the maltose binding protein-derived insulator domain comprises an E. coli maltose binding protein sequence.
6. The isolated nucleic acid of any one of claims 1-5, wherein the maltose binding protein-derived insulator domain comprises an N-terminally truncated maltose binding protein.
7. The isolated nucleic acid of claim 6, wherein the N-terminally truncated maltose binding protein comprises dMBP.
8. The isolated nucleic acid of any one of claims 1-7, wherein the self-assembling scaffold domain is directly fused to the maltose binding protein-derived insulator domain without an intervening linker.
9. The isolated nucleic acid of any one of claims 1-7, wherein the self-assembling scaffold domain is fused to the maltose binding protein-derived insulator domain through a linker comprising 2 to 25 amino acids.
10. The isolated nucleic acid of claim 9, wherein the linker comprises 2, 6, 10, 12, or 18 amino acids.
11. The isolated nucleic acid of any one of claims 1-10, wherein the detectable tag is C-terminal to the maltose binding protein-derived insulator domain.
12. The isolated nucleic acid of any one of claims 1-11, wherein the detectable tag is selected from HA, V5, E-tag, OLLAS, FLAG, HaloTag, a fluorescent protein, an enzymatic tag, and combinations thereof.
13. The isolated nucleic acid of any one of claims 1-12, wherein the intracellular protein filament is thinner than an intracellular filament formed by an otherwise corresponding monomer lacking the hydrophobic amino acid-to-hydrophilic amino acid substitution.
14. The isolated nucleic acid of any one of claims 1-13, wherein the intracellular protein filament maintains substantially constant lateral width over at least 7 days, at least 14 days, at least 18 days, or at least 21 days in a live mammalian cell.
15. The isolated nucleic acid of any one of claims 1-14, wherein the intracellular protein filament is flexible and curls within a cytoplasm of the mammalian cell without detectably deforming a plasma membrane of the mammalian cell.
16. A self-assembling protein monomer encoded by the isolated nucleic acid of any one of claims 1-15.
17. A vector comprising the isolated nucleic acid of any one of claims 1-15.
18. The vector of claim 17, wherein the vector is a plasmid, lentiviral vector, retroviral vector, adenoviral vector, or adeno-associated viral vector.
19. The vector of claim 17 or 18, wherein expression of the isolated nucleic acid is controlled by a constitutive promoter, tissue-specific promoter, cell-type-specific promoter, inducible promoter, or activity-responsive promoter.
20. A cell comprising the isolated nucleic acid of any one of claims 1-15, the self-assembling protein monomer of claim 16, or the vector of any one of claims 17-19.
21. The cell of claim 20, wherein the cell is a mammalian cell, neuron, glial cell, HEK cell, HeLa cell, stem cell, progenitor cell, mitotic cell, cancer cell, immune cell, muscle cell, cardiac cell, or secretory cell.
22. A genetically encoded intracellular recording system comprising:(a) a structural expression cassette encoding a structural monomer comprising a self-assembling scaffold domain and a structural detectable tag;(b) a timestamp expression cassette encoding a timestamp monomer comprising the self-assembling scaffold domain and a timestamp detectable tag; and(c) a signal expression cassette encoding a signal monomer comprising the self-assembling scaffold domain and a signal detectable tag, wherein expression of the signal monomer is controlled by an activity -responsive promoter;wherein the structural monomer, timestamp monomer, and signal monomer co-assemble in a live cell into a common intracellular protein filament.
23. The genetically encoded intracellular recording system of claim 22, wherein the selfassembling scaffold domain of each of the structural monomer, timestamp monomer, and signal monomer comprises a 1POK-derived scaffold comprising E239Y and L349K, or substitutions at corresponding positions.
24. The genetically encoded intracellular recording system of claim 22 or 23, wherein each of the structural monomer, timestamp monomer, and signal monomer further comprises a maltose binding protein-derived insulator domain.
25. The genetically encoded intracellular recording system of claim 24, wherein the maltose binding protein-derived insulator domain comprises dMBP.
26. The genetically encoded intracellular recording system of any one of claims 22-25, wherein the timestamp detectable tag comprises HaloTag.
27. The genetically encoded intracellular recording system of claim 26, wherein the timestamp monomer is labelable by two or more spectrally distinguishable HaloTag ligands.
28. The genetically encoded intracellular recording system of any one of claims 22-27, wherein the activity-responsive promoter is responsive to transcription factor activity, gene promoter activity, cellular stress, neuronal activity, depolarization, cAMP signaling, calcium signaling, heat shock, drug exposure, or disease-associated signaling.
29. The genetically encoded intracellular recording system of any one of claims 22-28, wherein the activity-responsive promoter comprises a c-fos promoter, Egrl promoter, SARE-ArcMinpromoter, N-RAM promoter, F-RAM promoter, 6xCRE-CMVMin promoter, HSPA1 A promoter, a Npas4 promoter, or a functional variant of any of the foregoing.
30. The genetically encoded intracellular recording system of any one of claims 22-29, comprising at least two signal expression cassettes encoding at least two signal monomers.
31. The genetically encoded intracellular recording system of claim 30, wherein the at least two signal monomers comprise different detectable tags and are controlled by different activity-responsive promoters.
32. The genetically encoded intracellular recording system of claim 30 or 31, comprising at least three, at least four, or at least five signal expression cassettes encoding signal monomers comprising mutually distinguishable detectable tags.
33. The genetically encoded intracellular recording system of claim 32, wherein the signal monomers are configured to record at least two activities selected from CREB activity, Fos activity, c-fos promoter activity, Egrl promoter activity, Arc promoter activity, Npas4 activity, HSPA1 A promoter activity, and inducible TRE promoter activity.
34. The genetically encoded intracellular recording system of any one of claims 22-33, wherein the common intracellular protein filament stores a time-resolved record of cellular activity as a spatial distribution of signal detectable tags along the common intracellular protein filament.
35. A method of recording a cellular activity history in a live cell, comprising:(a) introducing into the live cell the genetically encoded intracellular recording system of any one of claims 22-34;(b) expressing the structural monomer, timestamp monomer, and signal monomer in the live cell such that the monomers co-assemble into a common intracellular protein filament;(c) applying, at a first defined time, a first timestamping event to the live cell or to a subject comprising the live cell, wherein the first timestamping event comprises (i) contacting the live cell with a first label that binds to the timestamp monomer, or (ii) inducing, terminating,increasing, or decreasing expression or incorporation of the timestamp monomer, thereby producing a first timestamp signal at a spatial position along the common intracellular protein filament;(d) detecting a spatial distribution of the first timestamp signal and a spatial distribution of the signal monomer along the common intracellular protein filament; and(e) reconstructing a time-resolved cellular activity history from the spatial distributions.
36. The method of claim 35, further comprising applying, at a second defined time, a second timestamping event to the live cell or to the subject comprising the live cell, thereby producing a second timestamp signal at a second spatial position along the common intracellular protein filament.
37. The method of claim 36, wherein the first timestamping event and the second timestamping event comprise contacting the live cell with spectrally distinguishable HaloTag ligands.
38. The method of claim 36 or 37, wherein the first defined time and the second defined time are separated by at least 0.5 hours, at least 1 hour, at least 3 hours, at least 12 hours, at least 1 day, at least 3 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, at least 18 days, or at least 21 days.
39. The method of any one of claims 35-38, further comprising fixing the live cell, wherein fixation defines a terminal timestamp corresponding to a terminus of the common intracellular protein filament.
40. The method of any one of claims 35-39, wherein detecting comprises immunostaining one or more epitope tags on the common intracellular protein filament.
41. The method of any one of claims 35-40, wherein detecting comprises fluorescence microscopy, confocal microscopy, spinning disk confocal microscopy, super-resolution microscopy, expansion microscopy, or multiplexed immunofluorescence imaging.
42. The method of any one of claims 35-41, wherein reconstructing comprises fitting a transfer function between spatial position along the common intracellular protein filament and real time.
43. The method of claim 42, wherein the transfer function is generated using a dye-switch point, an inducer-on point, an inducer-off point, a fixation endpoint, or any combination thereof.
44. The method of claim 42 or 43, wherein the transfer function comprises a linear fit, polynomial fit, B-spline fit, power fit, or other interpolation.
45. The method of any one of claims 35-44, wherein reconstructing comprises converting signaltag intensity along the common intracellular protein filament into a time-resolved waveform.
46. The method of claim 45, wherein the time-resolved waveform identifies onset, amplitude, peak time, duration, full width at half maximum, decay, oscillation, frequency, baseline fluctuation, or time-lagged correlation of the cellular activity.
47. The method of any one of claims 35-46, wherein the cellular activity history is recorded for at least 1 day, at least 3 days, at least 5 days, at least 7 days, at least 14 days, at least 18 days, or at least 21 days.
48. The method of any one of claims 35-47, wherein the cellular activity history comprises two or more discrete cellular activity events occurring in the same live cell.
49. The method of claim 48, wherein the two or more discrete cellular activity events are separated by at least 0.5 hours, at least 1 hour, at least 12 hours, at least 1 day, or at least 3 days.
50. The method of any one of claims 35-49, wherein the live cell is a neuron, glial cell, HEK cell, HeLa cell, mitotic cell, cancer cell, immune cell, cardiac cell, muscle cell, or secretory cell.
51. A method of multiplexed recording of cellular activities in a live cell, comprising:(a) expressing in the live cell:(i) a structural monomer comprising a self-assembling scaffold domain and a structural detectable tag;(ii) a timestamp monomer comprising the self-assembling scaffold domain and a timestamp detectable tag; and(iii) at least two signal monomers, each signal monomer comprising the self-assembling scaffold domain, a distinct signal detectable tag, and an activity-responsive promoter different from the activity-responsive promoter of another signal monomer;(b) co-assembling the structural monomer, timestamp monomer, and at least two signal monomers into the same intracellular protein filament;(c) detecting spatial distributions of the distinct signal detectable tags along the same intracellular protein filament; and(d) determining time-resolved histories of at least two cellular activities in the live cell.
52. The method of claim 51, wherein the at least two cellular activities comprise promoter activities of c-fos and Arc.
53. The method of claim 51, wherein the at least two cellular activities comprise promoter activities of Arc and Egrl.
54. The method of claim 51, wherein the at least two cellular activities comprise CREB activity and Fos activity.
55. The method of any one of claims 51-54, wherein at least five cellular activities are recorded from the same intracellular protein filament.
56. The method of claim 55, wherein the at least five cellular activities comprise CREB activity, c-fos promoter activity, Egrl promoter activity, Arc promoter activity, and Npas4 activity.
57. The method of any one of claims 51-56, wherein determining comprises comparing onset times, peak times, amplitudes, durations, oscillations, or time-lagged correlations of the at least two cellular activities.
58. An isolated nucleic acid encoding a CytoTape-vivo monomer, the CytoTape-vivo monomer comprising:(a) a 1POK-derived self-assembling scaffold comprising E239Y and L349K, or substitutions at corresponding positions;(b) a maltose binding protein-derived insulator domain;(c) a linker positioned between the 1POK-derived self-assembling scaffold and the maltose binding protein-derived insulator domain; and(d) a detectable tag;wherein expression of the CytoTape-vivo monomer in a neuron forms one or more intracellular protein filaments suitable for optical readout in brain tissue.
59. The isolated nucleic acid of claim 58, wherein the linker comprises 6 amino acids.
60. The isolated nucleic acid of claim 58 or 59, wherein the CytoTape-vivo monomer comprises 1POK(E239Y,L349K)-linker6-MBP-HA.
61. A viral vector comprising the isolated nucleic acid of any one of claims 58-60.
62. The viral vector of claim 61, wherein the viral vector is an adeno-associated viral vector.
63. The viral vector of claim 62, wherein the adeno-associated viral vector is AAV9.
64. A method of recording neuronal activity in vivo in a non-human mammal, comprising: (a) delivering to neurons in a brain region one or more viral vectors encoding:(i) a CytoTape-vivo structural monomer;(ii) a CytoTape-vivo timestamp monomer controlled by an inducible promoter; and(iii) a CytoTape-vivo signal monomer controlled by an immediate early gene promoter;(b) administering an inducer to the non-human mammal to induce expression of the CytoTape-vivo timestamp monomer;(c) exposing the non-human mammal to a neuronal stimulus;(d) detecting spatial distributions of a timestamp tag and a signal tag along CytoTape-vivo filaments in brain tissue; and(e) reconstructing a time-resolved neuronal activity history from the spatial distributions.
65. The method of claim 64, wherein the brain region comprises hippocampus.
66. The method of claim 64 or 65, wherein the brain region comprises dorsal CA1.
67. The method of any one of claims 64-66, wherein the inducible promoter comprises a TRE promoter or TRE3G promoter.
68. The method of any one of claims 64-67, wherein the inducer comprises doxycycline.
69. The method of claim 68, wherein doxycycline is administered orally.
70. The method of any one of claims 64-69, wherein the immediate early gene promoter comprises a c-fos promoter.
71. The method of any one of claims 64-70, wherein the neuronal stimulus comprises kainic acid administration, seizure induction, sensory stimulation, behavioral stimulation, pharmacological stimulation, electrical stimulation, or optogenetic stimulation.
72. The method of any one of claims 64-71, wherein reconstructing comprises using an inducer-on time point, an inducer-off time point, and a tissue fixation or perfusion time point to convert spatial position along a CytoTape-vivo filament into real time.
73. The method of any one of claims 64-72, further comprising determining spatial heterogeneity of neuronal activity across the brain region.
74. A genetically encoded system forbrain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a mammalian subject, the system comprising:(a) a structural expression cassette encoding a structural monomer comprising a self-assembling recording substrate and a first detectable tag, wherein expression of the structural monomer is controlled by a constitutive regulatory element;(b) a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element; and(c) a timestamp expression cassette encoding a timestamp monomer comprising the selfassembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element;wherein the structural monomer, signal monomer, and timestamp monomer are configured to coassemble in cells of the mammalian subject into a common intracellular protein filament, such that cellular activity and timestamp information are encoded as spatial distributions of the second and third detectable tags along the common intracellular protein filament.
75. The system of claim 74, further comprising a transactivator expression cassette encoding a transactivator that activates the inducible regulatory element in response to an inducing agent, wherein the common intracellular protein filament elongates bidirectionally from a central reference position.
76. The system of claim 74 or 75, wherein the self-assembling recording substrate is a GLOBE-compatible substrate that:(a) forms an intracellular linear self-assembling protein filament in the cytosol of a mammalian neuron in vivo;(b) accepts incorporation of the signal monomer driven by the activity-dependent regulatory element;(c) accepts incorporation of the timestamp monomer driven by the inducible regulatory element; and(d) permits post-fixation immunofluorescence readout of the second and third detectable tags along a spatial axis of the filament.
77. The system of any one of claims 74-76, wherein the self-assembling recording substrate comprises XRI, CytoTape, CytoTape-vivo, or a functional variant of any of the foregoing.
78. The system of any one of claims 74-77, wherein the self-assembling recording substrate comprises a 1POK-derived self-assembling scaffold comprising an E239Y substitution, an L349K substitution, or both, and further comprises a maltose binding protein-derived insulator domain.
79. The system of any one of claims 74-78, wherein the first, second, and third detectable tags are mutually distinguishable epitope tags, and wherein the mutually distinguishable epitope tags comprise HA, V5, FLAG, E-tag, OLLAS, or combinations thereof.
80. The system of any one of claims 74-79, wherein the constitutive regulatory element comprises a UbC promoter, CAG promoter, CMV promoter, CBA promoter, or EFla promoter, and wherein the activity-dependent regulatory element comprises a Fos promoter, c-fos promoter, Arc promoter, SARE-ArcMin promoter, N-RAM promoter, Egrl promoter, Npas4 promoter, HSPA1 A promoter, CREB-responsive promoter, F-RAM promoter, or 6xCRE-CMVMin promoter.
81. The system of any one of claims 74-80, wherein the signal monomer comprises a proteindestabilizing sequence, an mRNA-destabilizing element, or both.
82. The system of claim 81, wherein the protein-destabilizing sequence comprises a PEST sequence, and wherein the signal monomer comprises XRI-V5-P1N4.
83. The system of any one of claims 74-82, wherein the inducible regulatory element comprises a tetracycline-responsive element, wherein the tetracycline-responsive element comprises TRE or TRE3G, wherein the transactivator comprises rtTA or rtTA3G, and wherein expression of rtTA or rtTA3G is controlled by an hSyn promoter.
84. A recombinant viral vector composition for brain-wide, single-cell, spatiotemporal ly resolved recording of cellular activity in a mammalian subject, the composition comprising:(a) a first recombinant viral vector comprising a structural expression cassette encoding a structural monomer comprising a self-assembling recording substrate and a first detectable tag; (b) a second recombinant viral vector comprising a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element;(c) a third recombinant viral vector comprising a timestamp expression cassette encoding a timestamp monomer comprising the self-assembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element; and(d) a fourth recombinant viral vector comprising a transactivator expression cassette encoding a transactivator configured to activate the inducible regulatory element in response to an inducing agent.
85. The recombinant viral vector composition of claim 84, wherein the first, second, third, and fourth recombinant viral vectors are adeno-associated viral vectors, and wherein at least one of the adeno-associated viral vectors comprises AAV9, AAV-PHP.eB, or AAV.CAP-B10.
86. The recombinant viral vector composition of claim 84 or 85, wherein the first recombinant viral vector is present at a greater viral -genome-copy number than the second recombinant viral vector, the third recombinant viral vector, or both.
87. The recombinant viral vector composition of claim 86, wherein the viral-genome-copy ratio of the first recombinant viral vector to the second recombinant viral vector to the third recombinant viral vector is about 100: 1: 10.
88. The recombinant viral vector composition of any one of claims 84-87, wherein:(a) the first recombinant viral vector comprises AAV9-UbC-XRI-HA;(b) the second recombinant viral vector comprises AAV9-c-fos-XRI-V5-P1N4;(c) the third recombinant viral vector comprises AAV9-TRE3G-XRI-FLAG; and (d) the fourth recombinant viral vector comprises AAV9-hSyn-rtTA3G.
89. The recombinant viral vector composition of any one of claims 84-88, wherein the selfassembling recording substrate comprises XRI, CytoTape, CytoTape-vivo, or a functional variant of any of the foregoing.
90. The recombinant viral vector composition of any one of claims 84-89, wherein the recombinant viral vector composition is formulated for multi-site, multi-depth intracranial administration or intravenous administration.
91. A method of brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in a non-human mammalian subject, the method comprising:(a) delivering to cells in a brain of the non-human mammalian subject a genetically encoded recording system comprising:(i) a structural expression cassette encoding a structural monomer comprising a self-assembling recording substrate and a first detectable tag;(ii) a signal expression cassette encoding a signal monomer comprising the self-assembling recording substrate and a second detectable tag, wherein expression of the signal monomer is controlled by an activity-dependent regulatory element;(iii) a timestamp expression cassette encoding a timestamp monomer comprising the selfassembling recording substrate and a third detectable tag, wherein expression of the timestamp monomer is controlled by an inducible regulatory element; and(iv) optionally, a transactivator expression cassette encoding a transactivator that activates the inducible regulatory element in response to an inducing agent;(b) expressing the structural monomer, signal monomer, and timestamp monomer in cells of the brain such that the monomers co-assemble into intracellular protein filaments;(c) administering the inducing agent to the non-human mammalian subject during a recording window;(d) subjecting the non-human mammalian subject to a behavioral, pharmacological, physiological, environmental, or pathological manipulation during the recording window;(e) fixing brain tissue of the non-human mammalian subject;(f) detecting spatial distributions of the first, second, and third detectable tags along the intracellular protein filaments; and(g) reconstructing, from the spatial distributions, time-resolved cellular activity histories for individual cells across multiple anatomically distinct brain regions.
92. The method of claim 91, wherein delivering comprises multi-site, multi-depth intracranial injection of recombinant AAV vectors, intravenous administration of an AAV-PHP.eB vector, intravenous administration of an AAV. CAP-B10 vector, or any combination thereof.
93. The method of claim 91 or 92, wherein the cells comprise neurons, and wherein the multiple anatomically distinct brain regions comprise at least two, at least three, at least five, or at least ten brain regions selected from isocortex, olfactory area, cortical subplate, hippocampal formation, pallidum, striatum, thalamus, hypothalamus, midbrain, and combinations thereof.
94. The method of any one of claims 91-93, wherein the recording window is at least 1 day, at least 3 days, at least 5 days, at least 5.5 days, at least 7 days, at least 14 days, or at least 21 days, and wherein time-resolved cellular activity histories are reconstructed for at least 1,000, at least 10,000, at least 100,000, or at least 200,000 cells in the brain.
95. The method of any one of claims 91-94, wherein recording is achieved at a local recording density of at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of Nissl -positive neurons in one or more recorded brain regions.
96. The method of any one of claims 91-95, wherein the behavioral, pharmacological, physiological, environmental, or pathological manipulation comprises contextual fear conditioning, contextual fear memory recall, kainic acid administration, seizure induction, sensory stimulation, behavioral stimulation, pharmacological stimulation, electrical stimulation, optogenetic stimulation, or any combination thereof.
97. The method of any one of claims 91-96, wherein the activity-dependent regulatory element comprises a Fos promoter or c-fos promoter, and wherein detecting comprises immunostaining the first, second, and third detectable tags in fixed brain tissue and imaging the fixed brain tissue using multi-channel volumetric fluorescence microscopy.
98. A method of encoding one or more in vivo timestamps along intracellular protein filaments in brain cells of a non-human mammalian subject, the method comprising:(a) delivering to the brain cells a timestamp expression cassette encoding a timestamp monomer comprising a self-assembling recording substrate and a detectable tag, wherein expression of the timestamp monomer is controlled by a tetracycline-responsive regulatory element;(b) delivering to the brain cells a transactivator expression cassette encoding a tetracycline-controlled transactivator;(c) administering doxycycline to the non-human mammalian subject during a first time interval, thereby inducing expression and incorporation of the timestamp monomer into intracellular protein filaments;(d) withdrawing doxycycline from the non-human mammalian subject during a second time interval;(e) detecting, in fixed brain tissue, a spatial distribution of the detectable tag along the intracellular protein filaments, wherein the spatial distribution comprises a Dox-ON timestamp, a Dox-OFF timestamp, or both; and(f) correcting a spatial position of the Dox-ON timestamp, the Dox-OFF timestamp, or both using an empirically determined latency value;wherein the tetracycline-responsive regulatory element comprises TRE or TRE3G, wherein the tetracycline-controlled transactivator comprises rtTA3G, wherein expression of rtTA3G is controlled by an hSyn promoter, and wherein doxycycline is administered orally in drinking water.
